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ABSTRACT 
 Yersinia pestis, the gram-negative causative agent of plague, is a master of 
immune evasion.  The bacterium possesses a type three secretion system which 
translocates Yop effector proteins into host immune cells to inhibit a number of immune 
and cell signaling cascades.  Interestingly, this apparatus is not expressed at low 
temperatures such as those found within the flea vector and is therefore neither in place 
nor functional when the bacteria are first transmitted into a mammalian host.  However, 
the bacterium is still able to avoid activating the immune system, even very early during 
infection.  
 When grown at 37°C (human body temperature) Y. pestis produces a tetra-acyl 
lipid A molecule, which is antagonistic to the human Toll like receptor 4/MD2, the major 
lipopolysaccharide recognition receptor.  Although tetra-acyl lipid A binds this receptor 
complex, it does not induce signaling, and in fact inhibits the receptors interaction with 
other stimulatory forms of lipid A.  The work undertaken in this thesis seeks to determine 
if the production of tetra-acyl lipid A by Y. pestis is a key virulence determinant and was 
a critical factor in the evolution of Y. pestis from its ancestral parent Yersinia 
pseudotuberculosis.  
 By examining the enzymes involved in the lipid A biosynthesis pathway, it has 
been determined that Y. pestis lacks LpxL, a key enzyme that adds a secondary acyl chain 
on to the tetra acyl lipid A molecule.  In the absence of this enzyme, Y. pestis cannot 
produce a TLR4 stimulating form of lipid A, whereas Y. pseudotuberculosis does contain 
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the gene for LpxL and produces a stimulatory hexa acyl lipid A.  To determine if the 
absence of LpxL in Y. pestis is important for virulence, LpxL from E. coli and Y. 
pseudotuberculosis were introduced into Y. pestis.  In both cases the addition of LpxL led 
to bacterium which produced a hexa-acylated lipid A molecule and TLR4/MD2 
stimulatory LPS.  To verify the LpxL phenotype, lpxL was deleted from Y. 
pseudotuberculosis, resulting in bacteria which produce tetra-acylated lipid A and non-
stimulatory LPS.  Mice challenged with LpxL expressing Y. pestis were found to be 
completely resistant to infection.  This profound attenuation in virulence is TLR4 
dependent, as mice deficient for this receptor rapidly succumb to disease. These altered 
strains of the bacterium also act as vaccines, as mice infected with Y. pestis expressing 
LpxL then challenged with wild type Y. pestis do not become ill. These data demonstrate 
that the production of tetra-acyl lipid A is a critical virulence determinant for Y. pestis, 
and that the loss of LpxL formed a major step in the evolution of Y. pestis from Y. 
pseudotuberculosis.  
 These bacterial strains were also used as tools to determine the contributions of 
different innate immune receptors and adaptor molecules to the host response during Y. 
pestis infection.  The use of LpxL expressing Y. pestis allowed identification of the innate 
immune pathways critical for protection during Y. pestis infection. This model also 
established that CD14 recognition of rough LPS is critical for protection from Y. pestis 
expressing LpxL, and activation of the IL-1 receptor and the induction of IL-1β plays a 
major role in this infection as well.  
xi 
 
 The lipid A acylation profile of gram negative bacteria can have a direct and 
profound effect on the pathogenesis of the organism. This work illustrates a previously 
unknown and critical aspect of Y. pestis pathogenesis, which can be extended to other 
gram-negative pathogens.  The greater detail of the contributions which different host 
adaptor and receptor molecules make to the overall innate immune signaling pathway 
will allow a better insight into how gram negative infections progress and how they are 
counteracted by the immune system.  Alterations of the lipid A profile of Y. pestis have 
important implications for the production of vaccines to Y. pestis and other gram negative 
pathogens.  Taken together, this work describes a novel mechanism for immune evasion 
by gram negative bacteria with consequences for understanding the immune response and 
the creation of more effective vaccines, both of which will decrease the danger posed by 
this virulent pathogen.   
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CHAPTER I: 
INTRODUCTION 
1
1:1 Yersinia  
The genus Yersinia 
The genus Yersinia is a member of the family Enterobacteriaceae of Gram-
negative bacteria.  They are rod-shaped, non-spore forming organisms which can grow in 
both aerobic and anaerobic conditions.  The majority of the Yersinia are peritrichously 
flagellated, with the exception of Y. pestis which is non-motile (Minnich and Rohde, 
2007).  This genus contains fifteen species, of which only three are known to be 
pathogenic to humans, Yersinia enterocolitica, Yersinia pseudotuberculosis, and Yersinia 
pestis.  Y. enterocolitica and Y. pseudotuberculosis are soil and water borne pathogens 
that cause self limiting gastroenteritis in humans, whereas Y. pestis is associated with 
bubonic plague, a radically different and highly dangerous disease (Smego et al., 1999; 
Zhou and Yang, 2009).  However, despite the differences in pathological presentation, 
these three species of Yersinia share a great degree of genetic homology and contain 
similar virulence determinants.  All three species contain a 70-75kb virulence plasmid 
(pCD1 in Y. pestis, pIB1 in Y. pseudotuberculosis, and pYV in Y. enterocolitica) that 
contains both a type three secretion system (T3SS) and the Yersinia outer proteins (Yops) 
which strongly inhibit the host immune response (Cornelis et al., 1998).  Despite their 
genetic similarities, Y. pestis, Y. pseudotuberculosis, and Y. enterocolitica cause diverse 
clinical symptoms with unique characteristics, and determining the manner in which they 
evolved can help elucidate how the bacterium became pathogenic and thus facilitate the 
discovery of preventative and curative treatments.   
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Yersinia enterocolitica and Yersinia pseudotuberculosis 
 Yersinia enterocolitica is the oldest pathogenic Yersinia, and is the evolutionary 
parent of both Y. pseudotuberculosis and Y. pestis (Achtman et al., 1999).  Although there 
are numerous serotypes of Y. enterocolitica, not all are associated with disease.  Those 
serotypes that are pathogenic lead to a zoonotic, food borne illness that is transmitted via 
the oral-fecal route, and produces disease in both humans and animals.  This is thought to 
be a very common infection, especially in young children, but usually the symptoms are 
subclinical and are therefore rarely seen or diagnosed (Fredriksson-Ahomaa et al., 2006; 
Smego et al., 1999).    
Despite the millions of years since their evolutionary divergence, Y. 
pseudotuberculosis remains very similar to its parent Y. enterocolitica in its pathogenesis.  
Both bacteria are associated with a food borne disease with self limiting gastroenteritis, 
spread by oral-fecal route.  The name pseudotuberculosis is derived from the formation 
of granuloma-like lesions in mesenteric lymph nodes during infection (Smego et al., 
1999; Zhou and Yang, 2009). 
 After ingestion, Y. enterocolitica and Y. pseudotuberculosis travel to the small 
intestine and invade microfold (M) cells, which are specialized epithelial cells that act as 
antigen sampling cells.  The bacteria then move across the epithelial barrier, travel to the 
mesenteric lymph nodes and colonize these organs, resulting in mesenteric 
lymphadenitis.  This migration may be aided by phagocytes, which internalize the 
bacteria and transport them to the lymph nodes  (Pujol and Bliska, 2005), where they are 
able to multiply extracellularly.  The presence of the bacterial T3SS and Yop proteins are 
3
thought to allow the bacteria to colonize the lymphoid organs, despite the presence of 
immune cells and macrophages  (Pujol and Bliska, 2005) (Fredriksson-Ahomaa et al., 
2006).  
 
Yersinia pestis 
Yersinia pestis is the causative agent of plague, a disease firmly embedded in the 
collective memory of humanity.  The bacterium can be found on every continent except 
Australia and Antarctica and is estimated to have caused approximately 200 million 
deaths worldwide in at least three separate pandemics.  The first known large scale 
pandemic was the Justinian plague, which began around 541 AD in Egypt and recurred in 
8-12 year cycles throughout the Mediterranean.  The second pandemic, commonly known 
as the Black Death, was spread throughout Europe beginning in the 12th century and 
occurred in continuous 2-5 year cycles up until the 17th century.  This pandemic is 
thought to have killed up to 30-40% of the medieval European population and due to its 
longevity and severity it is the most historically significant and well known of the 3 
major pandemics.  It is credited with having had a huge impact on western society and 
human civilization as a whole.  Numerous economic, religious, moral, medical and 
societal changes that occurred during the Middle Ages can be traced back to the 
widespread and dramatic depopulation caused by Yersinia pestis and other diseases 
common during this time period.  Many popular images and conceptions about plague 
emanate from this time period, and have helped the bubonic plague to remain one of the 
most feared pathogens (Cantor, 2002; Perry and Fetherston, 1997; Smego et al., 1999). 
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 The third pandemic began sometime in the mid-1800’s and continues to this day.  
This pandemic is important both because of its current status and also because during this 
time the Yersinia pestis bacterium was isolated and identified as the causative agent of 
plague.  The bacterium was identified by Alexandre Yersin (Yersin A, 1894) and 
Shibasaburo Kitasato in Hong Kong in 1894, and shortly thereafter the role of the flea as 
an insect vector was identified.  These discoveries, along with others during this time, 
have led to an increased understanding of the disease.  When this understanding and the 
resulting implementation of public health measures were combined with the discovery 
and use of antibiotics, considerable reduction of plague associated mortality was achieved 
(Perry and Fetherston, 1997).  However, plague infections still occur worldwide, 
including in the United States.  The prairie dog population, along with other rodents, in 
the southwestern United States provides a natural reservoir for the disease, and people in 
close contact with these rodents have contracted the illness.  In 2006 there were 13 case 
of plague in this region, resulting in two fatalities.  This bacterium is also a concern for 
bioterrorism, and is a category A select agent (Butler, 2009). 
 The life cycle of Y. pestis is very different from the other pathogenic Yersinia.  Y. 
pestis is spread by flea vector between rodent hosts, who form the natural reservoirs for 
this bacterium.  Because a flea only ingests between 0.03-0.5μL of blood during each 
feeding, there must be a high titer of bacteria in the bloodstream of the host to complete 
the Y. pestis life cycle, in order to ensure transmission of the bacteria (Hinnebusch and 
Schwan, 1993).  Y. pestis then obstructs the midgut of the flea, so that the next time the 
flea feeds, it will regurgitate bacteria into the next host (Bacot, 1919; Eisen et al., 2006; 
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Eisen et al., 2007; Hinnebusch and Erickson, 2008; Perry and Fetherston, 1997; Smego et 
al., 1999). 
Humans living in close contact with infected rodents acquire the disease when 
they are bitten by infected fleas.  Three to seven days post infection; the classical bubonic 
plague develops with the associated fever, headaches, body aches and other flu like 
symptoms, along with the characteristic swollen lymph nodes, or buboes.  Septicemic 
plague occurs when the bacterium enters the blood stream directly and as a consequence 
buboes are not typically observed.  The bubonic and septicemic forms of plague are very 
serious infections, and without antibiotic treatment are fatal in 30-70% of cases.  The 
third and most dangerous form of Y. pestis infection is pneumonic plague.  This type of 
plague occurs when an individual inhales the bacteria, by coming into close contact with 
an infected animal or an infected individual in later stages of the disease.  As an 
individual becomes seriously ill and the bacteria invade the lungs, the bacteria can 
aerosolize when the individual coughs and hence be transmitted to other individuals.  
Pneumonic plague has a much shorter incubation period of only 1-3 days, and without 
treatment has almost a 100% fatality (Dennis, 2008; Gage Kl, 2005; Perry and 
Fetherston, 1997). 
After infecting the host subdermally, the bacteria are taken up by neutrophils and 
macrophages.  While the bacteria are successfully killed by neutrophils, they are able to 
survive and replicate inside the phagolysosomes of macrophages located in lymphoid 
organs such as the spleen (Marketon et al., 2005; Straley and Harmon, 1984).  After 
several days, the bacteria break free of the macrophage and enter the bloodstream, where 
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they rapidly reach very high titers leading to septic disease (Lukaszewski et al., 2005).  
The uptake of Y. pestis by macrophages forms a critical step in the survival of the 
bacteria, by providing a protected niche where replication to large numbers can occur.  
This also allows the bacteria to be disseminated throughout the body (Li and Yang, 
2008).  
The pathogenesis of Y. pestis has been extensively studied and it has become clear 
that Y. pestis is a master at evading the host immune response.  Perhaps the most studied 
aspects of Yersinia pathogenesis are the type three secretion system (T3SS) and Yop 
proteins.  The T3SS is specialized molecular machinery that acts to inject effector 
proteins into a host cell.  The apparatus resembles a needle that is assembled on the 
surface of the bacteria and may have its evolutionary roots in the flagellum apparatus 
(Cornelis, 2006).  The genes for this system are encoded on a virulence plasmid (pCD1) 
that is present in all three pathogenic Yersinia species (Viboud and Bliska, 2005).  Y. 
pestis also contains two other virulence plasmids, which are not found in the other 
Yersinia species.  These plasmids (pPCP1 and pMT1) contain important virulence 
proteins that help the bacteria escape detection by the host immune system (Chromy Ba, 
2005; Perry and Fetherston, 1997). 
T3SSs are common to many Gram-negative bacteria where they play an important 
role in virulence.  Two types of proteins involved in the T3SS are encoded by pCD1, 
structural proteins that form the injectosome and non-structural effector proteins (Perry 
Rd, 1998), along with many other different proteins.  The injectosome is a large multi-
protein needle like apparatus that is comprised of 25 Ysc proteins and assembled in the 
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cytoplasm near the inner membrane of the bacterial cell then inserted through bacterial 
membrane to protrude at the surface of the bacteria.  Its purpose is to penetrate the host 
cell membrane on contact and provide a channel through which the effector proteins can 
be introduced directly into the host cytoplasm.  YopB, D and LcrV are the translocator 
proteins located at the distal end of the needle like structure.  The hydrophobic YopB and 
YopD proteins act to form a pore in the host cell membrane, while LcrV forms a 
pentameric structure at the tip of the needle which aids the penetration of the host cell 
(Broz et al., 2007; Cornelis et al., 1998; Viboud and Bliska, 2005).  Once this needle is in 
place and the pore formed, the effector proteins are able to translocate through the needle 
and into the host cytoplasm.  These effector proteins, YopH,O,J,E,M, and T all have 
specific roles in the suppression of the host immune response (Cornelis, 2002; Zhang et 
al., 2008).  YopH is a protein tyrosine phosphatase that blocks several pathways, 
including those involved in oxidative burst, focal adhesion, and B and T cell activation 
(Black et al., 2000; Bliska et al., 1992; de la Puerta et al., 2009).  YopE, T and O all 
target the RhoGTPases, subsequently disrupting a large number of cellular processes 
including the actin cytoskeleton, cytokine production and phagocytosis  (Black and 
Bliska, 2000; Mejia et al., 2008; Schotte et al., 2004; Viboud and Bliska, 2001; Viboud et 
al., 2006).  YopJ acts as an acetyltransferase that inhibits MAP2 kinases and NF-κB 
signaling pathways by blocking phosphorylation  (Mittal et al., 2006; Mukherjee et al., 
2006).  YopM is a leucine-rich protein that targets and depletes host Gr1+ natural killer 
cells (Kerschen et al., 2004; Ye et al., 2009).  Together these proteins deal a significant 
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blow to the host immune response, facilitating the multiplication of the bacteria with in 
macrophages and lymphoid organs.  
The pPCP1 plasmid encodes for three proteins, plasminogen activator (pla), 
pesticin (pst), and pesticin immunity protein (pim).  The plasminogen protease, or Pla, is 
an outer membrane protease that induces fibrinolysis in the host, promotes adhesion to 
and degradation of host cell extracellular matrix, cleaves complement protein C3, and 
promotes invasion of epithelial cells at the site of infection (Lahteenmaki et al., 2001; 
Lahteenmaki et al., 1998; Sodeinde et al., 1992).  Pla is an essential virulence factor in 
flea borne bubonic plague, but is not necessary for septicemic plague (Sebbane F, 2006).  
Strains that lack Pla trigger a massive inflammatory response at the site of infection, have 
a million-fold reduction in virulence by subcutaneous infection and are taken up and 
killed by neutrophils, whereas Y. pestis strains containing Pla do not trigger an immune 
response at the site of infection (Sodeinde et al., 1992).  Pesticin is an acidic, bacteriocin 
protein that acts as a muramidase which can lyse other Yersinia strains and E. coli, an 
action which is thought to promote survival of Y. pestis (Elgat and Ben-Gurion, 1969; 
Rakin et al., 1996; Vollmer et al., 1997).  The pesticin immunity protein is encoded in 
opposite polarity on the pPCP1 plasmid and, as its name implies, allows Y. pestis to be 
immune to its own pesticin protein (Rakin et al., 1996; Sodeinde and Goguen, 1988; 
Vollmer et al., 1997). 
The second unique virulence plasmid pMT contains the genes for murine toxin 
and fraction 1 (F1) capsule protein.  Murine toxin is a member of the phospholipase D 
superfamily and when purified is toxic to mice and rabbits, however inactivating murine 
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toxin in Y. pestis does not attenuate virulence (Hinnebusch et al., 2000; Montie, 1981).  
Instead, it is required for the survival of Y. pestis in the flea by protecting the bacteria 
from digestion in the flea gut (Hinnebusch et al., 2002).  The F1 capsule protein is a 
surface polymer expressed at 37°C and may have functions to inhibit invasion and 
prevent uptake of Y. pestis by macrophages (Cowan et al., 2000; Du et al., 2002).  It also 
seems to play a critical role in the transmission of Y. pestis to the host via the flea 
(Sebbane et al., 2009). 
Evasion of the immune system by Y. pestis is also aided by their resistance to the 
activity of serum and complement, which may be mediated in two different ways.  
Firstly, elevated levels of N-acetylglucosamine found in the Y. pestis LPS molecule 
protects the bacteria from complement, but this alone is not sufficient for the protection 
seen (Anisimov et al., 2005).  The second possible mechanism is the expression and 
surface exposure of the outer membrane protein Ail, which acts as an adhesin or invasion 
enzyme and blocks complement mediated lysis (Bartra et al., 2008) .  
 
Evolution of the pathogenic Yersinia 
 The three pathogenic species of Yersinia are all closely related. Y. enterocolitica 
believed to be the evolutionary parent of Y. pseudotuberculosis, which is thought to have 
diverged away 41-186 million years ago (Zhou and Yang, 2009).  While these two 
species are fairly distantly related, they occupy the same natural reservoirs and give rise 
to similar diseases (Wren, 2003).  Y. pestis is a much more recently evolved pathogen.  It 
has been suggested to have evolved from Y. pseudotuberculosis between 1,500-20,000  
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years ago, although more current work suggests that the split occurred greater than 
10,000 years ago (Achtman et al., 2004; Achtman et al., 1999).  Although, Y. 
pseudotuberculosis shares a high degree of homology to Y. pestis, with 75% of the 
chromosomal proteins sharing 97% identity, their route of infection and pathogenesis is 
remarkably different (Chain et al., 2004).  Because of this paradox, a great deal of recent 
research has been dedicated to determining how these two very similar bacteria can cause 
two very different diseases.  
 Guinet et al. 2008 demonstrated that, when compared directly, both pathogens 
have the ability to cause inflammation at the site of interdermal infection and travel to the 
draining lymph node.  Two days after interdermal infection, mice infected with Y. 
pseudotuberculosis display a large infiltration of polymorphonuclear cells that are able to 
contain and eliminate the infection.  This infiltration was absent in Y. pestis infected 
mice, which had a complete lack of immune cell recognition, allowing the bacteria to 
invade the bloodstream leading to septicemia.  This result is interesting in that it revealed 
that it was not necessarily the route of infection that made Y. pestis more virulent, but its 
ability to suppress the immune response allowing it to escape the draining lymph nodes 
and invade the rest of the body (Guinet et al., 2008).  While experimentally these two 
bacteria are able to cause infection via interdermal inoculation, Y. pseudotuberculosis is 
very toxic to fleas, resulting in death of these animals, while fleas are generally resistant 
to Y. pestis infections (Erickson et al., 2006; Erickson et al., 2007).  
 The sequence of a number of Y. pestis and Y. pseudotuberculosis strains is now 
available and has allowed for whole genome comparisons to establish the point of 
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divergence and how such a virulent pathogen could have evolved from a relatively minor 
one (Eppinger et al., 2007; Garcia et al., 2007; Parkhill et al., 2001; Voskressenskaya et 
al., 2005).  It has been determined that Y. pestis contains only 32 unique chromosomal 
genes compared to Y. pseudotuberculosis and two additional plasmids. Conversely, 317 
genes were absent from the Y. pestis chromosome and 208 genes inactivated, which 
means up to 13% of the Y. pseudotuberculosis genome no longer functions or is present 
in Y. pestis (Chain et al., 2004).  These data indicate that, while Y. pestis has acquired 
virulence genes during its divergence from Y. pseudotuberculosis, the genes that were 
lost could also be an important factor in its evolution.  Further research has demonstrated 
that some of the deleted or inactivated regions are essential for Y. pseudotuberculosis 
viability yet dispensable in Y. pestis (Pouillot et al., 2008) which may hold clues as to 
how Y. pestis evolved.  These genes may be important in the oral-fecal route of 
transmission, but dispensable for transmission in the insect vector; or critical for survival 
in the blood stream and lymphoid organs as opposed to the gut (Pouillot et al., 2008). 
 Y. pestis is a young pathogen, and because of this it is hard to determine exactly 
when and how the strain evolved.  To resolve this issue, Achtman et al. utilized a three 
pronged approach to determine the age and divergence of Y. pestis.  Single nucleotide 
polymorphisms (SNPs) and IS100 elements were screened for and analyzed, and multi-
locus VNTR (variable copy numbers of tandem repeats) analysis (MLVA) was also used.  
Using these methods, it was determined that Y. pestis arose in Asia and split from Y. 
pseudotuberculosis greater than 10,000 years ago and probably had spread substantially 
before the first recorded pandemic.  It was also suggested that the grouping of Y. pestis 
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according to three biovars (or historically and physiologically variant groups of strains) is 
inaccurate, and should be grouped according to molecular signatures which indicate the 
existence of eight separate Y. pestis populations (Achtman et al., 2004).  
 
1.2 Bacterial Lipopolysaccharide/Lipid A Biosynthesis 
Lipopolysaccharide 
Gram-negative bacteria have a unique and distinct membrane structure, comprised 
of inner and outer membranes (Figure 1.1).  The outer membrane is exposed to the 
environment, and because of this has adapted specific molecules and proteins to protect it 
from osmotic pressure, toxic molecules, and other challenges presented to it.  The largest 
component of the external portion of the outer membrane is lipopolysaccharide (LPS) 
comprising 75% of the surface and accounting for 3-10% of the dry weight of the 
bacterium (Raetz Cr, 2002; Vaara, 1999).   
 Lipopolysaccharide, also called endotoxin, is important not only for protecting the 
bacterium from environmental pressures, but also has a role in a wide range of bacterial-
host interactions, particularly in regards to the host immune response.  The concept of 
endotoxin dates back to the 18th century when scientists first began to understand the 
concept of a toxic substance found in diseased or decomposing flesh that could trigger 
fever.  However, it was not until the discovery of infectious microorganisms by Louis 
Pasteur in the 19th century and further studies by Robert Koch and Sir Alexander Ogston 
that scientists discovered that it was the individual components of these microorganisms, 
not the infection itself, that could lead to fevers and septic disease.  During the middle of 
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the 20th century endotoxin was directly identified by Richard Pfieffer, and soon after LPS 
was able to be purified and its exact impact on the host immune system was able to be 
studied (Westphal et al., 1952) (Galanos et al., 1969; Rietschel and Westphal, 1999).  
 
Lipopolysaccharide structure 
LPS is a complex heteropolysaccharide molecule with three genetically and 
structurally distinct regions, the hydrophilic O-antigen polysaccharide, the core 
oligosaccharide, and the hydrophobic lipid A (Figure 1.2).  This mix of hydrophobic and 
hydrophilic components creates an amphiphilic molecule that forms micelles or 
aggregates, in aqueous solutions.  The O-antigen extends away from the membrane into 
the environment and is connected to the Kdo/lipid A moiety by the core region.  Lipid A 
is the hydrophobic anchor of the LPS molecule, embedding the molecule into the outer 
membrane of the bacteria and is the source of the endotoxin potential (Luderitz et al., 
1973) (Raetz et al., 2007).  LPS is an essential molecule for most Gram-negative bacteria, 
the exception being N. meningitidis, which can survive without an LPS as a component of 
its outer membrane (Steeghs L, 2001).  
 Lipopolysaccharide can be found in two different forms, smooth (S-form) LPS, 
which has a long O-saccharide chain of up to 15 sugar residues, or rough (R-form) LPS 
which contains a truncated or absent O-saccharide chain linked to a heptose containing 
core region (Miller et al., 2005).  This core region can be varied, for example E. coli has 
five varieties.  Common structural elements are found within this core region comprising 
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of D-Hep-(1→7)-L,D-Hep(1→3) L, D-Hep(1→5)-Kdo.  The core region is then bound to 
lipid A by Kdo, or 3-deoxy-D-manno-oct-2-ulosonc acid (Raetz et al., 2007).   
The hydrophobic anchor lipid A molecule is the most structurally conserved 
element of the LPS molecule.  It is generally composed of a β-(1’-6)-interlinked D-gluco-
configurated hexosamine (GlcN) disaccharide backbone with phosphates bound at the 4’ 
position of the distal GlcN and α-glycosidically liked to the proximal GlcN (Figure1.3).  
The four primary fatty acids, or acyl groups, are bound to the disaccharide backbone by 
amine bonds at the 2’ and 2 positions and by ester linkages at the 3’ and 3 positions of the 
molecule.  This tetra-acylated molecule is also referred to as Lipid IVA (Figure 1.3a), and 
has unique biological and immune stimulatory characteristics.  The secondary acyl 
groups are attached to the Lipid IVA molecule by ester linkages to the β-hydroxl groups 
on the two primary acyl groups located on the distal GlcN molecule (Figure 1.3b).  This 
structure creates an asymmetrical fatty acid distribution on the molecule, which is a 
critical characteristic of the molecule.  The arrangement, length, and chemical 
characteristics of these acyl chains strongly influence the immune stimulating potential of 
the molecule (Raetz et al., 2007). 
 
Lipid A biosynthesis in E. coli 
The biosynthesis of lipid A in E. coli has been examined in detail, allowing a 
greater understanding of the enzymatic pathway involved with the production and 
modification of the molecule (Figure 1.4).  The enzymes involved in this pathway are 
encoded by single copy genes which are highly conserved across Gram-negative bacteria, 
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but can have some functional variability.  The evolutionarily conserved enzymes are 
located on the intracellular side of the inner membrane, and are involved in the 
production of the base Kdo-lipid A molecule.  The variable enzymes, including a number 
of modifying enzymes, are located on the outer leaflet of the inner membrane, facing the 
periplasmic space.  These enzymes are environmentally regulated, and can be suppressed 
or induced by changes in temperature, nutrient availability, or growth conditions (Raetz 
et al., 2007).    
The biosynthesis pathway of lipid A is very tightly regulated with each enzyme 
having tight substrate specificity.  This means that the enzymes act in a sequential 
manner to produce the lipid A molecule.  The first step in this pathway is the fatty acid 
acylation of the UDP-GlcNAc molecule by the LpxA enzyme (Figure1.4), requiring the 
R-3-hydroxymyristolyl acyl carrier protein (ACP) to donate the C14 acyl chain to the 
molecule.  This reaction can occur in both directions, with the acyl chain able to be 
removed from GlcNAc (Raetz et al., 2007; Ulaganathan et al., 2007).   
The second step is the deacetylation of the newly formed UDP-3-O-(acyl)-
GlcNAc by the zinc dependant enzyme LpxC (Figure 1.4).  This is the first committed 
step of the lipid biosynthesis pathway and from this point on the pathway is 
unidirectional ending in the formation of a complete lipid A (Raetz et al., 2007; Young et 
al., 1995).  LpxC is the target for a new and highly effective antimicrobial CHIR-090 
which irreversibly binds to the enzyme in a two step, time dependent manner, 
inactivating the enzyme and shutting down the lipid A biosynthesis.  As most Gram-
negative bacteria cannot survive without lipid A, this compound displays a remarkable 
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potency at nanomolar concentrations across a broad spectrum of Gram-negative bacteria, 
including E. coli, P. aeruginosa, H. pylori and N. meningitidis  (Barb et al., 2007a; Barb 
et al., 2007b; McClerren Al, 2005).  
The next step in the pathway is the addition of a second C14 acyl chain at the site 
where LpxC removed the acetate molecule from GlcNAc.  The second step is undertaken 
by enzymes LpxH and LpxD which mediate the formation of the lipid A disaccharide 
molecule.  LpxH cleaves the pyrophosphate linkage of UDP-2,3-diacyl-GlcN to create 
2,3-diacyl-GlcN-1-phosphate, a molecule called lipid X (Figure 1.4d).  This molecule is 
half of the tetra-acyl lipid A molecule, which is then joined to another lipid X molecule 
by LpxB to create the β, 1-6’-linked dissacharide tetra-acyl lipid A precursor molecule 
(Figure 1.4) (Babinski et al., 2002; Buetow et al., 2007).  
The next enzymes to act on this molecule are integral inner membrane proteins 
that contain membrane spanning regions within their N-terminal regions and active 
domains which are likely to face the cytoplasm.  One of these enzymes, LpxK, 
phosphorylates the 4’ position of the disaccharide 1-phosphate molecule, creating Lipid 
IVA (Figure 1.4) (Garrett et al., 1997).  Two Kdo residues are then added to the Lipid IVA 
molecule by KdtA (Figure 1.4) (Clementz and Raetz, 1991).  
The last three enzymes in the pathway, termed the late acyltransferases, add the 
secondary acyl chains to the Kdo- Lipid IVA molecule.  In E. coli, LpxL is next to act on 
the molecule, linking a lauroyl residue to the 2’ position on the (R)-3-hydroxymyristoyl 
residue (Figure 1.4).  The last enzyme in the pathway is LpxM, which adds a 3’ (R)-3-
hydroxymyristoyl residue (Figure1.4), creating the asymmetrical acyl distribution that is 
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characteristic of lipid A (Vorachek-Warren Mk, 2002).  E. coli also contains a alternative 
late acyltransferase, LpxP, which acts in place of LpxL at low temperatures and adds a 
palmitoleate to the molecule in place of a lauroyl residue (Carty et al., 1999). 
When lipid A assembly is complete, the molecule is then flipped to the outer 
leaflet of the inner membrane by the enzyme MsbA, via an as of yet undefined 
mechanism(Raetz et al., 2009; Zhou Z, 1998).  The O-antigen region of the LPS molecule 
is then attached to the lipid A-core molecule by the enzyme WaaL (Abeyrathne et al., 
2005).  The LPS molecule is then transported across the periplasmic space also by an 
unknown mechanism, and transferred to the outer leaflet of the outer membrane.   
While the above biosynthesis pathway is generally conserved across Gram-
negative bacteria, the lipid A molecule does display some variability.  Many bacteria 
produce a lipid A with different numbers of acyl chains, or acyl chains are longer, 
shorter, or branched.  These differences play a huge role in the immune activating or 
suppressing characteristics of the bacterium (Raetz et al., 2007). Acyl chain length is 
determined by the enzymes in the biosynthesis pathway.  The E. coli acyltransferases 
have very tight substrate specificity. In the case of LpxA, the enzyme that adds on the 
first acyl chain to the glucosomine molecule, it preferentially adds a C:12 residue 
(Anderson and Raetz, 1987) (Bainbridge et al., 2008).  However, it will add on acyl 
chains that have either eleven or thirteen carbon residues if that is all that is currently 
available in the substrate pool (Bainbridge et al., 2008).  However, LpxA from other 
gram negative pathogens, like N. meningitidis, L. interrogans, Bordetella species, P. 
gingivalis, and C. trachomatis have either different acyl chain length requirements, or 
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have more relaxed specificities, and this is determined by changes in specific residues at 
the catalytic site of the enzyme (Sweet et al., 2001) (Sweet et al., 2002) (Bainbridge et al., 
2008) (Odegaard et al., 1997) (Robins et al., 2009).  The other enzymes in this pathway 
exhibit the same sort of substrate specificity mechanisms, indicating that the enzymes are 
the determinants for acyl chain length on lipid A (Bartling and Raetz, 2009) (Raetz et al., 
2007) (Bainbridge et al., 2008).  Rhizobium species have a lipid A that contains an 
especially long acyl chain and contain a unique enzyme which transfers these long acyl 
chains on to the lipid A molecule (Brozek et al., 1996).  Lipid A with longer or branched 
acyl chains increases the thickness of the membrane, therefore altering how other 
proteins can function in the membrane (Uratani et al., 1987). 
 
Late-acyltransferase LpxL 
 The gene for LpxL was first identified in 1991 by Karow et al.  and named htrB, 
or high temperature requirement gene type B (Karow and Georgopoulos, 1991).  
However, at this time the actual gene product remained unidentified.  It was known that 
this gene was necessary for bacterial growth in rich media at temperatures over 33°C, and 
that mutations in this gene caused cell division arrest and profound morphology 
differences in the cell wall suggesting that the gene product was involved in membrane 
functions (Karow et al., 1991; Karow and Georgopoulos, 1991).  At the same time as 
Karrow and colleagues were investigating the htrB gene, Brozek et al. were 
demonstrating the presence of late acyltransferase enzymes that added laurate and 
19
myristate residues to Lipid IVA (Brozek and Raetz, 1990).  It was later established that 
htrB (also called lpxL) encoded the lauroyl transferase (Clementz et al., 1996).   
Overexpression of htrB in E. coli leads to an increased rate of enzymatic activity, 
while mutants have no detectable lauroyl transferase activity (Clementz et al., 1997).  
Also, when htrB is mutated in E. coli, the bacteria accumulate tetra-acyl lipid A in the 
inner membrane, due to severely reduced MsbA-mediated transported to the outer 
membrane.  Overexpression of MsbA within the htrB mutant bacteria promotes the 
export of tetra-acyl lipid A to the outer membrane, although this transfer remains highly 
inefficient (Zhou et al., 1998).  However, at lower temperatures (below 33°C), the 
alternative late acyltransferase LpxP is active and can modify the tetra-acyl molecule, 
thus accounting for the temperature sensitivity (Figure 1.5) (Vorachek-Warren et al., 
2002a).  When both LpxL and LpxP are mutated the ability to grow at high temperatures 
is completely abolished, and primarily tetra-acyl lipid A is produced, although a small 
amount of pent-acyl lipid A is present due to leaky LpxM enzyme function.  When all 
three late acyltransferases are mutated, E. coli produces only tetra-acyl Lipid A, however 
this mutant can only grow on minimal media at low temperatures.  All these mutant 
strains are highly sensitive to antibiotics, although the absence of LpxL alone appears 
sufficient to cause this sensitivity  (Vorachek-Warren et al., 2002b). 
LpxL has recently been purified and the key residues for enzyme activity have 
been identified.  LpxL is a member of the glycerol-3-phosphate acyltransferase (GPAT) 
family, a diverse group of enzymes which all have a strongly conserved H(X)4D/E motif 
(where X is any amino acid) within their catalytic domain and utilize acyl-ACP or acyl-
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CoA as their acyl donors.  LpxL has four motifs which are critical for its enzymatic 
activity, all which show shared homology with other GPAT family members, and when 
mutated effect the activity of the enzyme.  Mutations in the classic H(X)4D renders the 
enzyme almost completely inactive, while mutations in the other 3 motifs also alter 
enzyme function  (Six et al., 2008).  
Several groups have mutated the htrB/lpxL gene in a variety of Gram-negative 
bacteria.  Mutating htrB in S. typhimurium resulted in a significant reduction in virulence 
in mice, a result of the inability of the bacteria to colonize lymphatic organs and 
increased killing by macrophages (Jones et al., 1997).  In H. influenza, mutating the htrB 
homologue resulted in initial temperature sensitivity, hypersensitivity to antibiotics and a 
loss of the secondary acyl chains from the molecule (Lee et al., 1995).  Similar results 
were found in N. meningitidis containing mutated htrB, where the bacteria showed a 
decreased ability to induce TNF in human macrophage cell lines and produced tetra- and 
pentacylated lipid A species in contrast the hexacylated species found in the parent strain 
(Ellis et al., 2001; van der Ley et al., 2001).  N. gonorrhoeae strains with a mutated lpxL 
showed a decrease in acylation over wild type, and a decrease in cytokine production in 
cells stimulated with LPS from the mutant strains (Ellis et al., 2001).  In F. tularensis, 
which produces an atypical tetra-acyl lipid A, an LpxL gene has been identified and when 
mutated a tri-acylated lipid A species is produced.  When complementing an E. coli strain 
which lacks lpxL with the F. tularensis lpxL, a hexa-acyl lipid A is produced, indicating 
that F. tularensis LpxL functions like other Gram-negative LpxL’s, despite the atypical 
lipid A produced by this bacteria (McLendon et al., 2007).   
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Yersinia  lipopolysaccharide and lipid A 
The pathogenic Yersinia species each have unique lipopolysaccharide 
characteristics, which may contribute to the growth and virulence differences observed 
between different serotypes and species.  Y. pseudotuberculosis and Y. enterocolitica both 
have the S-form of LPS, with O-antigen chains connected to the core region of the 
molecule.  These O-antigen chains display notable diversity, creating different serogroups 
of both Y. pseudotuberculosis and Y. enterocolitica and may account for the differences 
in antimicrobial and serum resistance, and other pathogenic properties seen between the 
different serotypes and species (Anisimov et al., 2005; Bengoechea et al., 2003; 
Bengoechea et al., 1998a; Bengoechea et al., 1998b; Bengoechea et al., 2004; Knirel et 
al., 2007).  However, Y. pestis lacks this O-antigen region in its LPS, instead expressing 
the R-form of the molecule (Albizo and Surgalla, 1970) (Bruneteau M, 2003; Hartley Jl, 
1974; Hitchen et al., 2002; Knirel et al., 2005b; Prior et al., 2001a), due to frame shift 
mutation in the O-antigen gene cluster in Y. pestis (Prior et al., 2001b).  Generally, the 
lack of an O-antigen can be detrimental to the bacteria due to increased serum sensitivity; 
however, Y. pestis is still are able to invade the host and be complement resistant 
(Anisimov et al., 2005).  Y. pestis expressing only lipid A are viable, and although these 
mutants survive, their growth is very poor and other serious defects are present (Tan and 
Darby, 2005).  The lipid A portion of the LPS molecule also differs between the Yersinia 
species.  Y. enterocolitica produces tetra- and hexa-acylated lipid A (Aussel et al., 2000) 
(Rebeil et al., 2004).  Y. pseudotuberculosis produces a heterogeneous mix of lipid A 
containing tetra-, penta-, and hexa-acylated species. They contain a variety of secondary 
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acyl chains lengths, varying from C12 to C16:1, resulting in a highly complex lipid A 
profile.  Within these two species however, no significant difference in acylation patterns 
are apparent when bacteria are grown at different temperatures (28°C vs. 37°C) (Rebeil et 
al., 2004; Therisod et al., 2002). 
 The lipid A in Y. pestis is very different from that of the other pathogenic 
Yersinia.  At low temperature (26°C-27°C), Y. pestis produces a heterogeneous mix of 
tetra-, penta-, and hexa-acylated lipid A with various modifications, similar to Y. 
pseudotuberculosis.  However, Y. pestis grown at 37°C has a notably different lipid A 
profile where tetra-acylated lipid A is the predominate species (Kawahara et al., 2002; 
Knirel et al., 2005b; Rebeil et al., 2004).  These differences in acylation patterns have a 
considerable effect on LPS bioactivity in Y. pestis.  When human cells, and to a lesser 
extent mouse cells, are cultured in the presence of either lipid A or LPS purified from Y. 
pestis grown at 37°C, it was unable to produce a strong cytokine response in comparison 
with LPS or lipid A from Y. pestis grown at lower temperatures (Kawahara et al., 2002; 
Matsuura et al., 2009; Rebeil et al., 2004).  In addition, Y. pestis is also more sensitive to 
antibiotics when grown at 37°C verses 26°C (Rebeil et al., 2004).  
 Examination of the late acyltransferases of Y. pestis has provided insights into the 
mechanisms underlying the different lipid A profiles with changes in temperature (Rebeil 
et al., 2006).  It was established that Y. pestis encoded lpxM and lpxP homologues, whose 
gene products acted as late acyltransferases, adding on a C12 and C16:1 respectively to 
tetra-acyl lipid A at 21°C.  When lpxM and lpxP were mutated, the bacterium was unable 
to produce hexa-acyl lipid A at lower temperatures.  However, no homologue to lpxL was 
23
found (Rebeil et al., 2006).  This data provides an explanation of how Y. pestis was able 
to produce hexa-acyl lipid A at low temperatures, but not at 37°C.  Despite the fact that 
LpxM is present and functional in Y. pestis, due to of the high substrate specificity of 
these enzymes, without LpxL to add on the first secondary acyl chain to the tetra-acyl 
molecule, LpxM does not function on the molecule, so the molecule remains with four 
C14 primary acyl chains.  
 
1.3 Innate Immunity 
Overview of the Innate Immune System 
 As science began to understand that microorganisms caused disease, an 
understanding of the body’s defenses also began to arise.  This field of study, called 
immunology, looks to examine how the body defends against pathogenic organisms.  
Since the discovery of antibodies in 1890 by Emil von Behring and Shibasaburo Kitasato, 
the idea that the body is able to mount a specific response to a pathogen has become well 
known.  This adaptive immune response utilizes antigen specific lymphocytes, such as B 
and T cells, to fight off specific pathogens and provide protection against further 
infection by that specific pathogen  (Janeway Jr, 2002).  However, the concept of innate 
immunity, how the body initially recognizes invading pathogens and starts the immune 
response, took longer to become established.  Elie Metchnikoff first postulated the idea of 
cell mediated immunity and the concept that cells could phagocytose foreign bodies 
(Janeway Jr, 2002).  However, it wasn’t until the discovery of the first Toll like receptor 
(TLR) in humans in 1997 (Medzhitov et al., 1997) that the picture of how the innate 
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immune system functioned to recognize pathogens and activate the immune response as a 
whole started to become clear.   
 The innate immune response is the first line of defense against invading 
pathogenic organisms.  It recognizes ‘danger’ signals, which in the case of 
microorganisms are evolutionarily conserved molecules known as pathogen associated 
molecular patterns (PAMPs).  These molecules include nucleic acids, bacterial cell wall 
components such as LPS, lipoproteins and flagellin, and viral proteins (Medzhitov and 
Janeway, 1998).  These structures have unique properties that are conserved across a 
wide range of bacteria and viruses, making them ideal targets for host recognition.  These 
molecules are recognized by pattern recognition receptors (PRR) (Akira et al., 2006).  
These are highly conserved germ line encoded receptor molecules that upon recognition 
of PAMPs initiate an intracellular signaling cascade that activates gene transcription of 
both pro- and anti- inflammatory cytokines, chemokines, adaptor molecules, and 
transcription factors.  This subsequently activates other components of the innate immune 
response, which in turn activates and educates the adaptive immune response (Akira, 
2006; Janeway Jr, 2002; Mogensen, 2009).  
 
Pattern recognition receptors 
Pattern recognition receptors are a large group of extracellular and intracellular 
receptors that recognize unique PAMPs.  They fall into 3 major families, the Toll-like 
receptors (TLR’s), the retinoid acid-inducible gene I (RIG-I) like receptors (RLR), and 
the nucleotide-binding oligomerization domain (NOD) like receptors (NLR’s) 
25
(Mogensen, 2009).  These receptors all occupy different cellular compartments, but they 
perform overlapping functions to ensure rapid responses to pathogens and other danger 
signals.  
 The TLR family is an evolutionarily conserved group of membrane bound 
receptors found in species from C. elegans to humans, and are probably the most 
extensively studied PRR to date  (Akira, 2006; Mogensen, 2009).  They are named after 
the Drosophila Toll, a receptor in the fly involved in development and immune 
responses, to which the TLRs bear homology (Medzhitov et al., 1997).  Currently, 10 
TLR’s have been identified in humans and 11 in mice.  These receptors are found on 
most cell types, and although they recognize different PAMP’s, they share similar 
structural and cytoplasmic signaling motifs.  TLR’s are formed by integral glycoprotiens 
containing a ligand binding domain that includes a leucine rich repeat (LRR) and a 
cytoplasmic region that contains a Toll/Interleukin-1 receptor (TIR) domain (Slack et al., 
2000).  The TLR’s can be divided into two groups; TLR’s 1, 2, 4, and 6, which are found 
on the cell surface and recognize lipids and proteins, while TLR’s 3, 7, 8, and 9 are 
located in the endosomal compartment and recognize nucleic acids (Mogensen, 2009). 
 The second class of PRRs are the RLRs, which are a group of cytosolic nucleotide 
receptors.  There are two receptors within this group; RIG-I, which detects virally derived 
dsRNA (Hornung et al., 2006; Kato et al., 2005; Yoneyama et al., 2004) and melanoma 
differentiation-associated gene 5 (MDA5) which recognizes polyI:C and dsRNA(Kato et 
al., 2006).  These receptors bind cytoplasmic nucleotides via their C-terminal domains 
(Takahasi et al., 2009), promoting the association with adaptor proteins with their N-
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terminal caspase recruitment domain (CARD).  The signaling cascade triggered by this 
association results in type 1 interferon response which is critical for the clearance of 
viruses  (Yoneyama et al., 2005). 
 The third class of PRR’s are the NLR’s, which are also cytoplasmic receptors that 
respond to intracellular bacteria and endogenous danger signals.  This group of receptors 
includes NOD1 and NOD2 which recognize components of Gram-positive and Gram-
negative bacterial peptidoglycan  (Girardin et al., 2003a; Girardin et al., 2003b).  This 
class of PRRs also includes the NALP proteins (the largest group of NLR’s) and IPAF, 
which recognize both microbial components in the cytosol, along with endogenous 
danger signals (misfolded proteins, crystals DNA).  The recognition occurs via a C-
terminal LRR and results in CARD oligomerization and the activation of inflammatory 
signaling  (Mariathasan and Monack, 2007; Martinon et al., 2009; Martinon F, 2007; 
Muruve Da, 2008).  These NLR proteins are a critical component of inflammasome 
complexes, will be described in a later section.   
 
1.4 Toll-Like Receptor 4  
 Toll like Receptor 4 (TLR4) is probably the most extensively studied TLR and 
PRR.  TLR4 was first identified as the receptor for lipopolysaccharide by examining the 
HeJ mutation in LPS resistant mice.  Mice with a mutation in the tlr4 gene were resistant 
to LPS toxic shock, but highly susceptible to Gram-negative infection (Poltorak et al., 
1998).  From there it was determined that TLR4, in conjunction with the adapter 
molecule MD2, recognized the lipid A component of LPS which triggers a signaling 
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cascade that eventually activates NF-κB, AP1 and other proinflammatory transcription 
factors (Figure 1.6).  
 LPS is first bound by LPS binding protein (LBP), an acute phase protein found in 
the host bloodstream (Mathison et al., 1992).  LBP then transfers LPS to CD14, a soluble 
glycosylphosphatidylinositol (GPI)-linked protein that is found on the membrane of 
mature monocytes, macrophages, and neutrophils (Arditi et al., 1993; Haziot et al., 1993).  
It contains a LRR domain and is considered a member of the PRR family.  LPS/lipid A 
bound to CD14 to increase the concentration of the lipid at the cell surface and is then 
transferred to the MD2 protein (Tapping and Tobias, 1997; Viriyakosol et al., 2001; 
Wurfel and Wright, 1997; Yu et al., 1997).  This increases the sensitivity of the TRL4 
receptor by aiding in the transfer of LPS/lipid A to TLR4/MD2 via a currently unknown 
mechanism (Delude et al., 1995) (Latz et al., 2002; Meng et al., 2008). 
 MD2 is an essential adaptor protein associated with TLR4, and is the primary 
endotoxin recognition molecule (Park et al., 2009).  It is a secreted soluble protein which 
is essential for the recognition of lipid A by TLR4 (Schromm et al., 2001), as mice 
deficient in MD2 are completely resistant to endotoxic shock, but hypersensitive to 
Gram-negative infections (Miyake et al., 2002; Nagai et al., 2002).  The oligomerization 
of the TLR4/MD2 complex causes a conformational change in the cytoplasmic region of 
the proteins, which initiates the immune signaling cascade.  The TIR domain of TLR4 is 
the essential signaling portion located in the cytoplasmic tail of the receptor.  It is about 
200 amino acids in length and contains three highly conserved areas, or boxes.  The first 
box contains the domain signal sequence, while the second and third boxes play critical 
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roles in signaling (Brikos and O'Neill, 2008; Xu et al., 2000).  Once TLR4 is dimerized, 
other TIR domain adaptor proteins are recruited to initiate the downstream signaling 
cascade (Carpenter and O'Neill, 2009).  Four TIR domain adaptor proteins that promote 
signaling that have been identified, MyD88 (myeloid differentiation factor 
88)(Medzhitov et al., 1998), Mal (MyD88 adaptor like protein) (Fitzgerald et al., 2001; 
Horng et al., 2001), TRIF (TIR domain containing adaptor inducing interferon-β) 
(Yamamoto M, 2002) and TRAM (TRIF related adaptor protein) (Yamamoto et al., 
2003c).  A fifth TIR domain adaptor protein SARM (sterile-α and HEAT/Armadillo 
motifs-containing protein) acts as a negative regulator of TRIF (Carty et al., 2006).  
These proteins form the distinct MyD88 dependant and TRIF dependant pathways that 
are activated by TLR4/MD2 signaling (Togbe et al., 2006) (Brikos and O'Neill, 2008) 
(Figure 1.6). 
The MyD88 dependent pathway is utilized by all of the TLR’s with the exception 
of TLR3.  Activation of the MyD88 dependant pathway results in a fast and robust 
activation of the IKK complex and translocation of transcription factors to the nucleus.  
After TLR4/MD2 activation, MyD88 and Mal are recruited to the complex and bind the 
TIR domain of the receptor (Nunez Miguel et al., 2007).  This allows the recruitment of 
members of the IL-1 receptor associated kinase (IRAK) family to the Mal/Myd88 (Figure 
1.6).  IRAK4 followed by IRAK1 and IRAK2 are sequentially phosphorylated and 
associate with TRAF6 (Qian et al., 2001) (Hacker and Karin, 2006).  TRAF6 acts as a 
ubiquitin protein ligase that adds K63- linked polyubiquinin chains on several different 
components of the Mal/Myd88 complex, including itself, TAK1 (transforming growth 
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factor-activated protein kinase 1), and NEMO (IκB kinase (IKK) subunit NF-κB essential 
modifier).  The K63 ubiqutinated Mal/Myd88 complex facilitates the phosphorylation 
and activation of the IKK complex and members of the MAP kinase family.  Activation 
of the IKK complex results in the phosphorylation and degradation of IκB, which frees 
NF-κB and allows it to translocate to the nucleus (Figure 1.6).  NF-κB in turn activates 
transcription of a number of proinflammatory proteins and cytokines required for the 
anti-microbial response.  Activation of MAP kinases leads to the stimulation of activator 
protein 1 (AP1), a transcription factor which in turn translocates to the nucleus and 
activates proinflammatory gene transcription (Carpenter and O'Neill, 2009; Mogensen, 
2009).   
The second TLR4/MD2 activated pathway is the MyD88 independent/TRIF 
dependent signaling pathway (Figure 1.6).  After TLR4/MD2 activation, TRAM and 
TRIF associate with the TIR domain of TLR4 (Nunez Miguel et al., 2007), which in turn 
interacts with RIP1 and TRAF6 to activate the IKK complex.  However, this activation is 
much slower and at a lower level than that seen in the MyD88 pathway.  In addition, 
TRAM and TRIF can also activate the interferon (IFN) response by interacting with 
TRAF3 and TANK (TRAF family associated NF-κB activator) (Hacker et al., 2006).  
This allows the IKK related kinases TBK1 and IKKε to phosphorylate IRF3 and IRF7, 
which translocate to the nucleus as either hetero- or homodimers and activate the 
transcription of the IFN and IFN inducible genes.  TRAM and TRIF also interact with 
NF-κB and AP-1 to induce IFN-β (Mogensen, 2009). 
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TLR4 expression 
 The type of cells on which TLR4 is expressed is crucial due to its ability to 
recognize pathogens and initiate a host response.  In humans, TLR4 is predominantly 
expressed on myeloid cells, including monocytes, macrophages, neutrophils dendritic 
cells and granulocytes, all of which are key in the initial recognition of pathogens by the 
innate immune system.  The promoter region of TLR4 contains features typical of a 
myeloid specific gene, including recognition sites for the transcription factor PU.1 and 
the absence of a TATA box.  Many studies have shown that the levels of TLR4 mRNA 
can differ between these myeloid cell types and is dependent on the activation state of the 
cell.  When alveolar macrophages were compared to autologous monocytes from healthy 
human subjects for example, the macrophages were found to contain lower levels of 
TLR4 mRNA than the monocytes, however, the surface expression levels of the receptor 
on both cell types was the same (Juarez et al.).  Dendritic cells also differentially express 
TLR4, with expression determined by their developmental stage (Kadowaki et al., 2001; 
Visintin et al., 2001).  This is illustrated by the high levels of TLR4 mRNA within 
monocyte precursor cells, compared with CD11b+ cells and plasmacytoid pre-dendritic 
cells which have no detectable TLR4 mRNA.  Other studies have shown that immature 
dendritic cells do express low levels of TLR4 mRNA, but these levels decrease over time 
after activation of the cell by LPS (Kokkinopoulos et al., 2005).  Langerhans cells, which 
are specialized dendritic cells found in the epidermis, do not express TLR4, possibly to 
prohibit reactions to commensal skin flora , while dermal dendritic cells, those found in 
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the deeper dermis layer of the skin, do express TLR4 (Takeuchi et al., 2003; van der Aar 
et al., 2007). 
 TLR4 expression is also found within other cell types with roles within the 
immune response, such as lymphoid cells.  Human hematopoietic stem cells and plasma 
cells express TLR4 mRNA, however B cells do not (Dorner et al., 2009; Hornung et al., 
2002; Mansson et al., 2006).  CD4 and CD8 T cells both express TLR4, and activated 
CD8 T cells secrete high levels of IFNγ, perforin and granzyme in response to LPS 
stimulation (Komai-Koma et al., 2009; Xu et al., 2005). TLR4 is also expressed in most 
other tissues and cells in humans, with the exception of the liver, which does not contain 
detectable levels of TLR4 mRNA transcripts. Of interest is the fact that TLR4 is 
expressed on both melanocytes and keratinocytes in the epidermis, which may help the 
body respond to subcutaneous infections (Ahn et al., 2008; Kollisch et al., 2005; Lebre et 
al., 2007). 
 A variety of mouse cells and tissues express TLR4, however, in many cases the 
distribution is different to that seen in humans.  Mouse myeloid cells have the similar 
levels of TLR4 to humans, however the expression in tissues such as lung, heart, kidney, 
and muscle are considerably higher (Dearman et al., 2009; Liu et al., 2002).  In contrast 
to humans, mouse B cells do express TLR4 mRNA and respond to LPS (Genestier et al., 
2007), whereas mouse  naïve CD8 T cells lack TLR4, although after injury both CD4 and 
CD8 T cells have been shown to express the receptor (Cairns et al., 2006; Komai-Koma 
et al., 2009).  Recent work also suggests that mouse serum contains different properties 
then human serum, which can reduce the response of macrophages to LPS, indicating that 
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cellular differences  are not the only factor in regulating the response of TLR4 to 
LPS(Warren et al.). This differential expression within the different cellular subsets and 
species is important to consider, both when examining the route of infection and the early 
responses to the pathogen, and also when utilizing mice as a model system of infection.  
 
TLR4/MD2 recognition of LPS/Lipid A 
 In human cells, the most potent activator of TLR4/MD2 signaling is hexa-acyl 
lipid A which can induce a strong TNF and IFNβ response at very low (picomolar) levels.  
However, modifications of the lipid A molecule can affect the signaling capabilities of 
TLR4.  These modifications include reduction in the number of acyl chains, modification 
or branching of these chains, and modification of the GlcNAc backbone such as altering 
the number of phosphates or arabinose modifications (Raetz et al., 2007).  In particular, 
tetra-acyl lipid A is known to be a potent antagonist for TLR4 signaling.  When cells are 
stimulated with Lipid IVA or synthetic tetra-acyl lipid A, there is no TLR4 activation or 
signaling.  Lipid IVA can also act as an inhibitor of TLR4/MD2 signaling when tetra-acyl 
lipid A is added to cells alongside stimulatory hexa-acylated lipid A signaling is 
significantly reduced or abolished (Golenbock et al., 1991; Saitoh et al., 2004a).   
Recent work resolving the crystal structure of the TLR4-MD2-lipid A complex 
has provided a clearer picture of the interaction between TLR4/MD2 and lipid A, and 
how differences in the acylation pattern of lipid A affect stimulation (Park et al., 2009).  
The hydrophobic pocket of MD2 binds the lipid A portion of the LPS molecule.  Five of 
the six acyl chains of hexa-acylated lipid A fit into this hydrophobic pocket, while the 
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sixth chain remains outside the pocket and forms a tight hydrophobic interaction with 
conserved phenylalanine’s of the TLR4 protein.  Two MD2 proteins complex in this 
manner with to two lipid A molecules, and then interact with two TLR4 receptors, 
creating a tight symmetric complex (Figure 1.7).  The phosphate groups on the lipid A 
molecule interact with both the MD2 and TLR4 molecules via positively charged 
residues on the TLR4 protein and a hydrogen bond with MD2.  This binding pattern 
explains why modifications to the acylation pattern of lipid A effect the stimulation of 
TLR4.  In the case of tetra-acyl lipid A, the four acyl chains fit neatly into the 
hydrophobic pocket, with no acyl chains outside the pocket and the glucosamine 
backbone oriented in a different manner.  This arrangement allows the lipid A molecule 
to fit deeper into the MD2 hydrophobic pocket and prevents proper interaction with 
TLR4, thus inhibiting immune activation (Park et al., 2009).  
 
Species specific recognition of Lipid IVA 
Lipid A specificity varies greatly among species.  For example in contrast to 
human TLR4/MD2, mouse TLR4/MD2 is able to recognize tetra-acyl lipid A leading to a 
signaling and immune activation (Akashi et al., 2001).  Early work to determine the cause 
of this species specificity was contradictory.  Several reports indicated that species 
specificity was conferred by MD2 (Akashi S, 2001; Muroi M, 2006), other reports 
indicated that TLR4 was the deciding factor (Lien et al., 2000; Poltorak et al., 2000).  In 
order to establish what causes these differences in species specific recognition, both MD2 
and TLR4 were examined and it was determined that surface charges at the lipid 
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A/TLR4/MD2 interface contribute to how the receptor complex recognizes lipid A.  
Lipid IVA is also an agonist for the equine TLR4/MD2 complex.  In order to determine 
what portions of TLR4 and/or MD2 are important in this recognition, comparative 
analysis between humans and horses was undertaken.  It was determined that the 
electrostatic surface potential of specific domains on the surface of both MD2 and TLR4 
were critical for recognition of different forms of lipid A.  By swapping these domains 
between horse and human TLR4 and MD2, the receptor was able to recognize and 
productively signal (Walsh et al., 2008).  
 Computational studies have shown that the ionic structure of the mouse 
TLR4/MD4/lipid A interface differs from that of the human complex, resulting in 
differential binding of Lipid IVA and activation of the receptor (Meng 2009).  The key 
residues that determine this surface charge difference have been identified as well, and 
mutating these residues to change their charges alters how the receptor complex functions 
(Meng 2009, in process).  These studies are critical to the understanding of how different 
forms of lipid A can activate TLR4/MD2.  
 
The effect of lipid A structure on bacterial pathogenesis and the host immune 
response 
As described previously, Gram-negative bacteria produce a wide range of lipid A 
species. TLR4 recognition of these different forms of lipid A has implications for both 
the hosts’ immune response and for the pathogenesis of the bacteria.  Gram negative 
pathogens like E. coli (Imoto et al., 1985; Raetz et al., 2007),  K. pneumonia (Clements et 
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al., 2007), E. cloacae (White et al., 1984),  H. influenzae (Mikhail et al., 2005), and some 
Shigella species  (Rallabhandi et al., 2008)  produce hexa-acylated lipid A which is able 
to stimulate human TLR4.  These pathogens infect through the mucosal pathways such as 
the GI tract, and while they do have the ability to cause severe disease, this usually occurs 
in hosts that may not be fully immunocompetent   (Munford, 2008), which is 
advantageous both for the host and pathogen.  In this situation the host is generally able 
to clear the infection without severe damage or septic shock, while the bacteria are shed 
from the host large numbers, allowing for effective dissemination and the opportunity to 
infect a new host.  However, when these pathogens with stimulatory LPS cross the 
mucosal/epithelial barrier and become systemic, they can have catastrophic effects.  
When introduced into the bloodstream, even non-pathogenic E. coli can cause severe 
septic shock and death of the host (Ender et al., 2009; Wray et al., 2001).  This is in part 
due to the TLR4/MD2 mediated immune response triggered in the bloodstream as well as 
other factors such as the activation of complement and clotting deficiencies, all of which 
can lead to hemorrhage and subsequent death (Munford, 2008).  
In addition to Y. pestis, many Gram negative bacteria produce a lipid A with a 
reduced ability to be recognised by TLR4, including F. tularensis  (Schilling B, 2007), B. 
abortus  (Qureshi et al., 1994), H. pylori  (Stead et al., 2008), L. pneumophilia 
(Palusinska-Szysz and Russa, 2009), P. aeruginosa  (Bedoux et al., 2004), C. burnettii 
(Schramek and Galanos, 1981), and V. cholerae  (Vinogradov et al., 1995).  Although not 
all Gram-negative bacteria that produce non-stimulatory lipid A are pathogenic, those 
that are usually invade the body through non-mucosal routes including abrasions, cuts or 
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injections into the skin or bloodstream, inhalation, and the conjuctival membranes.  These 
bacteria are characterized by their ability to become systemic and reach very high titers in 
the bloodstream of infected individuals.  They are also capable of causing septic shock, 
despite their inability to stimulate human TLR4/MD2, which is thought to occur either 
via toxins produced by the bacteria or due to the very high bacterial titer with in the 
bloodstream which can trigger other innate immune receptors (Munford, 2008).  
 
1.5 Lipid A Modifications and Vaccine Development 
 With the discovery of the TLRs and innate immune system, a great deal of work 
has gone into trying to utilize the responses from this arm of the immune system in 
vaccine development.  The key goal of this work has been to increase the efficacy of 
vaccines, decreasing any side effects or negative reactions.  Therefore, finding molecules 
that activate both innate and adaptive immunity but have low toxicity or antigen cross-
reactivity is of great interest.  TLR ligands are of particular interest because they have the 
ability to both activate and direct the adaptive immune response.  Recent work done by a 
number of groups has examined how modifying lipid A in Gram-negative bacteria can 
increase the immunological properties of vaccines.  A vaccine for Neisseria meningitidis 
serogroup B has been difficult to design, and the use of endogenous LPS in these 
vaccines is controversial because of its acute toxicity.  However, work has been done to 
create membrane vesicles that contain N. meningitidis outer membrane proteins with a 
variety of TLR agonists, including monophosphoryl lipid A, a TLR4 agonist that has 
lower toxicity than standard LPS/lipid A due to its bias for activating the TRIF/TRAM 
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pathway rather than MyD88 (Casella and Mitchell, 2008; Fransen et al., 2007).  N. 
meningitidis lpxL mutants have also been used in vaccine development, because of 
reduced toxicity of the LPS in these strains due to the decreased number of acyl chains on 
the molecule (Stoddard et al., 2009).  A similar approach has been taken in generating B. 
pertussis and F. tularensis vaccines.  LPS from the N. meningitidis lpxl2 mutant and 
monophosporyl lipid A was injected into mice along with the standard B. pertussis 
vaccine resulting in a higher efficacy of the vaccine in both cases.  With F. tularensis, a 
different strategy was utilized.  In this case, a strong TLR2 agonist, PorB from N. 
meningitidis, was co-administered to mice with LPS from F. tularensis LVS as a vaccine, 
after which the mice were challenged with live F. tularensis LVS.  Mice that were 
vaccinated with both PorB and LPS had a survival rate of 70% after bacterial challenge, 
whereas only 25% of mice injected with LPS alone survived the infection (Chiavolini et 
al., 2008).  This research demonstrates that the selective and potent activation of the TLR 
response can be an important strategy for vaccine development (Geurtsen et al., 2008). 
 
1.6  IL-1 pathway and inflammasome activation 
 The IL-1 pathway is a critical and essential immune regulatory pathway.  It plays 
a central role in the activation of the immune response, and causes the upregulation of a 
large number of chemokines, cytokines, growth factors, adhesion molecules and other 
key regulators of the immune response (O'Neill, 2002).  The IL-1R is the founding 
member of the IL-1/TLR superfamily that now encompasses a large number of receptors 
critical for the innate immune response.  It utilizes MyD88 as an essential adapter protein 
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and activates NF-κB through similar downstream signaling cascades (Medzhitov et al., 
1998; Stylianou et al., 1992).  Unlike TLRs which recognize PAMPs, the ligands for IL-
1R are endogenous cytokines produced upon stimulation of the TLRs.  Currently, 11 
ligands for IL-1R have been identified at this point; the most extensively are IL-1α, IL-
1β, and IL-18 (Dinarello, 2009; Slack et al., 1993). 
 The inflammasomes are a group of multiprotein cytoplasmic complexes that 
utilize NLRs to sense intracellular microbial elements and activate IL-1β and IL-18, two 
potent inflammatory cytokines.  The cytokines IL-1β and IL-18 are produced in response 
to TLR activation in the pro-form, and when activated by caspase cleavage, elicit an 
intense inflammatory response.  Therefore, the existence of two separate regulatory 
mechanisms provides an important safety mechanism to maintain control of their 
expression and release.  While this complex has only recently been discovered, it has 
been determined to play an important role in the detection of both endogenous and 
exogenous danger signals.  The NLR proteins act as both sensors and the molecular 
scaffold on which the rest of the complex is assembled (Martinon et al., 2009).   
 The NALP subfamily of NLR’s are comprised of 14 genes in humans and form 
the largest group of NLRs.  Three of these proteins, NALP1, NALP2, and NALP3 act as 
the central sensing and scaffold proteins for the caspase 1 inflammasome.  These proteins 
have an LRR region that functions to sense cytoplasmic pathogens, a NACHT region 
which is the central nucleotide domain essential for oligermerization of the complex, and 
an N-terminal pyrin domain (PYD) that bridges between the receptor and adaptor/effector 
proteins which also contain PYDs.  Although IPAF is evolutionarily distant from the 
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NALP subfamily, it also contains LRR and NACHT domains.  However, instead of 
having a PYD domain, it encodes a CARD domain in its N- terminal region which acts 
like PYD to link the receptor to other proteins containing a CARD region (Martinon et 
al., 2009).  
After activation, associated speck-like protein containing a caspase recruitment 
domain (ASC) complexes with the NLR and an inflammatory caspase, leading to the 
cleavage and activation of the associated caspase.  This activated caspase then cleaves the 
pro-IL-1β and pro-IL-18 present within the cytoplasm, facilitating their release from the 
cells (Martinon et al., 2009; Yamamoto et al., 2004).  Several NLR proteins are present 
within the cell allowing the production of many different types of inflammasomes.   
 The inflammasomes recognize a wide range of different danger signals, including 
various microbial products.  This is necessary because some microbes grow 
intracellularly or produce toxins which are injected into the cytoplasm.  Pathogens such 
as S. flexneri, S. typhimurium, P. aeruginosa and L. pneumophila all activate the IPAF-
caspase 1 inflammasome through factors secreted into the cytoplasm.  The NALP3 
inflammasome is known to be activated by bacterial pore-forming toxins like α toxin 
from S. aureus and listeriolysin O from L. monocytogenesis, and NALP 1 inflammasome 
is activated by anthrax toxin.  
 A number of different aspects of Y. pestis life cycle could trigger inflammasome 
activation.  It has been shown in Y. enterocolitica that the presence of the T3SS pore 
alone even in the absence of Yop expression triggers the activation of caspase 1, resulting 
in the cleavage and secretion of IL-1β.  However, in the presence of Yop effectors, 
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caspase 1 activation was inhibited resulting in a lack of cleavage or secretion of IL-1β 
(Shin and Cornelis, 2007).  Three types of Yop proteins have been implicated in this 
inhibition, YopE, YopT and YopJ.  In Y. enterocolitica YopE and YopT inhibit 
RhoGTPases, leading to a significant reduction in the activation of caspase 1, and 
resulting in the inhibition of IL-1β release (Schotte et al., 2004).  Conversely, in Y. pestis 
and Y. pseudotuberculosis YopJ seems to activate caspase 1 and promote apoptosis in 
macrophages (Bergsbaken and Cookson, 2007; Lilo et al., 2008).  However, in the case 
of Y. pestis, this effect was only seen in isolates of KIM5 strain, so this may be particular 
to this strain rather than an overall function of YopJ.  
  
1.7 Thesis Objectives 
 The long term objective of this thesis is to increase our understanding of how 
Gram-negative pathogens are able to evade the recognition of innate immune receptors 
by altering their LPS/lipid A profile.  I specifically wanted to examine how Y. pestis 
utilized this and other mechanisms to evade TLR4/MD2 activation in mammalian hosts 
by altering its lipid A profile at mammalian body temperature, and to determine if the 
absence of lpxL should be considered a major virulence determinant.  I also wanted to 
determine if the loss of the lpxL gene from Y. pseudotuberculosis formed a major 
evolutionary step in the development of Y. pestis into a distinct and highly virulent 
bacterium.  The experiments and data presented here were performed to determine how 
LPS/lipid A effect virulence of Gram-negative bacterial infections, and to determine if 
altering the lipid A profile during infection could change the course and outcome of any 
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disease condition.  The findings of this research have major and direct implications for 
our understanding of Gram-negative bacterial infections.  A greater appreciation of how 
bacteria evade the innate immune responses will allow us to design improved vaccines 
and treatments for these infections.  
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Figure 1.1
Reatz et al Annu. Rev. Biochem. 2007. 76:29.1–29.35
43
Figure 1.1 Schematic representation of the Gram-negative bacterial cell wall  
Representation of the inner and outer membranes of a Gram-negative cell wall.  
(Raetz et al., 2007) 
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Figure 1.2
Ohno N and Morrison DC (1989) Eur J Biochem 186 (3):629-36
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Figure 1.2 Chemical Structure of lipopolysaccharide 
Schematic representation of the structure of LPS, including lipid A, the core region, and 
the o-antigen outer portion of the molecule. (Ohno and Morrison, 1989) 
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Figure 1.3
a b
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Figure 1.3 Chemical structure of Lipid IVA and E. coli lipid A 
a) Structure of tetra acyl lipid A, also known as Lipid IVA, the precursor to lipid A in the 
E. coli biosynthesis pathway. 
b) Structure of classical E. coli lipid A 
48
Figure 1.4
Reatz et al Annu. Rev. Biochem. 2007. 76:29.1–29.35
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Figure 1.4 Lipid A biosynthesis pathway in E. coli 
The  biosynthesis pathway for E.coli K-12.  This general biosynthesis pathway varies 
between different bacterial species, including Y. pestis. (Raetz et al., 2007) 
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Figure 1.5
Carty et al JBC 1999. 274, 9677-9685
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Figure 1.5 Mechanism of LpxP 
LpxL is a cold shock induced enzyme in E. coli that at low temperatures acts in place of 
LpxL to add a secondary C:16 acyl chain to the Lipid IVA base molecule.  LpxM can then 
add the final secondary acyl chain to the molecule to produce hexa-acyl lipid A. (Carty et 
al., 1999) 
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Figure 1.6
Mogensen, TH  (2009) Clin Microbiol Rev 22(2) 240-273
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Figure 1.6 Toll-like Receptor 4 (TLR4) signaling pathway. 
A schematic of the TLR4 signaling pathway.  Not shown is MD2 interacting with the 
bound pathogen and TLR4.  Activation of TLR4/MD2 leads to the downstream activation 
of adaptor molecules, which in turn leads to activation of NF-κB, AP-1 and IRF3 
(Mogensen, 2009). 
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Figure 1.7
Park et al (2009) Nature 458 (7242) 1191-1195
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Figure 1.7 Crystal Structure of TLR4 complexed with MD2 and lipid A.  
The lipid A molecule is colored in red, with the core carbohydrates as pink.  The MD2 
molecules are gray, TLR4 is blue, TLR4* is green. 
a) Top view of the TLR4/MD2-lipid A complex. The primary and dimerization interface 
is shown. 
b) Side view of the TLR4/MD2-lipid A complex. 
(Park et al., 2009) 
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Table 1.1 Y. pestis lipid A species 
 
Lipid A species Number of 
Acyl chains 
Temperature 
expressed 
Activation Profile 
Mouse TLR4 Human TLR4 
Tetra-acyl 
 lipid A 
4 37°C/26 + - 
Penta-acyl  
lipid A 
5 26°C ++ + 
Hexa-acyl  
lipid A 
6 26°C +++ +++ 
 
Acylation profile of lipid A expressed by wild type Y. pestis at different temperatures, 
and how these species are able to activate either mouse or human TLR4. 
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CHAPTER 2 
VIRULENCE FACTORS OF YERSINIA PESTIS ARE OVERCOME BY A 
STRONG LIPOPOLYSACCHARIDE RESPONSE 
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Abstract 
Many Gram-negative pathogens produce a lipopolysaccharide (LPS)/lipid A with 
reduced ability to activate Toll-like receptor 4 (TLR4), but the role of this phenomenon in 
virulence has been unclear. Yersinia pestis, causative agent of plague, blunts TLR4-
signaling by altering its lipid A at 37°C. Here we show that the resulting evasion of 
immune triggering is required for virulence. When genetically modified to produce a 
highly stimulatory LPS at 37°C, normally lethal Y. pestis is rendered avirulent in wild 
type mice, but remains virulent in animals deficient in TLR4-signaling. Both adaptive 
and innate mechanisms contribute to sterilizing immunity against this modified strain, 
which also acts as an effective vaccine against plague. Escaping TLR4-activation by lipid 
A alteration may contribute to virulence of various Gram-negative bacteria.  
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Introduction 
Early recognition of invading bacteria by the innate immune system plays a 
crucial role in antibacterial defenses by triggering inflammatory responses that act to 
prevent the spread of infection and suppress bacterial growth. For many pathogens, early 
innate responses slow the progress of infection, buying time for adaptive immunity to 
develop. Pathogens with exceptional ability to evade or suppress innate responses may 
cause the death of the host before adaptive responses become effective. This is illustrated 
by the behavior of the Gram-negative pathogen Yersinia pestis, the causative agent of 
plague. In nature, Y. pestis depends primarily on the bite of infected fleas for transmission 
between mammalian hosts, causing bubonic plague (Perry and Fetherston, 1997). This 
requires the bacteria to establish a systemic infection distinguished by very high 
bacteremia -- exceeding 108 per ml of blood in some human plague patients -- following 
inoculation of a few bacteria in the skin via flea bite. Early foci of infection contain large 
numbers of bacteria and are often entirely devoid of inflammatory cells (Nakajima et al., 
1995; Sodeinde et al., 1992), despite the multiple and redundant mechanisms which 
normally trigger innate immunity. To suppress local inflammation, the pathogen employs 
several parallel approaches that are each necessary for virulence. These include a 
complex type III secretion system (T3SS) which delivers multiple effector proteins to the 
cytoplasm of host cells in contact with the bacteria, and the expression of Pla, an outer 
membrane protease with plasminogen activator activity (Cornelis, 2002; Perry and 
Fetherston, 1997; Sodeinde et al., 1992). The extracellular release of the T3SS-associated 
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protein LcrV has also been suggested to contribute to Yersinia-mediated immune 
suppression (Nakajima et al., 1995). 
Toll-like receptors (TLRs) are central to the host innate immune response against 
invading microbes (Akira and Takeda, 2004; Liew et al., 2005).  To achieve the profound 
suppression of inflammation observed in vivo, Y. pestis must either avoid inducing pro-
inflammatory responses via the TLRs or actively suppress the effects of such responses. 
Arguably, the combination of these two approaches has the greatest potential to be 
effective. Several of the T3SS effectors have activities that could serve to blunt the 
effects of TLR simulation, including derangement of intracellular signaling, induction of 
apoptosis, and interference with phagocytosis (Cornelis, 2002; Perry and Fetherston, 
1997; Sodeinde et al., 1992).  A key pathway inducing inflammation in response to 
Gram-negative bacteria is the activation of TLR4-signaling by lipopolysaccharide (LPS), 
a major component of the Gram-negative outer membrane (Hoshino et al., 1999; Lien et 
al., 2000; Poltorak et al., 1998; Raetz Cr, 2002).  Many types of LPS are extraordinarily 
potent, stimulating immune cells at picogram per milliliter concentrations. The immune-
activating moiety of LPS is lipid A, a di-glucosamine unit with covalently attached acyl 
chains, which interacts with the host LPS receptor complex consisting of TLR4 and MD-
2 to induce cellular responses (Hoshino et al., 1999; Lien et al., 2000; Poltorak et al., 
1998; Raetz Cr, 2002; Saitoh et al., 2004b; Shimazu et al., 1999). The GPI-anchored 
molecule CD14 binds LPS to the cell surface, transfers LPS to TLR4/MD-2 and enhances 
cellular activation (Wright, 1990; Miyake, 2004), whereas the TLR adapters MyD88, Mal 
62
(Tirap), TRIF and TRAM initiate the intracellular signaling cascade following interaction 
with the TIR domain of TLR4 (Akira and Takeda, 2004).  
Lipid A structure is conserved among Gram-negative bacteria, making it an 
archetypical example of a pathogen-associated molecular pattern; however, it is not 
invariant. For example, the number, location and composition of acyl chains varies 
among species, is influenced by the environment, and is often heterogeneous even within 
a single species (Dixon and Darveau, 2005; Raetz Cr, 2002; Zähringer et al., 1999).  
Based upon in vitro observations, it has been hypothesized that production of a weakly 
stimulatory LPS could play a role in virulence of several Gram-negative pathogens 
(Dixon and Darveau, 2005). Hexa-acylated lipid A structures are found in Y. pestis grown 
at 21°C to 27°C (flea temperatures), but are predominantly tetra-acylated at 37°C (host 
temperature) (Kawahara et al., 2002; Knirel et al., 2005b; Rebeil et al., 2004). While 
hexa-acylated LPS/lipid A is normally a strong activator of human cells, tetra-acylated 
lipids have lower stimulatory activity (Golenbock et al., 1991; Ingalls et al., 2000; 
Kawahara et al., 2002; Loppnow et al., 1989; Rebeil et al., 2004).  It has been suggested 
that the temperature-dependent remodeling of lipid A structure could be necessary for Y. 
pestis to achieve the high bacterial load in mammalian blood required for efficient flea 
infection prior to the induction of lethal shock.  It is also possible that Y. pestis may need 
to minimize TLR4 stimulation early in infection to prevent containment by local 
inflammation.  
Y. pestis provides an excellent model for testing the idea that LPS modification 
contributes to Gram-negative virulence via evasion of TLR4 signaling. In this report we 
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study a genetically modified strain of Y. pestis, that expresses a potent TLR4-activating 
hexa-acylated LPS at 37°C. We find that this strain is avirulent in wild-type mice, despite 
the presence of other well established virulence determinants. Hence, both active immune 
suppression and stealth are critical for evading anti-bacterial host responses during 
plague. This emphasizes the role of TLR4-mediated innate immunity in protection 
against life-threatening infections, and has broad implications for understanding bacterial 
virulence in Y. pestis and other organisms. 
 
Results 
37°C Y. pestis LPS inhibits TLR4 activation  
In contrast to bacteria grown at 26ºC, Y. pestis grown at 37ºC poorly activated 
TLR4 signaling, supporting the idea that 37ºC Y. pestis LPS has low stimulatory potential 
(Figure 2.1 a, b) (Kawahara et al., 2002; Rebeil et al., 2004). When grown at 26°C, heat-
killed Y. pestis KIM5, an attenuated strain deficient in iron acquisition, strongly activates 
HEK293 huTLR4/MD-2 cells to release IL-8 and to activate luciferase reporters 
dependent upon transcription factors NF-κB and IRF-3 (Figure 2.1a,b).  If the bacteria are 
grown at 37°C, this activation is not observed. Activation and nuclear translocation of 
these two transcription factors constitute two major branches of TLR4 signaling 
necessary for the induction of pro-inflammatory cytokines and type I interferons (Akira 
and Takeda, 2004; Liew et al., 2005). These data, together with the presence of poorly 
immune activating tetra-acylated Y. pestis lipid A structures at 37°C (Kawahara et al., 
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2002; Rebeil et al., 2004),  suggest that evasion of TLR4-signaling could represent a 
central mechanism by which Y. pestis avoids innate immune activation. 
 Since tetra-acylated LPS/lipid A may antagonize activity induced by potent 
endotoxin (Golenbock et al., 1991; Lien et al., 2000; Loppnow et al., 1989), we also 
analyzed the anti-inflammatory role of 37ºC Y. pestis LPS. LPS purified from Y. pestis 
KIM5 strain grown at 26ºC, but not 37ºC, activated human peripheral blood mononuclear 
cells (PBMC) (Figure 2.1c) and HEK293 huTLR4/MD-2 cells (Figure 2.1d). 
Furthermore, activation induced by 26ºC Y. pestis LPS and Escherichia coli LPS was 
inhibited by 37ºC Y. pestis LPS and by the synthetic tetra-acylated lipid IVA in human 
PBMC (Figure 2.1c). Stimulation of HEK293 huTLR4/MD-2 cells as measured by the 
release of interleukin (IL)-8 (Figure 2.1d) and activation of NF-κB and IRF-3 dependent 
reporters (Figure 2.1e,f) by the 26°C LPS was also inhibited by the 37°C preparation. 
These observations suggest that 37°C Y. pestis LPS has a general defect in activation of 
TLR4-signaling, potentially reflecting a failure to oligomerize the receptor complex 
(Miyake, 2004). We also observed repression of cytokine release in PBMC from 
cynomolgus macaques (Macaca fascicularis) (Figure 2.1g), a model organism for studies 
of plague in primates.  Bacteria may well contain a mixture of stimulatory and non-
stimulatory LPS species, especially during transition between flea and host temperatures, 
with the antagonistic activity of tetra-acylated LPS blunting the induction of primate 
immune signaling by the active LPS species. 
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Y. pestis expressing lpxL synthesizes a hexa-acylated potent LPS 
Mass spectroscopy studies (Kawahara et al., 2002; Knirel et al., 2005b; Rebeil et 
al., 2004) (Figure 2.2a) showed mainly tetra-acylated Y. pestis lipid A in Y. pestis grown 
at 37ºC (Figure 2.3a), with hexa-acylated structures present only at lower temperatures 
(Figure 2.2b, 2.3b).  LpxL (also called HtrB) and LpxM (MsbB) are late acyltransferases 
in E. coli and several other Gram-negative bacteria, adding the secondary acyl chains to 
the tetra-acylated precursor lipid IVA (Raetz Cr, 2002). LpxP, a third late E. coli 
acyltransferase, is active at low temperatures (Carty et al., 1999; Raetz Cr, 2002; 
Vorachek-Warren et al., 2002b). We could identify only two late acyltransferases, lpxP 
and lpxM, in the Y. pestis genome (Deng et al., 2002; Parkhill et al., 2001; Perry et al., 
1998). This suggests that the lack of LpxL together with the low temperature specificity 
of LpxP is responsible for the absence of hexa-acylated lipid A at 37ºC. 
We cloned lpxL from E. coli K12 and expressed the gene in Y. pestis KIM5 under 
control of its own promoter on the vector pBR322 (pMW::lpxL or pLpxL), generating the 
strain Y. pestis KIM5-pLpxL. Mass spectroscopy (Figure 2.2 c,d) showed that this strain 
contains novel hexa-acylated structures at both 37ºC and 26ºC (Figure 2.2c,d 2.3c), 
indicating that, as in E. coli, LpxL mediates addition of one 2’ secondary C12:0 acyl 
chain to lipid IVA. Presumably, a 3’ secondary C12:0 acyl moiety is added by the 
endogenous LpxM at both temperatures, suggesting that LpxM enzyme function is 
temperature-independent in Y. pestis. In contrast to results obtained with KIM5, both 
37ºC and 26ºC LPS from KIM5-pLpxL strongly activated HEK293 huTLR4/MD2 cells 
(Figure 2.3d), but not TLR2-expressing cells (Figure 2.3e). A similar observation was 
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made with human PBMC: only the KIM5 37ºC LPS showed profoundly reduced 
induction of TNF, IL-6, and IL-8 release (Figure 2.3f,g). Responses of human PBMC 
from several healthy volunteers (n=9) followed a similar pattern (not shown), as did 
PBMC from Cynomolgus macaques (Figure 2.3h), indicating that primates have very low 
ability to respond to native 37ºC Y. pestis LPS. Mouse cells have a higher capacity to 
respond to tetra-acylated lipid A than human cells, a phenomenon attributed to species 
differences in TLR4/MD-2 (Akashi et al., 2001; Hajjar et al., 2002; Lien et al., 2000; 
Poltorak et al., 2000). Indeed, mouse macrophages released limited amounts of TNF in a 
TLR4- and MD-2-dependent manner when exposed to the 37ºC LPS from KIM5, but this 
response was much weaker than observed with 37ºC LPS from KIM5-pLpxL or 26ºC 
LPS from either strain (Figure 2.3i,j,k). In summary, a major deficit in response to 37ºC 
Y. pestis LPS was common to cells from all species tested, and the expression of E. coli 
LpxL in Y. pestis resulted in the production of a novel hexa-acylated LPS at 37ºC, with 
strong ability to activate TLR4-signaling. 
 
Y. pestis harboring a potent LPS is unable to produce bubonic plague 
Mammals have multiple surveillance pathways that can trigger antibacterial 
responses.  On the other hand, Y. pestis has sophisticated active mechanisms for 
suppressing these responses, including a T3SS that intoxicates host cells in contact with 
the bacteria (Cornelis, 2002; Perry and Fetherston, 1997). To determine the significance 
of LPS stimulatory activity in this complex environment, we conducted infection 
experiments in mice. Many rodents are natural hosts for Y. pestis (Perry and Fetherston, 
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1997), and mice are a well established model for the study of plague. Fully virulent Y. 
pestis (KIM1001 strain (Sodeinde et al., 1992)) contains all known virulence factors, 
hence, we could evaluate the effect of a potent LPS in the context of all these other 
activities. KIM1001 produced 100% mortality in mice after subcutaneous (SC.) injection 
(a model in which the resulting disease is similar to bubonic plague) of 1,000 colony 
forming units (CFU) (Figure 2.4a), while infection with 100 CFU resulted in 80% 
mortality. In a striking contrast, the same doses of KIM1001 expressing lpxL (KIM1001-
pLpxL) did not cause disease (Figure 2.4a). The effect of LpxL is profound: at doses of 
up to of 107 CFU, approximately 106 mean lethal doses for the KIM1001 parent strain, no 
mortality or apparent signs of illness were detected (Table 2.1). Limited swelling at the 
infection site could be observed at the higher dose of KIM1001-pLpxL bacteria. The 
phenotype of KIM1001-pLpxL was not confined to the C57Bl/6 mouse strain, as four out 
of four 129Sv mice died when infected with 1,000 CFU of  KIM1001, whereas four out 
of four 129Sv animals survived infection with KIM1001-pLpxL. 
Although the mouse TLR4/MD-2 system has a limited but significant response to 
tetra-acylated LPS/lipid A (Fig 2.3i) (Akashi et al., 2001; Hajjar et al., 2002; Lien et al., 
2000; Poltorak et al., 2000), the resulting innate immune signaling is apparently 
insufficient to protect infected mice. Our data suggest that the development of systemic 
disease following infection at peripheral sites – as occurs in bubonic plague -- is 
dependent on the production of LPS with reduced TLR4/MD-2 stimulating activity.  
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Y. pestis-pLpxL retains key virulence determinants 
 We wanted to ensure that the presence of the pLpxL plasmid did not alter key 
features of the bacteria, so a number of experiments were done to examine this question. 
These experiments indicated that other Y. pestis virulence determinants were not affected 
by pLpxL. The presence of pLpxL had minimal effect on bacterial growth rate (Figure 
2.5a), the T3SS remained fully functional, as exemplified by normal secretion of the 
central T3SS virulence factor YopM (Figure 2.5b), retention of Ca2+-dependent growth at 
37ºC, and retained T3SS – dependent cytotoxicity towards HeLa cells (data not shown).  
Furthermore, resistance to polymixin B, and serum-dependent bacterial killing was 
preserved (Figure 2.5 c,d), the activity of the Pla protease remained normal (Figure 2.5e), 
and the presence of the plasmid vector by itself had no effect on virulence (Figure 2.5f). 
We also determined that pLpxL was stable in the absence of selection (no plasmids 
segregants detected among 1000 colonies after 40 generations of growth in liquid 
culture), and that native Y. pestis plasmids were retained in the presence of pLpxL. 
Bacteria obtained from spleens of mice infected IV with KIM1001-pLpxL all remained 
ampicillin resistant following patching of 100 colonies.  LpxC is the second enzyme in 
the lipid A biosythesis pathway and is critical for the formation of lipid A (Raetz Cr, 
2007).  It has been reported that an LpxC inhibitor, CHIR-090, is a potent antibiotic, 
because it inhibits the formation of lipid A, which is essential for outer membrane 
development and survival (Barb et al., 2007a; Barb et al., 2007b; McClerren Al, 2005).  
CHIR-090 binds tightly to the active site of LpxC, therefore not allowing the binding of 
the natural substrate and stopping the formation of the base lipid A molecule.  We tested 
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CHIR-090 against both KIM5 and KIM5-pLpxL, and found that both strains have a 
similar level of susceptibility to CHIR-090, and that this compound is also a potent 
antimicrobial agent to Y. pestis (Figure 2.5g) 
 
Protection from plague induced by Y. pestis pLpxL is dependent on TLR4 signaling 
A critical experiment in testing this hypothesis is verification that resistance to 
KIM1001-pLpxL is dependent on functional TLR4-signaling. Accordingly, we infected 
wild type and TLR4-/- mice with KIM1001 or KIM1001-pLpxL SC. at a dose of 1,000 
CFU.  Both mouse strains succumbed to infection with KIM1001, while only TLR4-/- 
animals died when infected with KIM1001-pLpxL (Figure 2.4b). It should be noted that 
the progression of disease (median time to death, Figure 2.4b), bacterial growth in 
vivo/systemic dissemination of disease as reflected by bacterial titers in the spleen (Figure 
2.5h) and the development of symptoms (activity, posture, appearance of buboes) were 
comparable in TLR4-/- mice infected with either KIM1001 or KIM1001-pLpxL. This 
demonstrates that in the absence of TLR4, KIM1001-pLpxL remains fully virulent. This 
is consistent with other evidence suggesting that this strain retains all other virulence 
factors found in KIM1001 except for the ability to produce primarily tetra-acylated LPS.  
In contrast to the experiments shown in Figure 2.4b, three out of three TLR4-/- 
animals survived SC infection with 105 CFU of a Y. pestis KIM1001 based strain 
defective for the surface protease known as Pla, a strain that does not cause systemic 
infection by SC route (Sodeinde et al., 1992).  The containment of this strain is also 
dependent on a substantial inflammatory reaction, although the mechanism by which Pla 
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suppresses this response is not known. This result suggests that TLR4 deficiency does not 
grossly compromise innate responses to Y. pestis in general, and that loss of Pla and 
production of stimulatory LPS, while both permitting effective innate responses, do so 
via distinct pathways.  
MD-2, a small molecule attached in a non-covalent manner to the extracellular 
portion of TLR4, is a critical component of the LPS receptor complex (Shimazu, 1999; 
Schromm, 2001; Nagai, 2002; Miyake, 2004).  The phenotype of animals deficient in 
MD-2 and infected with KIM1001-pLpxL should therefore resemble the one observed in 
TLR4-/- mice. When animals deficient in MD-2 were infected with 1,000 CFU of 
KIM1001 or KIM1001-pLpxL, all of the animals in both groups died (Figure 2.4c).  
Hence, the protection from disease induced by KIM1001-pLpxL requires both TLR4 and 
MD-2.  
Foci of infection containing virulent Y. pestis are often devoid of inflammatory 
cells, reflecting the ability of this pathogen to evade immune responses (Nakajima et al., 
1995; Sodeinde et al., 1992).  Intravenous (IV) infection is a useful model for examining 
inflammation in tissues remote from injection site trauma. When mice are infected IV 
with KIM1001-pLpxL, an enhanced anti-bacterial response was revealed by extended 
survival time (Figure 2.4d) and a 100-fold reduction (p=0.008) in spleen bacterial titers 
(Figure 2.4e).  Despite lower bacterial load, KIM1001-pLpxL infected animals had two-
fold more TNF in spleen homogenates compared to mice infected with KIM1001 (Figure 
2.4f).  Livers of mice infected with wild type Y. pestis were characterized by masses of 
free bacteria, without distinct indications of local inflammation (Figure 2.4g). In contrast, 
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KIM1001-pLpxL provoked microabcess formation in livers from wild type mice, but not 
in TLR4-/- animals (Figure 2.4g).  Liver tissue was normal in animals receiving 1,000 
CFU of KIM1001-pLpxL SC (Figure 2.4g), and no bacteria were detected in spleens 
(Figure 2.4e).  This indicates that SC. administration of KIM1001-pLpxL fails to 
establish systemic infection, presumably due to containment by effective local immunity 
at the infection site.  
 
Impact of TLR adapters and CD14 on LPS-mediated protection from plague 
Four TIR-containing adapter molecules, MyD88, Mal (also called Tirap), TRIF, 
and TRAM, participate in mediating cellular responses following exposure to LPS (Akira 
and Takeda, 2004).  The adapters have different roles in inducing TLR4-dependent 
responses; the MyD88/Mal branch of TLR4 signaling leads to the early activation of NF-
κB and the release of a number of pro-inflammatory mediators, such as TNF and IL-6 
(Akira and Takeda, 2004). In the MyD88-independent pathway, TRAM/TRIF mediate 
activation of IRF-3 and the release of type I IFN and IFN- regulated genes such as 
Rantes, as well as late activation of NF-κB (Akira and Takeda, 2004).  Few studies have 
addressed the relative contribution of the adapters in protection against Gram-negative 
pathogens. When we infected MyD88, Mal, TRIF and TRAM-deficient mice SC. with 
1,000 CFU of KIM1001-pLpxL, MyD88-/- mice were the only animals that displayed 
100% mortality Figure 2.6a).  Forty percent of Mal-/- mice survived, whereas 80% of 
TRIF or TRAM mice survived (Figure 2.6a). TLR2-/- mice behaved as wild type mice 
following infection with KIM1001-pLpxL (Figure 2.6a). This result suggests that 
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MyD88-dependent anti-bacterial responses are essential for the TLR4-mediated 
protection against plague. Mal also has a significant role; whereas TRAM and TRIF 
mediated signaling is less important.  
Most members of the family Enterobacteriaceae synthesize a smooth chemotype 
of LPS, that consist of lipid A, an oligosaccharide core, and an O-specific polysaccharide 
containing 20-40 repeats of a defined unit (Raetz Cr, 2002). In contrast, Y. pestis 
generates a rough LPS (Skurnik and Bengoechea, 2003), with a core comprising of 5-8 
saccharides but lacking an O-polysaccharide (Knirel et al., 2005a; Vinogradov et al., 
2002). CD14, which exists as both a GPI-anchored and soluble protein, has been shown 
to enhance responses to LPS, but is not absolutely necessary for LPS signaling via 
TLR4/MD-2. Recent studies have questioned the role of CD14 in responses leading to 
immune activation by rough chemotypes of LPS (Huber M, 2006; Jiang Z, 2005). In 
particular, CD14 was suggested to be dispensable for TNF release and MyD88-dependent 
rough LPS responses (Jiang Z, 2005). However, these conclusions were based upon 
experiments that utilized a deep rough Re mutant form of purified LPS (only containing 
lipid A plus two KDO saccharide moieties), which is not naturally found in pathogenic 
bacteria.  
Similar to its parent strain, Y. pestis -pLpxL produce a rough LPS (Figure 2.6b). 
We were interested in determining if CD14 has any effect on the protection from lethal 
infection provided by the LpxL strain. Macrophages from CD14-/- animals were 
defective in their ability to respond to rough Y. pestis-pLpxL 37ºC LPS, measured by the 
release of both TNF and Rantes (Figure 2.6c). Subsequently, we inoculated CD14-/- mice 
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SC. with 1,000 CFU of KIM1001-pLpxL to determine the role of CD14 in the protection 
against infection mediated by rough LPS. Six of nine CD14-/- animals infected with 
KIM1001-pLpxL died following infection; indicating a shift in LD50 of more than 4 
orders of magnitude compared to wild type mice (Figure 2.6d). Our results support the 
idea that CD14 has a function in transferring many types of rough LPS to TLR4/MD-2 to 
amplify release of TNF and Rantes and anti-bacterial responses.  
  
Bacteria with increased TLR-activating ability as vaccine strains 
Activation of TLR signaling leads to strong induction of adaptive immune 
responses, mediated in part by a strong upregulation of co-stimulatory molecules on 
antigen-presenting cells (Akira and Takeda, 2004). In fact, many TLR ligands are 
promising constituents of vaccines, serving as adjuvants (van Duin et al., 2006). Bacterial 
strains containing increased TLR stimulation capabilities could, through their increased 
content of adjuvant activity, provide elevated activation of adaptive immunity and have 
useful properties as vaccine strains. A problem in the development of new vaccines 
against Y. pestis has been to provide protection against both pneumonic and bubonic 
disease. Effective humoral and cellular immunity are both thought to be necessary for 
optimal protection (Parent et al., 2005). We hypothesized that the attenuated Y. pestis 
strain producing potent LPS might be effective as a vaccine against plague. Mice were 
vaccinated with a single SC. dose (1,000 or 100,000 CFU) of KIM1001-pLpxL. Thirty to 
forty days later, both vaccinated and naïve mice were challenged with virulent KIM1001 
at SC doses between 1,000 and 1,000,000 CFU (the latter corresponding to 
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approximately 105 x LD50), or at intranasal (IN) administration, mimicking pneumonic 
disease, of 5,000 or 50,000 CFU (the latter approximately 150 x LD50). All mice 
vaccinated with KIM1001-pLpxL survived while all naïve mice died (Figure 2.7a,b, 
Table 2.2, Table 2.3), demonstrating that Y. pestis producing potent LPS is an effective 
vaccine against both bubonic and pneumonic plague. Thus, our experiments provide a 
proof of principle for the generation of attenuated strains of microorganisms with 
enhanced TLR-activating potential as a strategy for vaccine production. 
 
Contributions by adaptive immunity to LPS-mediated protection against plague 
We have demonstrated that strong innate immune activation is essential to survive 
acute infection with Y. pestis synthesizing a potent LPS. However, this does not imply 
that innate responses are sufficient to produce sterilizing immunity. To determine if 
adaptive responses were also required for protection, we infected Rag1-/- animals, 
lacking B and T cells and thus adaptive immunity, with KIM1001-pLpxL. While infected 
TLR4-/- animals all died of acute disease within six days, the Rag1-/- animals remained 
healthy until day 9, when the first animal appeared sick. All Rag1-/- animals died within 
the next few days (Figure 2.8). This implies that innate immunity contains the infection 
until adaptive responses sufficient for sterilization develop. We conclude that even in the 
face of a potent TLR4-mediated innate immunity, adaptive responses are required to fully 
clear infection by the Y. pestis -pLpxL strain, and are crucial for the long-term survival of 
the host.  
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Discussion 
Our results emphasize the double-edged nature of the sensitive TLR4-dependent 
LPS detection system. Injection of high amounts of purified LPS into humans and 
research animals induces a well established syndrome called endotoxic shock. As a result, 
potent endotoxin is often thought of as harmful during Gram-negative infections. Our 
report propose that the expression of a potent LPS by some pathogens may in fact be 
beneficial for the host, providing early recognition of infection and effective onset of 
immune signaling. Subversion of TLR4-mediated immune responses by lipid A 
modification may be a central strategy for various Gram-negative pathogens to evade 
anti-bacterial mechanisms. 
The general picture that emerges from our current understanding of Y. pestis 
virulence is that successful systemic infection is dependent on efficient and simultaneous 
suppression and/or evasion of multiple pathways ordinarily capable of eliciting protective 
local inflammatory responses. Our results establish that evading stimulation of TLR4 is 
an essential part of this strategy. This implies that the strong capacity to induce TLR4-
signaling of Y. pestis-pLpxL is dominant over the anti-host bacterial defenses provided 
by T3SS and other bacterial activities. Our findings also highlight the remarkable 
efficiency of TLR4-mediated responses in the control of Gram-negative infections.  
Despite retention of the active means used by Y. pestis to suppress host responses, a strain 
producing hexa-acylated LPS and thus quickly detectable via TLR4/MD-2 fails to cause 
disease even when the subcutaneous inoculum exceeds 106 mean lethal doses. This 
implies strong selection against TLR4 recognition, and suggests that adaptations to 
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prevent this stimulation should be common among pathogens. Several other Gram-
negative pathogens have been shown to synthesize lipid A with weak stimulatory 
activity, associated with differences in number and composition of acyl chains (Dixon 
and Darveau, 2005; Zähringer et al., 1999). To our knowledge, this is the first report to 
establish the significance of the synthesis of such modified lipid A forms for 
pathogenesis. It is also notable that Y. pestis LPS has reduced stimulatory activity for 
both murine and primate systems, reflecting the broad host range of this pathogen. 
Although we did not detect measurable stimulation in the primate system, murine cells 
showed a limited but significant response. However, these responses were clearly not 
sufficient to protect mice during infection.  
The production of a weakly stimulatory LPS is not the only mechanism needed by 
Y. pestis to escape destruction or containment by local inflammation. For example, key 
proteins injected into host cells via T3SS and which act to block proinflammatory 
signaling, along with, in most Y. pestis strains, Pla protease activity, are also required 
(Cornelis, 2002; Perry and Fetherston, 1997; Sodeinde et al., 1992). Another potentially 
important activity is the antagonism of TLR4 stimulation by native Y. pestis LPS 
demonstrated above (Figure 2.1).  Membranes may contain a mixture of stimulatory and 
non-stimulatory LPS species, especially immediately following the flea bite. In primates, 
and potentially other species, this antagonistic activity could ensure that membranes 
containing multiple LPS species become inert with respect to TLR4 stimulation as soon 
as the tetra-acylated LPS species achieves sufficient concentration in the host.  
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Our findings also have potential implications for the development of therapeutics 
and vaccines. The strong TLR4-mediated protection against Y. pestis producing potent 
LPS suggests that the development of anti-infectives based on stimulation of innate 
immunity, now in its infancy, has significant promise (Agrawal and Kandimalla, 2003; 
Ulevitch, 2004).  However, incorporation of adjuvant activity into pathogens by LPS 
modification or other means may also be effectively applied as a novel principle for 
development of vaccines against some infections. The protection we observe is due to the 
incorporation of adjuvant activity into the bacteria, ensuring that its activity is focused 
precisely where needed. Such modifications may strongly attenuate virulence and 
stimulate immune responses, both desirable characteristics for vaccine strains. 
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Materials and methods: 
Bacterial strains and growth conditions:  
The lpxL gene from E. coli K12, including 435 bp upstream and 140 bp downstream of 
coding region, was cloned using Pfu Ultra polymerase (Stratagene) and ligated into the 
BamHI and SalI sites of pBR322, creating pMW::lpxL (or pLpxL). The control plasmid 
pBR322Δtet was constructed by digesting empty pBR322 with Nae1 and EcoRV and 
then ligating the plasmid to remove the major part of the tetracycline resistant gene. The 
resulting plasmids were electroporated into Yersinia pestis strain KIM5(Goguen et al., 
1984) or KIM1001(Sodeinde et al., 1992) and selected by growth on tryptose-beef extract 
(TB) agar supplemented with 0.25 mM CaCl2 and 0.6 mg/mL glucose in the presence of 
100 µg/ml ampicillin.  All strains containing either pBR322Δtet or pMW::lpxL remained 
tetracycline sensitive. KIM1001 (pPCP1+, pCD1+, pMT1+) is highly virulent (Sodeinde 
et al., 1992), while the KIM derivative KIM5 bears a chromosomal deletion designated 
Δpgm, which strongly attenuates virulence.  KIM5 was used to limit risk of infection in in 
vitro studies where a virulent strain was not required, and the pgm locus contains no 
genes thought to impact LPS biosynthesis  
For growth analyses, the overnight cultures were diluted into 25 ml of TB broth with 
CaCl2 to an OD600 of ~0.15. Growth of the cultures was monitored every 2 hours at 
OD600. For the generation of heat killed bacteria, cultures were resuspended in PBS and 
incubated at 60°C for 1 hr. 
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Antimicrobial assays 
Polymixin B  was obtained from Sigma-Aldrich. CHIR-090 was a generous gift from Dr 
CRH Raetz (Duke University). Overnight cultures of KIM5 and KIM5-pLpxL were 
swabbed on to TB agar plate as described. Antimicrobial agents  were then spotted on 
7mm filter paper disks (Blotting paper 703 VWR International), and growth was 
monitored and the diameter of diffusion was measured after 2 days.  All experiments 
were done in triplicate.  
 
Serum sensitivity assay 
Y. pestis KIM5 and KIM5-pLpxL was diluted to a concentration of 2x104 CFU/mL. Of 
this dilution, 150 μL of bacterial culture was added to 150 μL of human serum, to make 
the final concentration of serum 50%. The bacteria and serum were incubated at 37°C for 
1 hour, with 25 μL taken in duplicate at time 0, 30 minutes and 60 minutes and plated on 
TB agar. The plates were incubated for 48 hours at 37°C and CFU was determined by 
counting colonies per plate.  
 
Lipid preparations:  
Pyrogen-free reagents and supplies were used to the greatest extent possible in the lipid 
preparations. Bacteria were harvested by centrifugation at 6,000 x g. LPS was purified 
from bacteria by hot water-phenol extraction (Westphal et al., 1952), followed by two 
phenol re-extractions to remove contaminating lipoproteins and TLR2-activity 
(Hirschfeld et al., 2000).  The chemical synthesis of the tetra-acylated precursor lipid 
IVA (also called 406, LA-14-PP or precursor Ia) has been reported (Liu et al., 1999).  
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LPS from E. coli O111:B4 (Sigma) was phenol re-extracted as indicated above. The 
absence of activation of TLR2-expressing cells (Fig. 2e), in spite of potent IL-8 release 
by bacterial Pam3CysSK4 lipopeptide (not shown), indicates the absence of 
contaminating lipoproteins in our highly purified LPS preparations. 
 
Lipid A preparation and mass spectroscopy 
Pyrogen-free reagents and supplies were used to the greatest extent possible in the lipid 
preparations. Bacteria were harvested by centrifugation at 6,000 x g. Lipid A was directly 
isolated from whole bacterial cells using the Bligh-Dyer two-phase chloroform-methanol-
water organic extraction (Vorachek-Warren et al., 2002b). Samples were subsequently 
analyzed by MALDI-TOF MS using a Kratos (Manchester, UK) AXIMA CFR high 
performance mass spectrometer operated in both positive and negative ion modes. 
 
Cell Stimulation Assays: 
Human PBMC were obtained from healthy volunteers with informed consent, and 
isolated by centrifugation on Lymphoprep density media (Axis-Shield/Nycomed, Oslo, 
Norway). The UMass Institutional Review Board approved the human subject protocol. 
HEK293 cells stably expressing human TLR4-YFP and retroviral MD-2, or human 
TLR2-YFP, or empty vector pcDNA3 were as published (Latz et al., 2002). NF-B-
luciferase (provided by K. Fitzgerald) and IRF-3-dependent 561-luciferase (a gift from G. 
Sen (Bandyopadhyay et al., 1995)) reporters were transfected into 293-huTLR4/MD-2 
cells using Genejuice (Novagen). PBMC were cultured in X-vivo 15 medium (Cambrex) 
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containing ciprofloxacin and 1% FCS or 1% human serum, whereas 293 cells were 
stimulated in DMEM/ciprofloxacin plus 10% FCS. Wild type C57Bl/6 or Rag1-/- mice 
(backcrossed 10 generations into C57Bl/6) were from Jackson Laboratories (Bar Harbor, 
ME). TLR4-/-, MyD88-/-, Mal-/-, TRIF-/-, TRAM-/- and TLR2-/- animals were 
generated as described(Adachi et al., 1998; Hoshino et al., 1999; Takeuchi et al., 1999; 
Yamamoto et al., 2003a; Yamamoto et al., 2002; Yamamoto et al., 2003b), and backbred 
11 (TLR4, TLR2, MyD88), 4 (Mal) or 5 (TRIF, TRAM) generations into C57Bl/6. MD-
2-/- animals(Nagai et al., 2002) (source: Dr. Miyake and Japan Science and Technology 
Corporation) and CD14-/- animals (Moore et al., 2000), a gift from K. Moore and M. 
Freeman, were backcrossed 7 and 10 generations into C57Bl/6, respectively. Mouse 
peritoneal macrophages were harvested from wild type C57Bl/6 or TLR4-/- mice 3 days 
after injection of 2 ml thioglycollate (3%) and cultured in RPMI 1640 medium containing 
10% FCS. Cells were plated at a density of 2x104 cells/well (293 cells) 5x104 cells/well 
(mouse macrophages) or 1x105 cells/well (PBMC) in 96-well dishes, and stimulated 16-
18 hrs before harvesting supernatant (for cytokine analysis) or cells for lysis 
(transfections and reporter assays, using reagents from Promega).  Cytokines were 
measured using ELISA kits from BD Pharmingen (moTNFα, moRantes) or R&D systems 
(huTNFα, IL-6, IL-8). Cell lysates from luciferase reporter assays were analyzed by the 
addition of luciferase substrate followed by luminometry. Results are shown as one 
representative out of three to eight experiments, as mean of triplicates (transfection 
assays) or triplicates/duplicates (cytokine assays) +/- standard deviation (s.d.). 
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Stimulation of non-human primate cells 
Cynomolgous macaque PBMC, purified by centrifugation of whole blood in CPT/sodium 
citrate tubes (Becton Dickinson), were obtained from Bioreclamation, Inc (Hicksville, 
NY). The PBMC were cultured in RPMI 1640 medium containing 10% FCS. Cells were 
plated at a density of 1x105 cells/well in 96-well dishes, and stimulated 16-18 hrs before 
harvesting supernatant. Cell stimulation was analyzed by the release of IL-8, using an 
ELISA kit from R&D systems (huIL-8 Duoset). Results are shown as mean of triplicates 
+/- standard deviation (s.d.). 
 
In vivo infections: 
Mice were infected with Y. pestis KIM1001, KIM1001-pLpxL or KIM1001-pBR322Δtet, 
either by SC. injection of 50 μl on the nape of the neck, IN infection with 50 μl dropped 
in the nostrils under ketamine/xylasine anesthesia, or IV injection of 500 μl in the tail 
vein. Inocula contained the indicated CFU suspended in PBS. Mice were euthanized by 
IP pentobarbital overdose when moribund. Survival was monitored up to 21 or 28 days, 
every 12 hrs during acute infection. For collection of organs, mice were sacrificed 48 hrs 
following IV infection or 72 hrs following SC. infection by pentobarbital overdose, 
spleens were homogenized in PBS to obtain bacterial titers and for cytokine analysis. 
Separate infection experiments with detection limits of 103 or 101 CFU per spleen 
showed similar results, with the absence of detectable bacteria in spleens following SC. 
infection with KIM1001-pLpxL. Livers were fixed in neutral buffered 4% formalin, 
followed by standard hematoxylin/eosin (H&E) staining and microscopy (100x 
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magnification). Inserts (KIM1001 and KIM1001-pLpxL IV) are at 1,000x magnification. 
A Nikon Eclipse E400 instrument and 10x or 100x-oil objectives were used. Images were 
captured with a Spot camera and corresponding software (Diagnostic instruments). All 
animal studies were approved by the UMass Institutional Animal Care and Use 
Committee, and the experiments followed their guidelines and regulations.  
 
YopM secretion analysis. 
KIM5 and KIM5-pLpxL were grown overnight at 26°C in TB medium without CaCl2. 
The cultures were then diluted 1:50 in BHI media (Difco) and grown at 26°C to an 
OD600 of 0.2. The cultures were then shifted to 37°C and allowed to grow for another 2 
hours both in the presence and absence of CaCl2. The bacteria were spun down at 12,000 
rpm and the supernatant was collected. YopM in the supernatant was precipitated with 
20% trichloroacetic acid and resuspended in SDS-PAGE buffer. The samples were run on 
an SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was 
blocked in 5% skim milk, then incubated with a YopM antibody (a gift from Susan 
Straley) in PBS/1% Tween 20 for 2 hrs. The membrane was then washed in PBS/tween 
and incubated with anti-mouse IgG peroxidase-conjugated secondary antibody (GE 
Healthcare) for 2 hours, washed in PBS/1% Tween 20, and the protein was detected using 
West Pico Chemiluminescent substrate (Pierce).  
 
Plasminogen activation assay 
KIM1001, KIM1001-pLpxL and a KIM1001 mutant in Pla(Sodeinde et al., 1992) were 
grown at 37°C on TB agar plates supplemented with 0.25mM CaCl2 and 100mg/ml 
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ampicillin if needed for selection. Conversion of plasminogen to plasmin was performed 
as described (Sodeinde et al., 1992). Briefly, bacteria were scraped off the plates and 
resuspended in 0.1M Tris/0.1%Tween. Each reaction was performed in a duplicate, and 
contained 5 μL of bacterial solution, 10 μL of the chromogenic plasmin substrate  S2251 
(Val-Leu-Lys-p-nitroanalide) at a concentration of 4mM, 10 μL of 160nM human 
plasminogen and 80 μL Tris/tween buffer. The reaction was monitored for 1 hour with 
readings taken at OD405. 
 
Statistical analysis 
Differences in spleen CFU and TNF concentrations were analyzed by Mann-Whitney U-
test. Statistical differences in survival were studied by Kaplan-Meyer survival analysis 
and the log rank test. 
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Figure 2.1 Y. pestis 37ºC LPS contains inhibitory activity.  
Y. pestis grown at 37 ºC is a poor stimulator of TLR4 signaling  
a) HEK293 cells stably expressing TLR4/MD2 or empty vector (pcDNA3) 
were exposed to media alone (black bars), or heat killed Y. pestis KIM5 grown at  
26 °C (vector temperature, light gray bars) or 37 °C (host temperature, dark grey 
bars) at a density of 10 bacteria per ml. Supernatants were analyzed for IL-8. 
b) HEK293 TLR4/MD-2 cells were transiently transfected with NF-κB- or IRF-3  
dependent 561-luciferase reporter constructs and then stimulated with heat- 
killed Y. pestis grown at 37 °C or 26 °C. Results are given as fold reporter  
induction above cells exposed to media alone. c) Human PBMC were treated with 10 or 
100 ng/mL of Y. pestis 37°C LPS or synthetic tetra-acyl lipid IVA, followed by the 
addition of Y. pestis 26°C LPS or E. coli LPS (10 ng/ml) and incubated for 16 hrs. d) 
HEK 293 cells expressing human TLR4/MD2 were exposed to Y. pestis 37°C LPS (100 
and 10 ng/ml), followed by addition of 26°C Y. pestis LPS (10 ng/ml). Cells were 
incubated for 16 hrs. To study influence on transcription factor activation, HEK293 
huTLR4/MD-2 cells were transiently transfected with e) NF-κB- or f) IRF-3 dependent 
561 promoter-luciferase reporters, treated with Y. pestis 37ºC and/or 26ºC LPS, and 
incubated for 18 hrs. Lipid concentrations are given in ng/ml. g) Y. pestis KIM5 37 ºC 
LPS or synthetic tetra-acylated lipid IV was added to PBMC from Cynomolgus macaque, 
followed by addition of KIM5 26 ºC LPS. Cells were incubated for 18 hours and 
supernatants were analyzed by human IL-8 ELISA. Results indicate that tetra-acylated 
lipid A /LPS species do not activate non-human primate cells, and can inhibit non-human 
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primate cellular activation by more potent lipid A species in a similar fashion as human 
cells. The LD50 for this primate is approximately 400 CFU by inhalation (Dr. J. 
Adamovicz, USAMRIID, personal communication, used with permission). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88
OHO
O
OO
HN
O
O
O
O
HO
O
PHO
O
OH
Figure 2.2
a:
OHO
HN
O
O
O
OHO
HO
OO
HN
O
O
OHO
HO
O
HO
P OH
O
OH
PO
O
OH
O
NH2
HO
OH
HN
O
O
OHO
HO
HO
HO P OH
OH
C14
C14 C14
C14
148
C14
C14 C14
C14
OHO
O
OO
HN
O
O
O
HO
PHO
O
OHOHO
O
OO
HN
O
O
O
O
HO
PHO
O
OH
6.1
b:
OHO
HNO
O
O
OHO
HO
OO
HN
O
O
OO
O
O
HO
P OH
O
OH
PO
O
OH
O
O
O
NH2
HO
OH
HN
O
O
OHO
HO
OO
O P OH
O
OH
O
O
C14
C14 C14
C14
C12
C16:1
HN
O
O
OHO
HO
HO
HO P OH
O
OH
C14
C14 C14
C14
OHO
OO
HN
O
O
O
HO
PO
O
OH
O
NH2
HO
OH
Ara
Ara
C14
C14 C14
C14
C12
C16:1
HN
O
O
O
OHO
HO
OHO
HO P OH
O
OH
C14
C14 C14
C14
*
89
OHO
HN
O
O
OO
HN
O
O
OO
O
HO
O
PHO
O
OH
O
NH2
HO
c:
C14
C14
C14
C14
C12
OOHO
HO
O P OH
OH
O
O
C12
C14
OHO
HN
O
O
O
OHO
HO
OO
HN
O
O
OO
O
O
HO
P OH
O
OH
PO
O
OH
O
O
OH
Ara
*
C14
C14
C14
C12
C12
OHO
OO
HN
O
O
O
HO
PHO
O
OH
O
O
NH2
HO
d:
OHO
HN
O
O
O
OHO
HO
OO
HN
O
O
OHO
HO
O
HO
P OH
O
OH
PHO
O
OH C14
C14
C14
C14
C12
HN
O
O
O
O
HO
HO
OO
O P OH
O
OH
O
O
C12
C14
C14C12
OHO
HN
O
O
O
OHO
HO
OO
HN
O
O
OO
O
O
HO
P OH
O
OH
PO
OH
O
O
OH
Ara
C14
C14 C14
C14
C14
C14
C12
90
Figure 2.2 Mass spectrometry analysis of lipid A from Y. pestis 
Wild type Y. pestis KIM5 was grown at 26 ºC and 37 ºC and the lipid A was purified 
from the whole bacteria by Bligh-Dyer two-phase organic extraction. The lipid was then 
purified over a DE52 column and analyzed by MALDI-TOF mass spectrometry. The 
negative ion spectra shown here are representative of multiple extractions. Analysis of 
the positive ion spectra (not shown) was also done to determine the location of the 
arabinose at the reducing end of the molecule.  a) When the bacteria is grown at 37 ºC, 
they produce predominantly tetra-acyl lipid A. Structural analysis was also carried out for 
the lipid A from Y. pestis KIM5-pLpxL expressing the acyltransferase LpxL from E. coli.  
b) At 26 ºC, the bacteria express at least three different species of lipid A: tetra-acyl lipid 
A with four C14:0 acyl groups (m/z 1405), a penta-acyl lipid A that has an additional 
secondary C12:0 acyl chain (m/z 1587), and a hexa-acyl lipid A with additional C12:0 
and C16:1 secondary acyl chains (m/z 1824). An additional species  
(m/z 1179) corresponds to a tri-acyl lipid A that may also be a fragment ion resulting 
from the loss of an acyl-linked C14:0 group from the tetra-acyl lipid A. In addition, peaks 
for all four of these species with the addition of an 4-amino-4-deoxy-L-arabinose (L-
Ara4N) moiety are also observed (m/z 1310, 1537, 1720 and 1955).  c) At 37 ºC the lipid 
A revealed the presence of a novel  hexa-acyl species (m/z 1769), 
which has a 12:0 acyl chain at the 2’ secondary position rather than a 16:1 acyl chain. 
The addition of L-Ara4N was also observed (m/z 1900).  d) At 26 ºC the mass spectra 
were similar, predominantly the hexa-acyl species (m/z 1769) and some penta-acyl lipid 
A (m/z 1587)  and a small amount of tetra-acyl lipid A (m/z 1405). The peaks at m/z 
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1349, 1363 and 1377 (observed more weakly in the other spectra) may not represent 
tetra-acyl lipid A heterogeneity, since the mature hexa-acyl species appear as single 
peaks. Hence, they may not be related to lipid A species, and may be other lipids (eg. 
cardiolipins) recovered from the extraction. 
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Figure 2.3 Y. pestis -pLpxL synthesizes a potent LPS. a-c) Lipid A was isolated from 
bacteria grown in liquid culture at 37ºC or 26ºC. The major forms of lipid A were 
determined by MALDI-TOF mass spectrometry (figure 2.2). Shown are the significant 
lipid A structures found in Y. pestis KIM5 at 37ºC a) or 26ºC b), or in KIM5-pLpxL at 
both temperatures c). HEK293 cells expressing d) human TLR4/MD2 or e) human TLR2 
were stimulated with LPS isolated from Y. pestis KIM5 grown at 26ºC (♦) or 37ºC (■), Y. 
pestis KIM5-pLpxL grown at 26ºC (◊) or 37ºC (□), or synthetic lipid IVA (●) for 18 hrs. 
Supernatants were analyzed by IL-8 ELISA. Human PBMC isolated from a healthy 
donor were exposed to LPS as described above for 16 hrs before supernatants were 
examined for f) TNF or g) IL-6 and IL-8 by ELISA. Similar results were obtained with 
cells from nine individuals.  h) PBMCs isolated from Cynomolgus macaques were 
stimulated with increasing doses of lipid IV or LPS isolated from wild type Y. pestis 
KIM5 or KIM5-pLpxLgrow at 26 ºC or 37 ºC for 18 hours. The supernatant was 
analyzed for human IL-8 by ELISA. The cells did not respond to KIM5 37 ºC LPS, but 
strongly responded to the other forms of LPS in a similar fashion as the responce 
observed in human PBMC. Peritoneal macrophages were isolated from i) wild type, j) 
TLR4-/- and k) MD-2-/-mice, and stimulated for 16 hrs with different forms of Y. pestis 
LPS and lipid IVA as described above. Supernatants were analyzed for TNF contents by 
ELISA. 
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Figure 2.4 Y. pestis -pLpxL is avirulent in wild type mice. a) Wild type C57Bl/6 mice 
(n=10 per infection group) were infected subcutaneously (SC.) with either parental Y. 
pestis KIM1001 at 1,000 CFU (♦) or 100 CFU (■), or with Y. pestis KIM1001-pLpxL at 
1,000 cfu (◊) or 100 cfu (□). Survival was monitored every 12 hrs. [(p<0.0001 in 
comparisons between 1000 CFU, KIM1001 vs KIM1001-pLpxL]. b) Wild type C57Bl/6 
and TLR4-/-  mice (n= 10 per infection group) were infected SC. with Y. pestis KIM1001 
(▲, ■)  or KIM1001-pLpxL (□,◊) at a dose of 1,000 CFU (p<0.0001 for KIM1001-
pLpxL, wild type vs TLR4-/-).  c) Wild type C57Bl/6 and MD-2-/-  mice (n= 8 per 
infection group) were infected SC. with Y. pestis KIM1001 (▲, ■)  or KIM1001-pLpxL 
(□,◊) at a dose of 1,000 CFU (p<0.0001 for KIM1001-pLpxL in MD-2-/- mice vs wild 
type mice). d) Y. pestis KIM1001-pLpxL IV infection is associated 
with increased survival times. Wild type C57Bl/6 or TLR4-KO mice (n=5 per group) 
were infected with 1000 cfu of KIM1001 or KIM1001-pLpxL iv in the tail vein. Survival 
was monitored every 12 hours. e) Colony forming units (CFU) were determined in spleen 
homogenates from wild type mice infected intravenously (IV) or SC. with KIM1001 or 
KIM1001(pLpxL).  f) TNF concentration in spleen homogenates from IV infected mice 
from D) were measured by ELISA (p=0.008).  g) Liver sections from wild type or TLR4-
/- mice infected SC. or IV with 1,000 CFU of KIM1001 or KIM1001-pLpxL were H&E 
stained. Arrows indicate bacteria-containing lesions, and the star indicates a microabcess 
containing infiltrating inflammatory cells [100x, inserts: 1,000x magnification of a 
bacterial mass (KIM1001 infection) or the microabcess, KIM1001-pLpxL.  
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Figure 2.5 Y. pestis containing pLpxL retains key features. 
a) KIM5, KIM5-pLpxL, and KIM5-pBR322Δtet were seeded in liquid cultures at an  
OD600 of approximately 0.15. The strains grew at similar rates at both 26 °C and  
37 °C in TB broth containing calcium. Hence, the presence of pLpxL and pBR322∆tet  
did not significantly affect growth in vitro.  b) KIM5 and KIM5-pLpxL were grown in 
the presence and absence of calcium at 37°C for 1 hour, and the supernantants were 
collected and analyzed for the presence of YopM by western analysis.  Secretion of 
YopM in KIM5-pLpxL was comparable to KIM5, as detected by anti-YopM antibody in 
the absence of calcium, while no secretion is seen in the presence of calcium. c)  Y. pestis 
and Y. pestis-pLpxL were diluted to an OD of 0.1, and the culture was then swabbed onto 
TB agar plates containing calcium and ampicillin for the modified strain. Whatman 7mm 
disks were then placed on the swabbed plates and inoculated with polymyxin B. The 
plates were then incubated at 37°C for 24 hours, and the zone of inhibition was measured.  
d) KIM5 and KIM5-pLpxL were incubated in 50% serum for one hour and then plated 
for CFU. Plates were incubated for 48 hours at 37°C and colonies were counted.  Three 
experiments were averaged together and standard deviation determined from the mean 
averages. e) Pla activity is conserved in both KIM1001 and KIM1001-pLpxL, as 
indicated by the ability of the bacteria to induce cleavage human plasminogen to plasmin. 
Subsequently, active plasmin is measured by the ability of plasmin to cleave the 
chromogenic Val-Leu-Lys-p-nitroanalide (S2251) plasmin substrate, and OD405 is 
measured as a function of time. A Y. pestis KIM1001 mutant that lacks Pla activity is 
unable to cleave the substrate, whereas KIM1001 and KIM1001-pLpxL both contain high 
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Pla activity.  f) The presence of plasmid vector does not affect KIM1001 virulence. Wild 
type C57Bl/6 (n-5 per group) were infected with 1000 CFU of KIM1001 or KIM1001-
pBR322Δtet SC in the nape of the neck. Bacteria were resuspended in 0.05 mL of PBS. 
Survival was monitored every 12 hours.  g) Y. pestis and Y. pestis-pLpxL were diluted to 
an OD of 0.1, and the culture was then swabbed onto TB agar plates containing calcium 
and ampicillin for the modified strain. Whatman 7mm disks were then placed on the 
swabbed plates and inoculated with CHIR-090, an LpxC inhibitor. The plates were then 
incubated at 37°C for 24 hours, and the zone of inhibition was measured.  
h) Three TLR4-/- mice were infected IV with 1,000 CFU of either KIM1001 or 
KIM1001-pLpxL. Sixty hours post-infection, spleen homogenates were prepared and 
plated on TB plates (KIM1001) or TB Amp plates (KIM1001-pLpxL).  
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Figure 2.6 MyD88, Mal and CD14 contribute to LPS-mediated survival for 
KIM1001-pLpxL. 
a) MyD88, Mal, TRAM, TRIF or TLR2-deficient mice (ten mice per group) were 
infected SC. with 1,000 CFU of KIM1001-pLpxL. Survival was monitored up to 28 days. 
(MyD88 vs Mal: p<0.0001. Mal vs TLR2; p=0.003). b) Purified LPS from Y. pestis 
KIM5 and KIM5-pLpxL grown at 37°C or 26°C, and LPS from E. coli 0111:B4 were run 
on a 12% Bis-Tris gel. The LPS was visualized by silver stain. The Y. pestis LPS is rough 
(lacking an o-polysaccharide), whereas the E. coli LPS is smooth. c) Peritoneal 
macrophages from wt or CD14-/- mice were stimulated with Y. pestis KIM5-pLpxL 37°C 
LPS (10 ng/ml) for 18 hrs. TNF and Rantes release was measured by ELISA. d) Wild 
type or CD14-/- animals were infected with KIM1001 (10 wt or 10 CD14-/- animals) or 
KIM1001-pLpxL (10 wt or 9 CD14-/- animals) SC. at a dose of 1000 CFU Survival was 
monitored up to 21 days. p=0.002 (CD14-/- vs. wt mice, KIM1001-pLpxL). 
 
 
 
 
 
 
 
 
 
101
Figure 2.7
102
Figure 2.7 Y. pestis harboring potent TLR4-activating ability is an effective vaccine 
against plague 
a) Wild type mice (ten mice per group) were challenged SC with 1000 CFU of 
KIM1001-pLpxL or left untreated. Thirty-five days later, mice were infected SC with 
1,000 CFU of virulent KIM1001 and survival was monitored. b) Wild type C57Bl/6 mice 
were vaccinated SC with 1,000 or 100,000 CFU of KIM1001-pLpxL or left untreated. 
Thirty to forty days later, the animals were challenged with 1,000 up to 1,000,000 CFU 
of virulent KIM1001. Survival was monitored up to 28 days. *Results from two 
experiments are pooled. c) Wild type mice were vaccinated SC with 100,000 CFU of 
KIM1001-pLpxL or left untreated. Thirty days later, the animals were infected 
intranasally (IN) with 5000 or 50,000 CFU of KIM1001. Survival was monitored up to 
28 days. *Results from two experiments are pooled. 
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Figure 2.8
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Figure 2.8 Adaptive immunity is critical for protection against KIM1001-pLpxL. 
Rag1-/-, TLR4-/- or wild type C57Bl/6 mice (5 mice per group) were infected SC with 
1,000 CFU of KIM1001-pLpxL. Survival was monitored up to 28 days. 
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Table 2.1 Survival of wild type mice with high doses of KIM1001-pLpxL 
 
Inoculum 
Survival 
KIM1001 KIM1001-pLpxL 
1x102 CFU 4 of 20 20 of 20 
1x103 CFU 0 of 30 29 of 29 
1x104 CFU - 14 of 14 
1x105 CFU - 5 of 5 
Survival of wild type mice after subcutaneous infection with increasing doses of  
Y. pestis KIM1001 or KIM1001-pLpxL, presented as surviving mice of total mice.  
- indicates not done. Data are representative of two to six experiments.   
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Table 2.2 Survival of vaccinated wild type mice after subcutaneous challenge 
 
Vaccination (KIM1001-pLpxL) 
 
Challenge (KIM1001) Survival 
None 1x103 CFU 0 of 20 
None 1x105 CFU 0 of 5 
1x103 CFU 1x103 CFU 19 of 19 
1x105 CFU 1x105 CFU 5 of 5 
1x105 CFU 1x106 CFU 5 of 5 
Survival of wild type mice vaccinated subcutaneously with Y. pestis KIM1001-pLpxL  
and naïve mice (None) after subsequent subcutaneous challenge with increasing  
doses of Y. pestis KIM1001, presented as surviving mice of total mice. Data  
representative of two to five experiments.  
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Table 2.3 Survival of vaccinated wild type mice after intranasal challenge 
 
Vaccination (KIM1001-pLpxL) 
 
Challenge (KIM1001) Survival 
None 5x103 CFU 0 of 19 
1x103 CFU 5x103 CFU 19 of 19 
1x105 CFU 5x103 CFU 5 of 5 
1x105 CFU 5x104 CFU 5 of 5 
Survival of wild type mice vaccinated subcutaneously with Y. pestis KIM1001-pLpxL  
and naïve mice (None) after subsequent intranasal challenge with increasing  
doses of Y. pestis KIM1001, presented as surviving mice of total mice. Data  
representative of two to three experiments.  
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Preface to Chapter III 
 
The work in this chapter has been performed by the following: 
Gregory Vladimer performed the in vitro IP2666 infection on PBMCs  Fig 3.7d 
Megan Murphy and Jon Goguen constructed the IP2666ΔlpxL strain Fig 3.3 
Dan Weng performed the growth curve and Polymyxin B assays Figure 3.3 b,c,d, 3.5a-d 
Ashley Beasley and Katie Stamper at John Hopkins University performed MALDI-TOF, 
Fig 3.2 
Egil Lien and Gregory Vladimer performed in vivo infections Fig 3.6, 3.7a,b 
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110
 Early detection of invading microbes by the host innate immune system is critical 
for mounting an effective inflammatory response to prevent the spread of infection.  
Some pathogens have evolved the ability to evade or actively suppress the innate immune 
response, allowing the rapid development of a fatal infection before the adaptive immune 
system can respond.  One such bacterium, Yersinia pestis, the gram-negative causative 
agent of plague, is a master of immune evasion.  Y. pestis relies in part on the bite of 
infected fleas for transmission between mammalian hosts (Perry and Fetherston, 1997).  
In order to develop bubonic plague via the flea vector, Y. pestis must establish systemic 
bacteremia from the small number of bacteria delivered by the fleabite.  After 
transmission via fleabite, the bacteria multiply producing foci of infection which contain 
a large number of bacteria, yet few inflammatory or immune cells (Sodeinde et al., 1992).  
In order to achieve this, Y. pestis utilizes a number of different mechanisms to avoid 
innate immune recognition and suppress inflammation.  Our group has previously 
determined that the structure of the lipopolysaccharide (LPS)/Lipid A molecule is a 
critical factor for the virulence of Y. pestis.  The bacterium expresses tetra-acyl lipid A in 
its LPS structure at 37°C, which is antagonistic to the human TLR4 (Toll-like receptor 4) 
and its co-receptor MD2, thus allowing Y. pestis to inhibit the TLR4/MD2 pathway at the 
initial stage of signaling, effectively halting innate immune activation.  Other virulence 
mechanisms include a type III secretion system (T3SS) which delivers effecter proteins 
(termed Yops) directly into the host cell cytoplasm, and Pla, an outer membrane protease 
with plasminogen activator activity (Cornelis, 2002; Perry and Fetherston, 1997; 
Sodeinde et al., 1992).   
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 Toll-like receptors (TLRs) are vital to the recognition of pathogen associated 
molecular patterns (PAMPs) expressed by invading pathogens such as LPS, lipoproteins, 
flagellum, CpG, unmethalated DNA, and viral RNA (Kumar et al., 2009; Takeda and 
Akira, 2004).  TLR4 is activated by the lipid A portion of lipopolysaccharide (LPS), a 
major component of the Gram-negative bacterial outer membrane.  Initially lipid A 
associates with MD-2, which acts as an essential co-receptor facilitating the binding of 
LPS to the cytoplasmic leucine rich repeat (LRR) portion of the TLR4 receptor, leading 
to the dimerization of two receptors.  This dimerization initiates an intracellular kinase 
cascade culminating in the activation of downstream transcription factors such as NF-κB 
and interferon regulatory factors (IRFs), which lead to the production of inflammatory 
cytokines such as TNFα, IL-8, pro-IL-1β, and pro-IL-18 along with type I interferons 
(IFNs) (Akira, 2006; Beutler, 2009; Kumar et al., 2009). 
 The IL-1 pathway is another immune signaling pathway that is critical for 
protection from bacterial pathogens. It activates a broad and potent range of pro-
inflammatory molecules that help control infection. The IL-1 receptor binds IL-1α and 
IL-1β, which then activates a downstream pathway that utilizes many of the same adaptor 
molecules found in the TLR pathway and potently activates NF-κB  (O'Neill, 2000).    
IL-1β is a very powerful pro-inflammatory molecule, and because of this its expression is 
under very tight control. Secretion of this molecule is dependent on two signals; first is 
the production of pro-IL-1β upon TLR4 mediated NF-κB activation. This pro- form of 
the cytokine is sequestered in the cytoplasm until a second signal stimulates the 
activation of caspase 1, which cleaves pro-IL-1β into its active form, after which it is then 
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secreted from the host cell. Once secreted, mature IL-1β binds to the IL-1 receptor which 
induces a potent inflammatory response including the induction of fever, edema, and the 
production of leukocytes  (Dinarello, 2009; Dunne and O'Neill, 2003).  
 Y. pestis expresses tetra-acyl lipid A at 37oC due of the absence of the enzyme 
LpxL, which plays a critical role in the lipid A biosynthesis pathway via the addition of a 
secondary acyl chain to the tetra-acyl lipid structure.  In order to determine if this tetra-
acyl lipid A structure is important for virulence of the bacteria we expressed E. coli LpxL 
in Y. pestis (Y. pestis-pLpxL), and found that the bacteria are now able to produce 
stimulatory hexa-acylated lipid A/LPS.  Y. pestis-pLpxL was also avirulent in wild-type, 
but not TLR4-/- mice.  This demonstrates that lipid A/LPS acylation patterns are a critical 
virulence determinant for Y. pestis and possibly other Gram-negative pathogens 
(Montminy et al., 2006).   
The divergence of Y. pestis from its ancestral parent Y. pseudotuberculosis is 
thought to have occurred between 1,500 and 20,000 years ago (Achtman et al., 1999), 
with recent research indicating the date is closer to 10,000 years ago (Achtman et al., 
2004).  Y. pseudotuberculosis causes self-limiting gastroenteritis, a mild disease when 
compared with a potentially lethal Y. pestis infection (Smego et al., 1999).  Y. 
pseudotuberculosis is transmitted by oral route, where they invade the ileum epithelial 
layer and then migrate to the Peyer’s Patches, where they replicate and further migrate to 
the mesenteric lymph nodes. At this point the disease is usually contained by the immune 
system and the patient recovers, where in Y. pestis, after lymph node colonization, the 
disease rapidly becomes systemic (Dennis, 2008).  However, despite the differences in 
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pathology, the two bacteria share a high degree of genetic homology, and both contain a 
virulence plasmid that encodes genes for a type three secretion system (T3SS) and Yop 
effector proteins.  When the whole genomes of both strains were compared, it was 
determined that the Y. pseudotuberculosis genome contains over 300 genes that have 
been lost or inactivated in Y. pestis, including lpxL (Chain et al., 2004; Pouillot et al., 
2008).  Interestingly, Y. pseudotuberculosis produces a number of lipid A species at 
37°C, including hexa-acylated lipid A which is able to stimulate TLR4 in human cells 
(Rebeil et al., 2004; Skurnik et al., 2000; Therisod et al., 2002) indicating that LpxL in 
this bacterium may be functional.  Conversely, while the acquisition of new genes such as 
Pla and the F1 capsule have proven important in Y. pestis’ divergent pathogenic profile, 
the loss of many genes, including lpxL, may also have played a critical role in the 
development of Y. pestis into a highly virulent pathogen.  Here, we examine how the 
presence of lpxL affects virulence in these two Yersinia species, and what other immune 
pathways besides TLR4/MD2 are important for host clearance of Y. pestis expressing 
LpxL. 
 
 
Results 
 
Absence of lpxL is a unique characteristic of Y. pestis 
 In-silico analysis comparing the genomes of all sequenced Yersinia species 
(including the Pestoides strains, which are thought to be the oldest strains of Y. pestis 
(Achtman et al., 2004; Bearden et al., 2009; Garcia et al., 2007)) revealed that Y. pestis is 
the only family member which does not contain a homologue for E. coli lpxL (data not 
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shown), a late acyltransferase in the lipid A biosynthetic pathway, which enables Y. pestis 
to produce hexa-acylated lipid A at 37°C.  However, other Yersinia species all contain 
lpxL homologues that have a high sequence similarity and identity (Figure 3.1a, b). 
Interestingly, Y. pseudotuberculosis, the evolutionary parent of Y. pestis, has a putative 
lpxL in a region of the chromosome that was lost from Y. pestis (Chain et al., 2004; 
Pouillot et al., 2008), as does Y. enterocolitica, the ancestor of both strains.  These 
bacteria produce a heterogeneous mix of lipid A species at 37°C and LPS that is 
stimulatory into human cells, indicating that LpxL enzyme could be functional (Rebeil R, 
2006; Therisod et al., 2002).  This suggests that the loss of lpxL may have been a critical 
step in the evolution of Y. pestis into a highly virulent pathogen.  
 
Activity of Y. pseudotuberculosis LpxL 
While it was known that Y. pseudotuberculosis had an lpxL homologue in a 
chromosomal region that was lost from Y. pestis, it had yet to be determined if that gene 
was functional. To address the activity of the Y. pseudotuberculosis LpxL enzyme, we 
cloned Y. pseudotuberculosis lpxL from the IP2666 (Simonet and Falkow, 1992) strain 
into pBR322 to create pYptbLpxL (pBR322::YptbLpxL), and introduced this plasmid 
into Y. pestis KIM5. When we isolated and analyzed the lipid A from KIM5-pYptbLpxL, 
we found that the lipid A profile bore a striking resemblance to the lipid A profile from 
IP2666 (Figure 3.2a, b). Previously we had cloned E. coli lpxL into pBR322 (pLpxL), 
and found that the addition of this enzyme drove the Y. pestis to produce almost 
exclusively a hexa acylated lipid A, similar to the lipid A profile seen in E. coli 
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(Montminy et al., 2006). However, with the addition of the Y. pseudotuberculosis LpxL, 
we found that Y. pestis now produced a much more heterogeneous mix of tetra-, penta-, 
and hexa-acylated lipid A (Figure 3.2b).  This profile closely resembles that seen with 
IP2666 (Figure 3.2a). The addition of Y. pseudotuberculosis LpxL to Y. pestis causes the 
bacteria to revert to its parental strain lipid A profile, rather than exclusively making 
hexa-acyl lipid A like in the case with KIM5-pLpxL (Montminy et al., 2006). 
 Many gram negative bacteria have survival or pathogenic defects when utilizing 
tetra acyl lipid A as the anchor for their LPS (McLendon et al., 2007; van der Ley et al., 
2001; Vorachek-Warren et al., 2002b). This is due to the increased outer membrane 
fluidity seen in these mutants, which make the bacteria more susceptible to both 
environmental pressures such as osmotic changes, and to the actions of complement and 
antimicrobial agents. However, Y. pestis survives quite well with tetra-acyl lipid A, and is 
resistant to the action of serum and antimicrobial peptides (Knirel et al., 2007).  To 
determine if the factors that allow Y. pestis to thrive while producing tetra-acyl lipid A 
were passed down from the parental Y. pseudotuberculosis, or were acquired during Y. 
pestis’ evolution we generated an in-frame, non polar deletion of lpxL from IP2666 
(Figure 3.3). As tetra-acylated lipid A is a critical virulence determinant for Y. pestis, this 
mutant was introduced into a Y. pseudotuberculosis pYV deficient strain of IP2666, 
which lacks the T3SS and Yop effector proteins in order to avoid possibly increasing 
virulence of the strain. When the lipid A was isolated and analyzed from the resulting 
strain, IP2666ΔlpxL, we found that tetra-acyl lipid A was the predominant species 
produced (1405 m/z), with some penta-acyl lipid A present as well (1587 m/z) (Figure 
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3.2c). The lipid A profile of IP2666ΔlpxL bore a striking resemblance to wild type Y. 
pestis, indicating that the loss of this enzyme from Y. pseudotuberculosis was sufficient 
for the production of tetra-acyl lipid A. The phenotype was rescued by the addition of 
LpxL, as the complement strain IP2666ΔlpxL-pYptbLpxL produced a lipid A profile like 
that of the parent IP2666 strain (Figure 3.2d).  This data demonstrates that the loss of 
lpxL in Yersinia leads to the production of tetra-acyl lipid A. 
  
Stimulatory Properties of Tetra- and Hexa-Acylated lipid A/LPS 
 Knowing that hexa-acylated lipid A was produced by LpxL expressing Yersinia 
strains, and that this form of lipid A is highly stimulatory to human cells, we wanted to 
examine the stimulatory capabilities of the LPS from KIM5-pYptbLpxL, IP2666ΔlpxL 
and IP2666ΔlpxL-pYptbLpxL. To that end, LPS was purified from both the KIM5 and 
IP2666 strains grown at 37°C, and then used to stimulate a variety of mammalian cell 
types. The LPS produced from the KIM5-pYptbLpxL and IP2666 strains were highly 
stimulatory for TNF in human PBMCs (Figure 3.4a).  These LPS samples were also able 
to stimulate the production of IL-8 in HEK293 cells expressing TLR4/MD2 (Figure 
3.4b). The LPS did not however stimulate HEK293 TLR2 cells, indicating that it is free 
of contaminating lipoproteins (Figure 3.4c), and no response was seen in HEK293 cells 
containing pcDNA3 alone (Figure 3.4d). 
 In contrast to the strains in which we added lpxL, IP2666ΔlpxL produced almost 
exclusively tetra-acyl lipid A, and was non-stimulatory in both the human PBMCs and in 
HEK293TLR4/MD2 cells (Figure 3.4a, b). This mimics what is seen in with KIM5 LPS, 
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which is also predominantly tetra-acylated.  When lpxL is added back to the deletion 
strain, the stimulatory capability LPS was restored, indicating that the lack of LpxL, and 
the resulting tetra-acylated lipid A, is responsible for the non-stimulatory characteristics 
of these strains.  
 Tetra-acylated lipid A is also known to be a strong antagonist for TLR4, and we 
have previously shown that KIM5 LPS can suppress pro-inflammatory response in 
human PBMCs. To examine whether this was also the case with IP2666ΔlpxL, human 
PBMCs were incubated with either 10ng/mL or 100 ng/mL of IP2666ΔlpxL LPS or 
KIM5 LPS and with 10 ng/mL of stimulatory LPS. Cells that were treated with either 
IP2666ΔlpxL or KIM5 LPS had a marked reduction in the amount of TNFα produced 
(Figure 3.4e). When equal amounts of stimulatory and non-stimulatory LPS were added 
to the cells, a 50% reduction was seen in TNFα production, and when a tenfold higher 
concentration of non-stimulatory LPS was added, the TNFα levels were near completely 
abolished (Figure 3.4e), indicating that tetra-acyl lipid A/LPS can act as antagonist.  
 Mouse TLR4 is able to respond to tetra-acyl lipid A due to differences in the 
receptor complex which have recently been identified.  Key differences in several amino 
acid residues on the surfaces of both TLR4 and MD2 alter how the lipid A molecule 
interacts with the receptor, allowing the mouse receptor to respond to tetra-acyl lipid A, 
while the human receptor is antagonized (Park et al., 2009; Meng, J, 2009). However, 
even though tetra-acyl lipid A is recognized to some degree, it still induces much less 
activation than the hexa-acyl lipid A. When immortalized mouse macrophages ere 
stimulated with KIM5 or IP2666ΔlpxL, they responded to a lesser degree then when the 
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cells were stimulated with LPS from the strains which contained LpxL (Figure 3.4f).  
Immortalized macrophages derived from TLR4-/- mice, however, did not stimulate at all, 
indicating both that this is a TLR4 mediated event, and that there were no contaminates in 
the LPS preps that may be stimulating the cells through a different pathway (Figure 3.4g).   
 
Characteristics of Yersinia strains with altered acylation patterns 
 Altering the LPS/lipid A molecule in gram-negative bacteria can drastically 
change how the bacteria grow and function. In order to determine if the changes in the 
acylation pattern modified any of the key characteristics of the strains, the growth and 
antimicrobial sensitivity of the strains were examined. Both the Y. pestis and Y. 
pseudotuberculosis mutant strains grew at the same rate as the parent strains (Figure 3.5 
a, b) indicating that the alteration of the lipid A did not affect growth in these strains. 
Sensitivity to polymyxin B was also determined by disk diffusion assay. Polymyxin B is 
a cyclic cationic peptide that is a very effective antimicrobial against gram negative 
bacteria by binding lipid A and altering the outer membrane, making it more permeable 
(Tsubery et al., 2000).  As Y. pestis grown at higher temperatures (37°C) has been shown 
to be more sensitive to polymyxin B then bacteria grown at lower temperatures 
(Anisimov et al., 2005), we wanted to determine if acylation pattern played any direct 
role in this difference in sensitivity.  We observed that none of the mutant strains were 
significantly more sensitive to serum than their parent strain. KIM5-pLpxL and KIM5-
pYptbLpxL were as resistant to polymyxin B as KIM5, while IP2666ΔlpxL and 
IP2666ΔlpxL-pYptbLpxL were not significantly more susceptible then IP2666 (Figure 
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3.5c,d).  Thus, the change in acylation pattern in this bacterium does not alter their 
susceptibility to polymyxin B.  
 We also analyzed the LPS by silver stain, and saw that the addition of Y. 
pseudotuberculosis LpxL did not drastically alter the migration pattern of the extracted 
LPS.  KIM5-pYptbLpxL still had a rough LPS phenotype and did not contain an O-
saccharide chain like Y. pseudotuberculosis (Figure 3.5e).  IP2666ΔlpxL did show a slight 
shift in the band present on the silver stain gel, which may be due to the reduction in acyl 
chains on the lipid A. The complemented strain appeared similar to IP2666, in that the 
slight downward shift is gone.   
 
Altered Y. pestis Acylation patterns attenuates virulence 
 We have previously shown that altering the lipid A pattern by expression of E. 
coli LpxL completely attenuates the virulence of Y. pestis in mice, demonstrating the 
expression of tetra-acyl lipid A is a critical virulence determinant. Y. pseudotuberculosis 
produces hexa-acyl lipid A at 37°C, and has a much higher LD50 in mice than Y. pestis 
(Pouillot et al., 2005). Mice are excellent models for both diseases, and are natural 
reservoirs for infection with Y. pestis, which provides an ideal system to examine the 
difference in acylation patterns during infection. In order to determine if expression of Y. 
pseudotuberculosis LpxL would have this same effect on virulence as expression of E. 
coli LpxL, we transformed fully virulent KIM1001 with pYptbLpxL and infected mice 
subcutaneously with 500 CFU of the bacteria. We found that at this dose, the bacterium 
was not able to produce bubonic plague, as we saw with the bacteria expressing E. coli 
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LpxL, while mice infected with the wild type strain completely succumbed to disease by 
day 8 (Figure 3.6a). We also found that this lethality was TLR4 dependent, and TLR4-/- 
mice are susceptible to infection at the same rate as mice infected with wild type Y. pestis 
(Figure 3.6b).  
 As Y. pestis expressing LpxL is able to elicit a TLR4/MD2 immune response and 
appears to be largely avirulent we next sought to determine if this strain could be used as 
a vaccine.. We found that infection with the Y. pseudotuberculosis LpxL expressing 
strain of KIM1001 provided protection from subsequent infection with the wild type 
KIM1001. Mice that were initially infected with 500 CFU KIM1001-pYptbLpxL and 
subsequently challenged 30 days post infection with KIM1001 were protected from 
disease when challenged with a subcutaneous dose of KIM1001 at a CFU of 1000, twice 
the infectious dose of the initial infection (Table 3.2). These mice were fully protected 
from disease.   
 
The IL-1 pathway protects against infection with Y. pestis-pLpxL 
 Strains of Y. pestis that express hexa acyl lipid A allow us to examine the 
potential contribution of different components of the innate immune system during active 
infection.  Normally, this cannot always be undertaken with Y. pestis due to high 
virulence and active immune evading characteristics of the pathogen. However, these 
mutant strains provide sufficient attenuation of the bacteria, without altering other 
important virulence component, therefore facilitating closer examine the critical 
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pathways involved in plague progression and by extension in many other gram negative 
infections.   
We therefore infected a number of key immune knockout mice, including TNFR 
I, IL-1RI, IL-12 p40, and Type 1 IFN-R with KIM1001-pLpxL. We found the most 
profound defect in survival was in IL-1R knockout mice (Figure 3.7a), and further 
infection experiments determined there was only 40% survival with the KIM1001-pLpxL 
in those animals compaired to wild type mice (Table 3.3). We had also infected MyD88 
deficient mice with 1000 CFU of wild type KIM1001, and found that they had a 
significantly higher rate of death then wild type mice (p=0.0004) (Figure 3.7b). MyD88 
is an essential adapter for the IL-1 pathway, indicating that the IL-1 pathway may play a 
key role in protection during Y. pestis infection.  
To further examine the role the IL-1 pathway plays in Y. pestis infection, we 
infected PBMCs in vitro with KIM5, KIM5-pLpxL, and KIM5-pYptbLpxL (Figure 3.7c). 
During active infection, the KIM5-pLpxL and KIM5-pYptbLpxL strains induced an IL-
1β response, while a response was absent from KIM5 (Figure 3.7c). PBMCs were also 
infected with the Y. pseudotuberculosis strains at an MOI of 10 (Figure 3.7d), and in 
these cells the deletion of lpxL leads to dramatic reduction in the production of IL-1β. 
IP2666 was able to induce a strong IL-1β response, as did the IP2666Δlpxl-pYptbLpxL 
strain. However, IP2666Δlpxl IL-1β stimulation levels are at the same levels as 
unstimulated cells (Figure 3.7d).   
In order to assess is TLR4 stimulation and subsequent activation of NF-κB is 
essential for the production of pro-IL-1β in this system, we also infected both wild type 
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and TLR4-/- immortalized mouse macrophages with KIM5, KIM5-pLpxL and KIM5-
pYptbLpxL (Figure 3.7e). TLR4 signaling is required for the secretion of IL-1β in this 
system, as cells deficient for this receptor do not have any IL-1β response, whereas the 
wild type cells have a robust response.  These data indicate that the production of tetra-
acyl lipid A is unable to induce the IL-1 response during Yersinia infection.  
 
Discussion 
 The deletion of lpxL from the Y. pestis chromosome appears to provide an 
evolutionary benefit to the bacteria. It enables the bacteria to effectively evade 
TLR4/MD2 signaling, providing another mechanism of innate immune evasion. Of the 
genus Yersinia, only Y. pestis is a highly virulent pathogen. However, all the pathogenic 
Yersinia contain the type three secretion system and Yop effector proteins, which are 
highly effective at suppressing the immune response in the host cytoplasm (Cornelis, 
2002; Pujol C, 2005). While the acquisition of such virulence determinants such as Pla, 
murine toxin, and the F1 protein are critical in Y. pestis virulence (Perry and Fetherston, 
1997), the loss of LpxL may have provided a turning point in the evolution of the 
bacteria. Pestoides F, a fully virulent strain of Y. pestis isolated from the former Soviet 
Union, lacks Pla and has an a number of characteristics that defines it as one of the most 
ancient Y. pestis strains isolated and sequenced (Garcia et al., 2007). This isolate also 
lacks the gene for LpxL, indicating the loss of this chromosomal region that contains the 
gene occurred very early in the evolution of Y. pestis.   
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All sequenced strains of Y. pseudotuberculosis contain lpxL (Figure 3.1a). 
However, unlike E. coli, which produces one major form of lipid A, Y. 
pseudotuberculosis contains a heterogeneous mix of lipid A. Early analysis of Y. 
pseudotuberculosis lipid A shows that there is a high degree of variability in the strain, 
more so than is seen in any of the other Yersinia or in gram negative bacteria in general 
(Krasikova et al., 1978). Subsequent mass spectrometry analysis confirmed that Y. 
pseudotuberculosis expresses a considerable number of lipid A species with a large 
number of different modifications  (Rebeil R, 2004; Therisod et al., 2002). Our analysis, 
however, show less heterogeneity. We see instead three major lipid A structures, with 
little of the acyl chain number and length variability or modifications seen in other 
published works. This may be due to the difference in strains used for this work. Previous 
work looked at either Y. pseudotuberculosis PB1 O:1b or ATCC 29833, whereas our 
work and analysis was done using IP2666. The isolation and treatment of the lipid A 
molecule may also play a role in the observed differences. While most other groups 
isolate their lipid A from previously purified LPS, we have isolated it directly from the 
bacteria, thus reducing the amount of harsh chemical treatments the molecule would be 
exposed to. Finally, differences in growth media, growth temperature, and nutrients can 
all affect the acylation pattern of lipid A, especially in Y. pseudotuberculosis. We are also 
repeating the mass spectrometry analysis of the lipid A from these strains with an 
independent collaborator to confirm our structures.  
When Y. pseudotuberculosis lpxL was introduced into Y. pestis and the lipid A 
from this strain isolated, we found that Y. pestis-pYptbLpxL produces a lipid A that 
124
closely mimics what we see with wild type Y. pseudotuberculosis strain IP2666.  This is 
likely due to the fact that the gene is under the control of its own promoter, thus 
mimicking the expression levels found in Y. pseudotuberculosis. However, since it is 
expressed on a plasmid, the copy number of the gene would be higher that what is found 
endogenously, thus possibly driving the expression of lpxL to a higher level and causing a 
shift to a completely hexa acyl species like what is shown with IP2666Δlpxl-pYptbLpxL. 
The reason for this discrepancy has yet to be determined and is being investigated.  
Our data with IP2666ΔlpxL shows that Y. pseudotuberculosis can survive without 
lpxL and with tetra acyl lipid A as the anchor molecule for LPS, which is interesting since 
many gram negative bacteria have growth or functional defects when only tetra-acyl lipid 
A is present (Lee et al., 1995; Vorachek-Warren et al., 2002b).  IP2666ΔlpxL shows no 
growth or survival defect when in comparison with either the parent or the complemented 
strain. The compensating mechanisms present that allow the bacteria to survive with only 
tetra-acyl lipid A are currently unknown, however they appear conserved in Y. 
pseudotuberculosis and Y. pestis. Part of the answer may be in the growth rate of the 
bacteria. Yersinia has a much slower doubling time than many gram negative bacteria, 
such as E. coli or H. influenza, which has a doubling time of 30 minutes.  Slower growth 
rate may allow for MsbA, a membrane enzyme that transports the lipid A molecule 
across the periplasmic space to the outer membrane, to move tetra-acyl lipid A across the 
membrane to the outer leaflet. MsbA transports tetra-acyl lipid A poorly (Zhou et al., 
1998) (Reynolds and Raetz, 2009),  so the slower growth rate may allow for the tetra-acyl 
lipid A to be transported to the outer membrane.  
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As we had shown previously, Y. pestis producing a hexa acylated lipid A is both 
avirulent and protects from subsequent reinfection. Wild type KIM1001 has a mean lethal 
dose of 10 CFU, while KIM1001-pYptbLpxL is avirulent in mice at a dose of 500 CFU. 
This effect is not seen in TLR4 deficient mice however, indicating that the protection 
seen by the LpxL producing strain is dependent on the activation of the innate immune 
response. Preliminary data suggests that TLR4 is critical as well for the protection of 
mice from Y. pseudotuberculosis. In a single experiment, 3 out of 4 TLR4-/- mice orally 
infected with 5x108 CFU of IP2666 succumbed to disease by day 5, whereas only 2 out 
of 5 wild type mice died (data not shown). While this experiment was only performed 
once with a low number of animals, it does indicate that TLR4 is involved in protection 
from disease during Yersinia pseudotuberculosis infection. A potentially interesting 
experiment to conduct would be to generate a ΔlpxL strain in IP2666 with pYV and then 
infect mice to see if there is an increase in virulence, however do to biosafety concerns, 
this has not been done. It can be speculated however, given the low potency LPS 
produced by this strain combined with its lack of growth defects, that this strain would 
prove to be more virulent then its parent. It is unlike to be as virulent as Y. pestis with this 
modification alone, however.  Y. pseudotuberculosis containing pPla does not become 
more virulent, even when the O-saccharide chain is reduced to allow for enzymatic 
activity (Pouillot et al., 2005). Therefore, it is likely that a number of modifications need 
to be made to Y. pseudotuberculosis to render it as virulent as Y. pestis. However, it can 
be assumed that the bacteria would be less likely to activate TLR4 in vivo, and would be 
able to survive longer and reach higher bacterial number in the host then the parent strain. 
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It was also established that KIM1001-pYptbLpxL protects against infection from 
wild type KIM1001. There is a great degree of interest in developing vaccines for gram 
negative infections, especially Y. pestis. This is due to the current lack of an effective 
vaccine for Y. pestis licensed in the United States, and because of its potential as a 
bioterrorism agent. Therefore, developing a highly protective vaccine is of great value. 
We have shown that infection with KIM1001-pYptbLpxL is able to initiate a successful 
protective response, and to provide immunity from subsequent infection against 
KIM1001, the wild type Y. pestis strain. This makes the strain an ideal vaccine candidate, 
because it is both avirulent my subcutaneous infection and provides complete protection 
from reinfection.  However, it still contains all critical virulence determinants so it cannot 
be used as a live-attenuated vaccine. Therefore, another strategy must be used. One such 
method would be to express Y. pseudotuberculosis LpxL in an attenuated Y. pestis strain 
and to see if this strain is also able to protect against disease. It has been shown that when 
E. coli LpxL was introduced to D27, an avirulent strain of Y. pestis and then used to 
infect mice, those mice survived infection and are also protected from disease when 
infected with fully virulent Y. pestis (Szaba et al., 2009).  This further demonstrates that 
Y. pestis expressing a potent LPS may be a vaccine candidate due to its ability to 
stimulate and be cleared by the immune system and to provide lasting immunity.   
 There has also been a great deal of work dedicated to developing vaccines that 
have TLR stimulating capabilities, because of the TLRs ability to activate not only the 
innate immune system, but to activate and educate the adaptive immune response. Recent 
work with N. meningitidis has shown that modifying the LPS/lipid A structure of this 
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bacterium to be less potent is useful as a TLR agonist in outer membrane vesicles. When 
this LPS is used in conjunction with other antigens, like outer membrane proteins,   in the 
development of  outer membrane vesicle vaccines against both N. meningitidis and B. 
pertussis, a higher degree of protection is seen (Steeghs L et al., 1999; Stoddard et al., 
2009; Geurtsen et al., 2008). With Y. pestis, increasing the potency of the LPS/lipid A 
molecule is advantageous because it allows for the bacteria to be recognized by TLR4 
and drive the immune response.  Developing a Y. pestis vaccine with an endogenous 
stimulatory LPS and other highly antigenic proteins, similar to work done with N. 
meningitidis, could be an effective strategy for a successful vaccine. There may be 
potential side effects to the increased potency of the LPS, as this may increase 
inflammation and lead to septic shock.  However, the mice infected with this strain do not 
have any apparent signs of illness, indicating that this may not be an issue with live 
bacteria. Further studies on the mice need to be done to determine what type of 
inflammation occurs in these animals, if any. This includes monitoring body temperature 
to look for disease and analysis of what cytokines are being produced during infection.  
This would allow us to more closely determine how robust the immune response to Y. 
pestis expressing LpxL is, and if it has the potential to be detrimental to the vaccinated 
individual.  
 Changes in the acylation pattern of lipid A can drastically alter how the immune 
system recognizes the bacteria. Tetra-acyl lipid A effectively suppresses TLR4/MD2 
signaling, and this in turn can have serious consequences on the function of other 
immune pathways (Zahringer et al., 2001) (Golenbock et al., 1991) (Matsuura et al., 
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2009).  Activation of TLR4 allows for the production of pro-IL-1β, a critical component 
of the IL-1 pathway, which activates a host of other downstream molecules that are 
critical for an effective immune response (Dunne and O'Neill, 2003) (Dinarello, 2009).  
Y. pestis has been suggested to shut down the IL-1 pathway by blocking activity of 
caspase 1, which cleaves pro-IL1β into the active form of the cytokine that can be 
released from the cell (Schotte et al., 2004) (Lilo et al., 2008) (Bergsbaken and Cookson, 
2007; Shin and Cornelis, 2007).  We show here that the production of tetra-acyl lipid A 
greatly inhibits the induction of pro-IL-1β, which in turn can suppress this pathway. This 
illustrates yet another critical mechanism by which the production of tetra-acyl lipid A 
suppresses the immune response against Y. pestis. When Y. pestis is modified to produce 
potent LPS, the IL-1 pathway can be activated, which is essential for clearance of 
infection. This effect is apparent in IL-1β deficient mice, as these mice have a severe 
defect in surviving infection with the modified strain. While much work has been done 
looking at Yersinia and the IL-1/caspase-1 response, this is the first time that the 
importance of the IL-1 pathway during Y. pestis infection in particular has been able to be 
examined using in vivo infection, due to the attenuated nature of the modified Y. pestis. 
The data presented here are preliminary, future work includes looking at the activation of 
caspase-1 in terms of the different inflammasome components, and creating strains that 
are both deficient in the Yop proteins but express lpxL, to determine if the presence of 
potent LPS is able to override the caspase-1 suppressing activities.   
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Taken together the data presented illustrate that production of tetra-acyl lipid A, 
which results in dampening of the immune response, was an important evolutionary step 
for the development of Y. pestis into a highly virulent pathogen.   
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Materials and methods: 
 
Yersinia lpxL Sequences 
The lpxL sequences from Yersinia were located by BLAST (NCBI) search using the E. 
coli K12 lpxL gene (Annotation NC_000913.2). The sequence of Y. pseudotuberculosis 
IP2666 lpxL was determined by sequencing of the cloned region in pBR322. The gene 
annotation for the other genes are as follows: Y. pseudotuberculosis IP31758-
CP000720.1, YPIII-CP000950.1, IP32953 BX936398.1, PB1/+-CP001048.1,  Y. 
enterocolitica 8081 NC_008800.1, Y. entercolitica type 0:9 AM941739. The Y. mollaretii 
ATCC43969 lpxL is between 9103 and 10023, Y. bercovieri ATCC43970 lpxL is between 
9617 and 10537, Y. frederiksenii ATCC33641lpxL is between 213902 and 214822, and Y. 
intermedia ATCC 29909 lpxL is between 30241 and 31161. These genomes have not yet 
been annotated.  
 
Bacterial strains and growth conditions:  
The bacterial strains used are listed in table 1. The KIM5 and KIM1001-pLpxL 
containing strains were made as previously described in Montminy, et. al., 2006.  The 
lpxL gene from IP2666, including 480 basepairs upstream and 266 basepairs downstream 
of the coding region, was cloned by colony PCR using Pfu Ultra polymerase (Stratagene) 
and ligated into the BamHI and SalI sites of pBR322, creating pYtbLpxL. This 
inactivated the tetracycline gene in pBR322, and the mutants are tetracycline sensitive. 
The resulting plasmid was electroporated into Yersinia pestis strain KIM5(Goguen Jd, 
1984) or KIM1001(Sodeinde et al., 1992) and selected by growth on tryptose-beef extract 
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(TB) agar supplemented with 0.25 mM calcium chloride in the presence of 100 µg/ml 
ampicillin.  KIM1001 (pPCP1+, pCD1+, pMT1+) is highly virulent while the KIM 
derivative KIM5 bears a chromosomal deletion designated Δpgm, which strongly 
attenuates virulence (Perry and Fetherston, 1997; Sodeinde et al., 1992).  KIM5 was used 
to limit risk of infection in in vitro studies where a virulent strain was not required, and 
the pgm locus contains no genes thought to impact LPS biosynthesis.  Y. 
pseudotuberculosis IP2666ΔlpxL was generated by PCR amplifying a 1052 bp upstream 
fragment and 569 bp downstream fragment of  lpxL. A nonspecific linker sequence was 
inserted, and the two fragments were then joined by sewing PCR, making an 879 bp 
deletion in the gene (Figure 3.3). This fragment was cloned into pRE107 and transformed 
into β2155, an E. coli mating strain.  This strain was then mated to IP2666 pYV-, and 
resulting colonies were screened for the deletion. The strains KIM-3001, KIM-
3001ΔYopB,J,E and KIM-3001ΔYopJ,E were a gift from Dr Greg Plano (University of 
Miami)  (Bartra et al., 2006). 
 
Lipopolysaccharide and lipid A purification:  
Pyrogen-free reagents and supplies were used to the greatest extent possible in the LPS 
and lipid A preparations.  Bacteria were grown in 1 liter cultures overnight and then 
harvested by centrifugation at 3,000 x g.  LPS was purified from bacteria by hot water-
phenol extraction (Westphal et al., 1952), followed by two phenol re-extractions to 
remove contaminating lipoproteins and TLR2-activity (Hirschfeld et al., 2000). LPS from 
E. coli O111:B4 (Sigma) was phenol re-extracted as indicated above.  The absence of 
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activation of TLR2-expressing cells (Figure 3.2c), in spite of potent IL-8 release by 
bacterial Pam3CysSK4 lipopeptide, indicates the absence of contaminating lipoproteins 
in our highly purified LPS preparations. LPS preparations were run on a NuPAGE® 
Novex 12% Bis-Tris Gels (Invitrogen) and then visualized by silver stain using BioRad 
Silver Stain kit (161-0443).  Lipid A was directly isolated from whole bacterial cells 
using the Bligh-Dyer two-phase chloroform-methanol-water organic extraction 
(Vorachek-Warren et al., 2002a).  Samples were subsequently analyzed by MALDI-TOF 
MS using a Kratos (Manchester, UK) AXIMA CFR high performance mass spectrometer 
operated in both positive and negative ion modes.  
 
Cell Isolation and Culture:  
Human PBMC were obtained from healthy volunteers with informed consent, and 
isolated by centrifugation on Lymphoprep density media (Axis-Shield/Nycomed).  The 
UMass Institutional Review Board approved the human subject protocol.  Red blood cells 
were lysed with red blood cell lysis buffer (Sigma).  Immortalized macrophage cell lines 
were a gift from Kate Fitzgerald and generated as described (Hornung V, 2008).  
HEK293 cells stably expressing human TLR4-YFP and retroviral MD-2, or human 
TLR2-YFP, or empty vector pcDNA3 were as published (Latz et al., 2002).  All cells 
were cultured in DMEM supplemented with ι-glutamine, 10% (vol/vol) FCS (HyClone) 
and with or without 100ug/mL ciprofloxacin.  PBMCs and mouse macrophages were 
plated at a density of 1x105 - 2x106 cells per mL in DMEM and simulated with either the 
indicated amount of purified LPS or bacteria.  Immortalized mouse macrophages were 
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stimulated in the presence of 1ng/mL recombinant GM-CSF (Peprotech).  Bacteria used 
to stimulate cells were grown overnight at 37°C, expanded the next day for three hours to 
enter log growth phase, then washed three times with DMEM to remove bacterial growth 
media.  The bacteria were added to cells, after three hours the cells were treated with 
50μg/mL of gentamicin and incubated for another three hours; the supernatants were 
spun to clear the bacteria. 
 
Growth Analysis 
For growth analysis of both KIM5 and IP2666 strains, overnight cultures were diluted 
into 3 ml of TB broth with calcium chloride to an OD600 of 0.1.  Growth of the cultures 
was monitored every 2 hours at OD600.   
 
Antimicrobial and serum sensitivity assays 
For antimicrobial and serum sensitivity assays of both KIM5 and IP2666 strains, 
overnight cultures were diluted into 3 ml of TB broth with calcium chloride to an OD600 
of 0.1.  These cultures were then allowed to grow for three hours to enter log phase. For 
the antimicrobial assay, the cultures were then swabbed on to TB agar plates of uniform 
concentration and volume, and then disks containing Polymyxin B (BD Sensi-Disc Cat 
no 230926 300units per disk) were placed on the agar. The plates were then inverted, 
placed at 37°C and incubated for 48 hours. The zone of inhibition was then measured. 
For the serum assay, the bacteria were diluted to 4 x103 CFU/mL, and then 50% serum 
was added to the cultures. At the timepoints, 25 ul of the culture was plated in triplicate. 
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The plates were then inverted, placed at 37°C and incubated for 48 hours. The colonies 
were then counted and CFU/percent survival from time zero was determined.  
 
Mice: 
C57BL/6 were originally obtained from Jackson Laboratories and bred in our facilities. 
TNFR1 KO, IL-1R KO, IL-12p40KO, and IL-1R-dificient (Ilir1-/-) mice were from 
Jackson Laboratories.  Mice deficient in TLR4 (Trl4-/-) were provided by S. Akira. Mice 
deficient in IFNAR KO were provided by J. Sprent at Scripps. All mouse strains were 
bred and maintained in specific pathogen-free conditions in the animal facilities at the 
University of Massachusetts Medical School. 
 
ELISA: 
Cell culture supernatants were assayed for TNFα, IL-8, IL-1β with ELISA kits (R&D 
Systems) according to the manufactures’ instructions. 
 
In vivo infections: 
Mice were infected in a contained animal biosafety level 3 facility with fully virulent Y. 
pestis KIM1001, KIM1001-pEcLpxL or KIM1001-pYtbLpxL by subcutaneous (SC) 
injection of 50 μL in the nape of the neck.  Inoculums containing the indicated CFU were 
suspended in PBS.  Mice were euthanized by IP pentobarbital overdose or CO2 affixation 
when moribund.  Survival was monitored up to 21 or 28 days, every 12 hrs during acute 
infection.  All experiments involving live animals and Y. pestis were regulated by the 
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University of Massachusetts Medical School Department of Animal Medicine, the 
Institutional Animal Care and Use Committee, and the Institutional Biosafety Committee. 
 
Statistical analysis 
Statistical differences in survival were studied by Kaplan-Meyer survival analysis and the 
log rank test. Alignments and statistical analysis was done using DNAstar and Prism.  
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Figure 3.1 lpxL in Yersinia 
Punitive genes for lpxL were identified by BLAST analysis using E. coli K12 lpxL within 
sequenced Yersinia strains.  Punitive LpxL genes were located in all sequenced Yersinia 
with the exception of Y. pestis.  
a) Clustal W alignment of punitive lpxL genes in sequenced Yersinia strains.  Yellow 
shading denotes area of sequence homology, with the consensus sequence is listed above.  
b) Percent identity and divergence of the lpxL sequences generated after clustal W 
alignment.  
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Figure 3.2 Mass spectrometry analysis of lipid A from Y. pestis and Y. 
pseudotuberculosis 
KIM5-pYptbLpxL, IP2666, IP2666ΔlpxL, and IP2666ΔlpxL-pYptbLpxL was grown at 
37 ºC and the lipid A purified from whole bacteria by Bligh-Dyer two-phase organic 
extraction.  The lipid was then further purified over a DE52 column and analyzed by 
MALDI-TOF mass spectrometry.  The negative ion spectra shown here are representative 
of multiple extractions.  Analysis of the positive ion spectra (data not shown) was also 
undertaken to determine the location of the modifications of the molecule.   
a) Negative mode MALDI-TOF analysis of the IP2666 strain.  Three predominant 
species present; tetra-acyl lipid A with four C14:0 acyl groups (m/z 1405), a penta-acyl 
lipid A with an additional secondary C12:0 acyl chain (m/z 1587), and a hexa-acyl lipid 
A with two additional C12:0 acyl chains (m/z 1769).  b) KIM5-pYptbLpxL analysis 
shows a very similar acyl chain pattern, there also appears to be some additional tetra-
acyl 1405 present, but in very low amounts.  c) In contrast, IP2666ΔlpxL has a 
predominant tetra acyl peak (m/z 1405), with a pent-acyl peak at m/z 1587.  There is no 
hexa acyl lipid A present in the spectra.  When the strain is complemented with 
pYptbLpxL, the hexa acyl form becomes the predominant peak (m/z 1771).  
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Figure 3.3 Deletion of lpxL from IP2666 
The IP2666 strain was generated by deleting a 879 base pair segment from the the lxpL 
gene.  The upstream and downstream regions of the gene were amplified by PCR and 
joined together with a small linker region to create a non polar deletion.  This fragment 
was then cloned into a suicide vector, introduced into an E. coli mating strain, and then 
transferred to IP2666 pYV-.  Colonies were tested for homologous recombination by 
PCR, with the mutant form exhibiting a smaller lpxL fragment when compared to the 
parent strain.  
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Figure 3.4 Yersinia strains expressing LpxL synthesis a potent LPS, while those 
lacking the gene produce non-stimulatory, antagonistic LPS 
LPS from both Y. pestis and Y. pseudotuberculosis was isolated by hot water-phenol 
extraction, repurified, and used to stimulate a) human PBMCs, or HEK293 cells 
expressing b) TLR4/MD2, c)TLR2, or d) empty vector.  Cells were stimulated for 18 
hours and the supernatants were analyzed by either TNF or IL-8 ELISA.  e) Human 
PBMCs were costimulated with LPS from either IP2666 ΔlpxL or KIM5, and various 
other stimulatory forms of LPS for 18 hours.  Supernatants were collected and analyzed 
for TNF by ELISA.  f) Immortalized wild type or g) TLR4-/- mouse macrophages were 
stimulated with LPS as above, and the supernatants were analyzed for mouse TNF.  LPS 
from Yersinia strains that expressed LpxL were able to stimulate a robust response from 
all the cell types, whereas the strains lacking lpxL produced non-stimulatory, antagonistic 
LPS.  
 
 
 
 
 
145
IP
26
66
  l
px
L 
IP
26
66
  
IP
26
66
  l
px
L-
pY
pt
bL
px
L 
K
IM
5 
LP
S
K
IM
5-
pY
pt
bL
px
L 
LP
S
IP
26
66
  l
px
L-
pY
pt
bL
px
L 
LP
S
E.
 c
ol
i L
PS
IP
26
66
  l
px
L 
LP
S
IP
26
66
  L
PS
K
IM
5 
K
IM
5-
pY
pt
bL
px
L 
K
IM
5-
pL
px
L 
Δ
Δ
Δ Δ
Figure 3.5
a b
c
d
e
146
Figure 3.5 Characteristics of Y. pestis and Y. pseudotuberculosis strains 
a)- b) KIM5 and IP2666 strains were seeded in triplicate and incubated at 37°C in three 
milliliter cultures at an OD of 0.1.  Cultures were then monitored every two hours at an 
OD600.  No significant difference in growth between the parent and mutant strains was 
apparent.  
c) - d) KIM5 and IP2666 strains were swabbed onto culture agar and then disks 
containing 300 units of Polymyxin B were placed on the agar in triplicate.  The plates 
were inverted and incubated at 37°C for 48 hours, and the zone of inhibition from the 
antibiotic was measured.  No significant difference was detected between the parent and 
mutant strains.  
e) One microgram of LPS from the KIM5 and IP2666 strains was separated on a 12% Bis 
Tris gel, and the LPS visualized by silver stain.  KIM5 and KIM5-pYptbLpxL exhibited a 
rough LPS phenotype, whereas IP2666 has more of an o-polysaccharide core region.  The 
mutant strains again resemble their parent.  The E. coli 0111:B4 displayed a smooth LPS, 
as denoted by the banding pattern of the molecule.  
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Figure 3.6 Y. pestis-pYptbLpxL is avirulent in wild type mice 
a) Wild type C57Bl/6 mice were infected with 500 CFU of KIM1001, KIM1001-pLpxL, 
or KIM1001-pYptbLpxL subcutaneously in the nape of the neck.  
b)Wild type C57Bl/6 or TLR4-/- mice were infected with 500 CFU of KIM1001-
pYptbLpxL subcutaneously at the nape of the neck.  
Survival was monitored every 12 hours during acute infection. 
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Figure 3.7 IL-1 response is critical for protection from Y. pestis infection 
a) Wild type C57Bl/6 or IL-1R-/- mice were infected with 1000 CFU of KIM1001 or 
KIM1001-pLpxL subcutaneously at the nape of the neck. Survival was monitored every 
12 hours during acute infection.  
b) Wild type C57Bl/6 or MyD88-/- mice were infected with 1000 CFU of KIM1001 or 
subcutaneously at the nape of the neck. Survival was monitored every 12 hours during 
acute infection.  
c) Human PBMCs were infected with KIM5, KIM5-pLpxL or KIM5-pYptbLpxL or d) 
IP2666, IP2666ΔlpxL, or IP2666ΔlpxL-pYptbLpxL for three hours, treated with 
gentamicin and then incubated for three hours longer.  The supernanants were collected, 
treated with cipro to kill any remaining bacteria, and then analyzed for IL-1β by ELISA. 
Bacteria expressing LpxL induce IL-1β, whereas KIM5 does not.  
e) Immortalized wild type C57Bl/6 or TLR4-/- mouse macrophages were infected with 
KIM5, KIM5-pLpxL or KIM5-pYptbLpxL for three hours, treated with gentamicin and 
then incubated for three hours longer.  The supernanants were collected and then 
analyzed for IL-1β by ELISA. Cells deficient for TLR4 did not secrete IL-1β in response 
to infection with any of the KIM5 strains, where as the wild type cells were able to mount 
a robust response.  
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Table 3.1 Bacterial strains used in this study 
 
Strains  Plasmid Phenotype Reference 
Y. pestis KIM5  Δpgm (Goguen et 
al., 1984) 
Y. pestis KIM5-pLpxL Contains E. coli 
K12 lpxL 
Δpgm, Amp 
resistant, tet 
sensitive 
(Goguen et 
al., 1984) 
Y. pestis KIM5-
pYptbLpxL 
pYptbLpxL 
Contains Y. 
pseudotuberculosis 
lpxL 
Δpgm, Amp 
resistant, tet 
sensitive 
This work 
Y. pestis KIM1001  Fully 
virulent 
(Sodeinde et 
al., 1992) 
Y. pestis KIM1001-
pLpxL 
Contains E. coli 
K12 lpxL 
Amp 
resistant, tet 
sensitive 
(Sodeinde et 
al., 1992) 
Y. pestis KIM1001-
pYptbLpxL 
pYptbLpxL 
Contains Y. 
pseudotuberculosis 
lpxL 
Amp 
resistant, tet 
sensitive 
This work 
Y. 
pseudotuberculosis 
IP2666   (Simonet and 
Falkow, 
1992) 
Y. 
pseudotuberculosis 
IP2666 pYV-  Lacks T3SS 
and Yops 
(Simonet and 
Falkow, 
1992) 
Y. 
pseudotuberculosis 
IP2666ΔlpxL In frame, non polar 
deletion of lpxL 
 This work 
Y. 
pseudotuberculosis 
IP2666ΔlpxL 
+pYptbLpxL  
Complement strain Amp 
resistant, tet 
sensitive 
This work 
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Table 3.2 Vaccination with KIM1001-pYptbLpxL 
 
Vaccination                 
(KIM1001-pYptbLpxL) 
 
Challenge (KIM1001) Survival 
None 1000 CFU 0 of 10 
500 CFU 1000 CFU 10 of 10 
Survival of wild type mice vaccinated subcutaneously with Y. pestis KIM1001-
pYptbLpxL and naïve mice (None) after subsequent challenge with Y. pestis KIM1001, 
presented as surviving mice of total mice. Data representative of two to three 
experiments.  
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Table 3.3 Survival of Receptor knockout mice after challenge with  
KIM1001-pLpxL 
 
Mouse Strain 
Survival 
Number surviving of 
total 
Percent Survival 
C57Bl/6 5 of 5 100% 
IFNαR KO 8 of 10 80% 
TNFR I KO 5 of 8 63% 
IL-12 p40 KO 6 of 11 55% 
IL-1RI KO 4 of 10 40% 
TLR4 KO 0 of 5 0% 
Survival of wild type and knock out mice after subcutaneous infection with 1000 CFU 
Y. pestis KIM1001-pLpxL, presented as percent and surviving mice of total mice. 
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CHAPTER IV 
DISCUSSION 
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Overview 
The focus of the research presented in this thesis has been to determine if the 
presence of tetra-acyl lipid A in Yersinia pestis LPS acts as a critical virulence and 
evolutionary determinant.  Specifically, I set out to determine if evasion of LPS-mediated 
TLR4/MD2 signaling and subsequent dampening of innate immunity are essential for the 
extreme pathogenicity of the bacteria.  I demonstrate that by producing tetra-acyl lipid A 
at 37°C (mammalian body temperature) Y. pestis is not only able to dampen TLR4 
activation, but also inhibit the IL-1 pathway, a critical component of the host response to 
gram negative bacteria.  I also illustrate that the production of tetra-acyl lipid A is a 
consequence of the loss of LpxL, a key enzyme in the lipid A biosynthesis pathway, and 
furthermore that expression of lpxL in Y. pestis severely attenuates virulence.  To that 
end, when lpxL was introduced to Y. pestis, the bacteria produced hexa-acyl lipid A 
which was able to activate the innate immune system.  Thus, the loss of this critical 
enzyme from Y. pestis formed a major evolutionary step in the development from its 
parent Y. pseudotuberculosis.  Unlike other Yersinia family members which produce mild 
disease upon infection, the loss of LpxL from Y. pestis has enabled the bacteria to evolve 
into a highly virulent pathogen able to completely evade the immune response leading to 
devastating disease.  This work describes the novel finding that the production of tetra-
acyl lipid A is an essential virulence determinant for Y. pestis, and a major factor in the 
evolution of a highly virulent pathogen.  
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Yersinia  lipid A acylation patterns 
It had been previously established that when grown at 37°C Y. pestis produced 
tetra-acyl lipid A, and that LPS from these bacteria was non-stimulatory (Kawahara et al., 
2002; Rebeil et al., 2004; Rebeil et al., 2006).  However, when grown at lower 
temperatures (21°C to 27°C), the bacteria produced stimulatory hexa-acylated lipid 
A/LPS.  It remained unclear why the bacterium produced the tetra-acyl lipid A at higher 
temperatures and what affect this had on virulence.  Generally, gram-negative bacteria 
produce a large array of lipid A species, which can be further altered by environmental 
cues such as temperature and can differentially activate TLR4/MD2(Miller et al., 2005).  
However, producing tetra-acyl lipid A exclusively is unusual, due to the increase in 
membrane fluidity which can leave the bacterium vulnerable to osmotic and 
environmental stress.  Also, the parent of Y. pestis, Y. pseudotuberculosis, contains a 
heterogeneous mix tetra, penta, and hexa lipid A, indicating that alteration of lipid A 
biosynthesis may have been acquired during the evolution of Y. pestis from its parent 
(Rebeil et al., 2004; Therisod et al., 2002).  The first question posed in this work was how 
Y. pestis is able to produce tetra-acyl lipid A at 37°C.  By examining the genes involved 
in the E. coli lipid A biosynthesis pathway, and comparing them to homologues found in 
Y. pestis, it was discovered that Y. pestis lacked the gene lpxL responsible for the addition 
of a secondary acyl chain to tetra-acyl lipid A late in the biosynthesis pathway.  Y. pestis 
does however contain a gene for lpxP, another late acyltransferase, which enables the 
bacterium to produce hexa-acylated lipid A only at lower temperatures.  During these 
studies E. coli lpxL was cloned into pBR322 under the control of its own promoter 
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(pLpxL), and introduced to Y. pestis.  The plasmid pBR322 was used because it is 
tolerated well by Y. pestis, which has three endogenous plasmids and typically does not 
tolerate exogenous plasmids.  The lipid A from this new strain was isolated and analyzed 
by MALDI-TOF mass spectrometry.  This revealed that Y. pestis was able to produce 
novel hexa-acyl lipid A with a mass of 1769 m/z at both 26°C and 37°C when expressing 
LpxL (Figure 2.2c, d).  This hexa-acyl lipid A included two C:12 secondary acyl chains 
on the tetra-acyl lipid, indicating that both E. coli LpxL and the endogenous Y. pestis 
LpxM (the last late acyltransferase in the pathway)  were capable of adding the C:12 acyl 
chains, which was novel finding.  In E. coli, LpxM adds a C:14 chain and LpxP attaches 
a C:16 chain.  While LpxP may function in the same manner in Y. pestis and E. coli, Y. 
pestis LpxM has a unexpected novel function of adding a C:12 chain to the lipid A, 
which is a new function for the LpxM enzyme.  
Analysis of lipid A from Y. pseudotuberculosis proved to be more challenging 
than Y. pestis.  The lipid A profile for Y. pseudotuberculosis has not been extensively 
studied, although two groups have undertaken mass spectrometry on the lipid A molecule 
directly (Rebeil et al., 2004; Therisod et al., 2002).  This data showed a high degree of 
heterogeneity in the spectra, much greater than that seen with Y. pestis at 26°C or with Y. 
enterocolitica, the distant ancestral parent of Y. pseudotuberculosis.  These spectra show 
tetra-acyl lipid A with a mass of 1405m/z, as well as several different forms of penta- and 
hexa-acyl lipid A with a C:16 modification.  While it is important to note that MALDI-
TOF is not quantitative, none of the previously published spectra identified one form of 
lipid A that seemed to dominate the spectra.  However, analysis of the IP2666 strain 
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revealed a notably different profile.  While a mix of lipids was still present, C:16 
modifications were absent and the 1769 hexa-acyl peak dominated the spectra (Figure 
3.2a).  This hexa-acyl species was unique for Y. pseudotuberculosis and has not currently 
been reported in literature.  There are several reasons this spectra may differ from 
published accounts.  First, the LPS/Lipid A from IP2666 has not previously been 
examined, and it may have different characteristics given the lipid A from this bacteria 
are so variable. Secondly, the isolation method used in this work is different that 
published accounts. While previous groups have isolated lipid A secondarily from 
extracted LPS, I used the Bligh-Dyer lipid A isolation technique (Vorachek-Warren et al., 
2002b).  Isolating lipid A from previously purified LPS subjects the sample to two hot 
acid extractions, the first during the repeated hot phenol extractions to purify the LPS, the 
second, a boil in an acidic sodium acetate/SDS solution. These two harsh chemical 
treatments can strip the lipid A molecule of secondary modifications and possibly remove 
acyl chains, resulting in the appearance of heterogeneity of the molecule. The Bligh-Dyer 
lipid A isolation technique extracts the lipid A directly from the bacteria and results in 
less fragmentation and degradation on the lipid A.  In this case, the lipid A is only 
exposed to a sodium acetate/SDS boil, and then an organic extraction that is much gentler 
to the molecule and results in less possible chemical modifications. The directly isolated 
lipid A is then purified over an anion exchange column, dried, and then frozen at -80°C 
immediately to ensure against further degradation of the molecule. This method is 
superior to isolating from LPS because, while more time consuming and lower yields, it 
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results in less degradation of the lipid A molecule, which is why it was used in these 
studies.  
  To address this issue and confirm the lipid A analysis, I analyzed the IP2666 
strain several times to confirm the spectra, although due to external technical difficulties 
the results were variable further analysis is underway.  MALDI-TOF performed on 
directly LPS confirmed the previously obtained lipid A profile shown in Figure 3.2a.  I 
also attempted to analyze the lipids on a Finnigan LTQ electospray mass spectrometer, 
however the sensitivity of this machine was less then with a MALDI-TOF.  Therefore, I 
was only able to detect residual SDS molecules remaining from the isolation procedure.  
This lab has now begun a new collaboration, and future experiments planned include a 
fresh isolation of IP2666 lipid A and a reanalysis to confirm the lipid A profile.  
Analysis of the lipid A from IP2666ΔlpxL and IP2666ΔlpxL-pYptbLpxL is much 
less complex (Figure 3.2c,d).  IP2666ΔlpxL displays a distinct primary tetra-acyl lipid A 
molecule which very closely mimics that seen with KIM5 lipid A (Figure 3.2c).  
IP2666ΔlpxL-pYptbLpxL by contrast has a major hexa-acylated peak at 1769 m/z, 
mimicking KIM5-pLpxL (Figure 3.2d).  The shift in the acylation patterns of Y. pestis 
between the wild type and LpxL expressing strains is pronounced, as is the shift between 
IP2666 and IP2666ΔlpxL-pYptbLpxL.  lpxL is under the control of its native promoter 
and therefore mimicking natural expression as much as possible.  However, the 
exogenously expressed gene is at higher copy number than normally found in E. coli or 
Y. pseudotuberculosis, and is subject to different levels of control.  This increase in copy 
number may strongly drive the system more than would normally occur with a single 
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copy of the gene.  Further experiments to be conducted involve placing a single copy of 
lpxL gene either directly into the chromosome or a Y. pestis specific vector, thus 
mimicking endogenous expression in order to determine if the acylation pattern remains 
the same.  If LpxL was expressed at a more endogenous level, it is possible that the 
acylation pattern seen in these bacteria would shift to a heterogeneous mix of lipids, 
similarly to that seen in Y. pseudotuberculosis 
 
Attenuation of Virulence in Y. pestis strains expressing LpxL 
   The LPS purified from Y. pestis strains expressing LpxL is stimulatory via 
TLR4/MD2, and unlike wild-type Y. pestis is able to activate human primary cells.  
However, apart from the changes in lipid A/LPS, Y. pestis contains a multitude of active 
mechanisms to suppress the immune response.  Together these mechanisms can override 
even the most robust innate immune response.  To determine if changes in acylation 
patterns had any significant effect on the virulence of Y. pestis, pLpxL and pYptbLpxL 
were introduced into fully virulent KIM1001.  The mice were subcutaneously infected 
with this strain in order to mimic natural infection from a flea bite.  Remarkably, all the 
mice infected with the LpxL expressing strains of Y. pestis survived the infection, and did 
not display any outward signs of sickness.  Mice were infected with up to 1x106 CFU of 
KIM1001-pLpxL and never appeared to suffer any ill effects (Table 2.1).  This extreme 
attenuation in virulence was remarkable given that all other virulence determinants were 
in place. Further experimentation showed that when delivered subcutaneously, infection 
with KIM1001-pLpxL did not become systemic, but instead remained as a localized 
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infection.  Mice that were infected intravenously did eventually succumb to disease, but 
at a notably reduced rate, with evidence of a robust and widespread immune response 
when compared to animals that received intravenous KIM1001 (Figure 2.4d-g).  The 
effect seen by this modification is profound, indicating that the acylation state of the LPS 
greatly affects the virulence of the bacteria. Previous work had shown that bacteria grown 
at 26°C had a higher LD50 in mice then bacteria grown at 37°C, however in both cases 
the bacteria were still extremely virulent (Perry and Fetherston, 1997).  These data show 
that by permanently altering the acylation state of Y. pestis to hexa acyl at 37°C, the 
bacteria can be rendered completely avirulent, unlike what is seen when the bacteria is 
merely grown at a lower temperature before inoculation. Wild type Y. pestis grown at 
26°C expressing hexa-acyl lipid A, while stimulatory, may not be cleared by the mouse 
before it changes its acylation pattern due to both the time it takes for the bacteria to be 
fully cleared at the site of inoculation, and due to the T3SS that also comes into effect 
upon temperature shift. The time between the flea bite inoculation with low temperature 
grown Y. pestis expressing immunostimulatory LPS and when the bacteria shift their 
genetic profile in response to the increased temperature may not be sufficient for 
complete clearance of the bacteria before both the lipid A profile changes and the T3SS 
becomes active. Also, the resident dendritic cells in the subcutaneous layer of the skin, 
the Langerhans cells, do not express TLR4 (van der Aar et al., 2007) (Takeuchi et al., 
2003), so they may not be able to recognize the bacteria. Melanocytes and keratinocytes 
do express TLR4 (Ahn et al., 2008) (Kollisch et al., 2005) (Lebre et al., 2007), and 
keratinocytes release proinflammatory cytokines in response to LPS stimulation (Lebre et 
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al., 2007), so these cells may be able to recognize and alert the immune system, but how 
effective they are at inducing the immune response has yet to be determined. The 
combination of low bacterial inoculation during the flea bite and the lack of cells 
available in the subcutaneous layer of the skin to recognize the hexa acyl lipid A and 
mount a rapid and effective immune response may explain why the bacteria are not 
cleared from the host before they can change their genetic profile and lipid A structure 
and become a systemic infection.  
This attenuation was TLR4-mediated, as mice deficient for the receptor quickly 
fall ill and succumb to disease (Figure 2.4b, Figure 3.6b).  However, the robust innate 
immune response initiated by TLR4/MD2 signaling is not sufficient to clear the infection, 
as when infected with KIM1001-pLpxL RAG-/- mice eventually die from the disease, 
although the time to death is delayed (Figure 2.8). The innate immune response may not 
be able to clear the infection entirely due to LPS tolerance that may be induced after 
prolonged stimulation.   Defining the cellular subsets responsible for the robust immune 
response seen at both the site of infection and systemically is of great interest, and is a 
future direction of the project.  This includes an examination of the cellular subsets that 
are recruited to the site of infection, as well as deciphering the adaptive immune response 
to the infection.  Further characterization of KIM1001-pYptbLpxL will also take place, 
with preliminary experiments shown in Figure 3.6 and Table 3.2.  These results indicate 
that this strain functions in a similar manner to KIM1001-pLpxL, and also appears to 
have no growth or survival defects.  It would be of interest to determine how different 
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adaptor and receptor mutant mice respond to infection with this strain, since the acylation 
pattern is somewhat different from that of Y. pestis expressing E. coli LpxL.  
 
Use of LpxL expressing strains as a vaccine 
 The idea of modifying the LPS/Lipid A molecule of a bacteria to activate TLR4 
during infection is a novel concept in vaccine development.  As discussed in the 
introductory Chapter 1, the idea of using TLR agonists to act as potent adjuvants in 
vaccines has been gaining recognition (Lahiri et al., 2008; Zhu et al., 2008).  As our 
understanding of the link between the innate and adaptive immunity grows, the concept 
of using specific TLR agonists to activate these host defense systems is becoming central 
to vaccine development.  This work proposes a new model for Y. pestis vaccine 
development, and vaccine development as a whole.  Wild type mice infected with the 
LpxL expressing strains are protected from subsequent infection with wild type Y. pestis, 
demonstrating that these strains are important potential vaccine candidates (Tables 2.2, 
2.3, 3.2).  The production of an attenuated Y. pestis strain as a vaccine candidate has long 
been the focus of research from various groups.  The majority of this work has been 
focused on generating deletional mutants of various Y. pestis virulence factors or 
isolating different bacterial components with high antigenicity (F1, LcrV) (Feodorova 
and Corbel, 2009).  However, these vaccines have failed to show complete protection 
from infection in non-human primates, and while tolerated well by humans in trials the 
degree of protection they impart in humans is controversial.  The work presented here 
illustrates potent protection with a live attenuated strain of Y. pestis in immunocompetent 
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mice.  Nevertheless, using this strain as a live attenuated vaccine in a human population 
is not feasible due to its pathogencity in immunocompromised mice or by intravenous 
infection.  Therefore, modifications would have to be made to the strain to further 
attenuate virulence while maintaining the high level of protection.  Work by Szaba et al 
has shown that adding pLpxL to the pgm deficient attenuated strain of Y. pestis D27 
attenuates the virulence of the strain during intranasal infection, and protects against 
subsequent reinfection with fully virulent Y. pestis (Szaba et al., 2009).  They also 
reported a robust T cell response is elicited by this vaccination, and that protection from 
reinfection is dependent on the memory T cell response not on antibody production.  This 
is critical as most Y. pestis vaccine research has been devoted to creating a vaccine that 
produces high vaccine antibody titers.  This report demonstrates that creating a vaccine 
that will elicit both antibody production and a potent memory T cell response is essential 
for creating an effective vaccine.  Further work to be undertaken includes continuing to 
modify Y. pestis to selectively attenuate virulence while expressing a potent LPS/lipid A, 
to create a live attenuated vaccine that produces a robust antibody and T cell response 
while making it safe for human use. Another possible strategy would be to create outer 
membrane vesicles containing both antigenic Y. pestis proteins and stimulatory LPS, in a 
similar manner to the strategy employed with N. meningitidis (Casella and Mitchell, 
2008; Fransen et al., 2007; Stoddard et al., 2009). 
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Examining the roles of different innate immune pathways during Y. pestis infection 
 The data presented in this thesis demonstrates that the production of immune 
stimulatory LPS is able to fully attenuate the virulence of a highly dangerous pathogen.  
In addition, these strains of Y. pestis expressing LpxL, allow us to further study in detail 
the role of individual adapters within the TLR pathway that are critical for protection 
during active infection, and also which other innate immune pathways may be essential 
for protection from disease.  
 In chapter 2, different components of the TLR4 downstream signaling cascade 
were identified as being important for protection from Y. pestis infection.  MyD88 is 
essential not only because of its role as a central adapter for TLR4, but also possibly due 
to its roles in other immune pathways which were further explored in Chapter 3.  The 
adaptor Mal was also crucial, in that over half the Mal deficient mice infected with 
KIM1001-pLpxL succumbed to disease, demonstrating the most pronounced phenotype 
of any of the adaptor knockouts tested with the exception of MyD88 (Figure 2.6a). 
Interestingly, TRIF and TRAM deficient mice were not particularly susceptible to the 
disease, indicating that the alternative TLR4 signaling pathway does not play a critical 
role in protection against Y. pestis (Figure 2.6a).  We also explored the contribution of the 
TLR4 signaling protein CD14, which had previously been reported to not be involved in 
the recognition of deep rough LPS from a mutant strain of E. coli (Huber M, 2006; Jiang 
Z, 2005).  Mice deficient in CD14 were found to be highly susceptible to Y. pestis 
infection and produced significantly lower chemokines in response to Y. pestis-pLpxL 
LPS, indicating that CD14 does recognize rough LPS and is essential for protection from 
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disease (Figure 2.6c,d).  These data illustrate not only the components of the LPS-
TLR4/MD2 pathway that are being utilized during infection, but also the unique infection 
model that these strains present.  The virulent strains of Y. pestis-pLpxL contain all the 
remaining powerful virulence factors, allowing us to explore which TLR4 adaptor or 
accessory proteins are involved in the TLR4 signaling cascade during active and 
fulminant infection, not just those required during LPS stimulation or some other phase 
of infection.  These virulent strains also allow us to further explore which other 
components of the innate immune system interact with or are mediated by TLR4.  
 One such example is the IL-1 pathway, which activates a number of very potent 
cytokines such as IL-1α, IL-1β, and IL-18.  IL-1β in particular has been the subject of 
intense study recently due to its ability to strongly suppress infection, and its role in 
autoimmune disease when disregulated (Dinarello, 2009).  In chapter 3, we illustrated 
that when IL-1R mice were infected with KIM1001-pLpxL, they displayed a 
substantially decreased survival, more than was apparent with other receptor knockouts 
that were thought to be involved in the response to Y. pestis (Table 3.3, Figure 3.7b).  The 
MyD88 knockout mice also had a significantly higher rate of mortality than wild type and 
TLR4 knockout mice (Figure 3.7a).  This indicates MyD88 is important, not just for 
protection mediated by TLR4 or potentially other TLRs, but also for the involvement of 
the IL-1 pathway.  This illustrates the complex nature of the innate immune signaling 
pathway, and the high degree of redundancy and crosstalk between the pathways. MyD88 
is a central adapter to TLR4 and IL-1, which explains why mice deficient in this protein 
succumb to disease so quickly. Without this adapter, two major protective arms of the 
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innate immune system are deactivated, which leads to rapid onset of disease and death 
(Figure 4.1).  Many of the other downstream adapters in the pathway, such as TRIF and 
TRAM, have much less of an impact on the outcome of Y. pestis-pLpxL infection (Figure 
2.6a). This is due to the fact that this arm of the TLR4 pathway plays more of a role in 
activating IFN and IFN-inducible genes, which is not essential for protection in this 
model (Table 3.3) (Fitzgerald Ka, 2003; Sato et al., 2003; Yamamoto et al., 2003a).     
Therefore, to address the importance of the IL-1 pathway, experiments were 
undertaken to examine the levels of Il-1β release in cells infected with Y. pestis then 
stimulated with LPS.  It was determined from these experiments that cells infected with 
Y. pestis secreted small amounts of IL-1β, whereas cells infected with the LpxL 
expressing strains secreted a much higher level of the cytokine (Figure 3.4).  This 
increase in IL-1β release is TLR4 mediated, as cells deficient for this receptor did not 
secrete substantial amounts of the cytokine (Figure 3.4).  This indicates that a strong 
TLR4 mediated signal is necessary for the production of pro-IL-1β, which during active 
infection is cleaved by caspase-1 and released from the cell.  Without this strong TLR4 
signal, only low levels of the cytokine are released (Figure 3.4g).  Future experiments 
will include the examination of the levels of pro and active IL-1β in the cell by western 
analysis, in order to assess the amount of pro-IL-1β production verses the level cleaved 
into activated IL-1β.  While it is highly likely that the increase of IL-1β secretion during 
infection with LpxL expressing strains is due to TLR4 activation and subsequent 
production of pro-IL-1β, a second possibility is that the increase cleavage by caspase-1 is 
due to additional inflammasome activation (Figure 4.1).  
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 IL-1β is activated by caspase-1 cleavage, which is in turn activated by the 
assembly of an inflammasome complex that cleaves pro-caspase-1 into its active form 
(Mogensen, 2009).  The signals that initiate the assembly of an inflammasome complex 
remain under intensive study, although it does appear to involve at least two danger 
signals.  The first signal is the activation of a PRR, while the second signal may involve 
some sort of cellular damage (Mogensen, 2009).  In the case of Y. pestis, there may be 
multiple mechanisms to dampen or eliminate either of these signals to prevent activation 
of caspase-1.  The production of tetra-acyl lipid A blocks activation of TLR4, which may 
effectively block the production of pro-IL-1β, however, the presence of the T3SS of Y. 
pestis may act as a secondary signal of cellular damage.  Previous reports have shown 
that the T3SS needle apparatus alone can induce the activation of caspase-1 (Shin and 
Cornelis, 2007), and that several of the Yop proteins work to suppress this activation 
(Schotte et al., 2004).  However, other research on the activity of YopJ have contradict 
this finding (Bergsbaken and Cookson, 2007; Lilo et al., 2008).  Therefore, the exact role 
the inflammasome plays during Y. pestis infection is still remains unclear.  The modified 
strains of Y. pestis that express LpxL and a potent LPS provide an excellent tool to help 
distinguish how the inflammasome is being activated by Y. pestis, what inflammasome 
components are being assembled, and which Yop proteins may be working to thwart this 
activation.  The first step in answering these questions is to determine which NLR 
proteins, such as NALP3; Ipaf; ASC; and caspase-1, are involved in Y. pestis induced 
inflammasome activation. This can be undertaken by both in vitro methods involving  
cell lines deficient in these proteins, such as immortalized mouse macrophages or bone 
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marrow derived macrophages from knockout mice, and in vivo utilizing inflammasome 
deficient mice.  The NALP3 inflammasome is perhaps the best candidate for activation 
by Y. pestis, as it has previously been shown to be involved in activation of caspase-1 
(Sutterwala et al., 2006), and is upregulated by NF-κB activation (Bauernfeind et al., 
2009).  However, it is a possibility that other sensors may also be involved, therefore all 
inflammasome components will be investigated in future experiments.  
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Figure 4.1 Interaction between TLR4 and IL-1 pathways during stimulation with 
Yersinia expressing LpxL  
Model of the interaction between TLR4/MD2 and hexa-acyl lipid A produced by Yersinia 
expressing LpxL and the activation of the MyD88 pathway which leads to the 
upregulation of proinflammatory cytokines like pro-IL-1β. Pro-IL-1β is then cleaved by 
activated caspase-1, secreted from the cell and binds to the IL-1R. The IL-1R pathway 
also utilizes MyD88 and potently activates NF-κB, which in turn further upregulates the 
pro-inflammatory response.  
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